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INTRODUCTION
Over the last century, remarkable advances have been made in the treatment of 
cancer. Th e improvement of chemotherapy, hormonal therapy and targeted systemic 
therapies has considerably improved patient prognosis. Despite these developments, 
surgery remains the cornerstone of primary treatment, especially in patients were the 
disease is localized and distant metastases are absent. Th e prognosis and quality of 
life of these patients depends in particular on the extent and quality of the surgical 
treatment. At present, residual of malignant cells (or so called R1 resection) remains 
a substantial issue in cancer surgery. In contrast to the many imaging modalities 
that can be used preoperatively for diagnosis, staging, and surgical planning (i.e. CT, 
MRI, PET and SPECT), real-time, intraoperative imaging modalities to assess the 
extent of disease and to determine adequate resection margins are lacking1,2. As a 
consequence, surgeons still have to rely only on visual appearance and palpation to 
discriminate between tumor tissue and normal tissue. Misidentifi cation of residual 
disease can result in a local recurrence, and subsequent deprived prognosis. Since 
this situation has not been changed for many decades, there is a need for a diagnostic 
tool that can discriminate tumor tissue from normal tissue during surgery.
NEAR-INFRARED FLUORESCENCE IMAGING
Optical imaging using near-infrared (NIR) fl uorescence is a relatively new technique 
that has emerged as a promising intraoperative imaging modality2-4. NIR fl uorescence 
imaging has several characteristics that are advantageous for implementation in a 
surgical setting2. First, the wavelength of NIR light is between 700 to 900 nanometers, 
which is invisible to the human eye, and therefore does not alter the look of the 
surgical fi eld. At this wavelength, light has relatively low tissue absorbance, resulting 
in high tissue penetration (up to several millimeters) and low autofl uorescence3-6. 
Second, only low concentrations of a non-ionizing tracer are needed and no direct 
tissue contact is employed in NIR fl uorescence imaging making it an inherently safe 
technique7. Finally, images can be acquired within a few milliseconds and this tech-
nique can be easily combined with zoom lenses using a “hands-free” setup, which 
allows the surgeon to operate under real-time image guidance8-10. Th e introduction 
of minimally invasive techniques has increased the need for additional intraoperative 
imaging modalities. For example, NIR fl uorescence imaging has already been used 
during robot-assisted laparoscopic surgery for several indications11-14.
Multiple NIR imaging systems have been developed for both open and laparo-
scopic surgery15-21. Several of these systems are commercially available7,15. Optimized 
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imaging systems have the ability to provide a real-time overlay of the NIR fl uores-
cence signal with visible color images. Th is provides the NIR fl uorescence signal 
in relation to the surgical anatomy, enabling true image-guidance. Along with the 
introduction of image-guided surgery, several minimal invasive alternatives have 
been validated to replace the conventional open approach22,23. For several indications 
the laparoscopic approach shows a more favorable outcome than open surgery with 
regard to postoperative pain, hospital stay and blood loss24-27. However, minimally 
invasive surgery also limits visualization and palpability of the surgical fi eld. NIR 
fl uorescence imaging could therefore contribute to this fi eld of surgery by providing 
additional information.20,28-31.
Besides intraoperative imaging systems, for NIR fl uorescence image-guided sur-
gery, a NIR fl uorescent contrast agent (i.e. fl uorophore or “probe”) is also needed to 
visualize specifi c structures that need to be resected (e.g. tumor tissue) or should be 
spared (e.g. bile ducts). Indocyanine green (ICG) and Methylene blue are currently 
the only NIR fl uorophores that are registered with the Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA) for clinical application, 
albeit for other indications. ICG has been used since the 1950s to measure cardiac 
output, hepatic function, and retinal perfusion. Th e absorbance of ICG is around 
800 nm, and adverse events following administration are rare, making it a safe con-
trast agent. Most studies report ICG doses between 1 and 10 mg for intraoperative 
imaging applications, but intravenous injection up to 25 mg has been reported to 
be safe32. Aft er intravenous injection, ICG is cleared rapidly by the liver and almost 
completely excreted into bile. Methylene blue is also currently applicable for clinical 
use and at certain concentrations has fl uorescent properties. However, its emission 
peak lies around 700 nm, which is less optimal due to higher tissue absorbance and 
higher auto-fl uorescence. Both ICG and MB are non-targeted dyes as their chemical 
structures do not allow conjugation to tissue-specifi c ligands. Novel NIR fl uorescent 
probes are being developed, to permit targeted imaging33-35. An ideal fl uorophore 
should be simply to conjugate to tumor specifi c antibodies or ligards, have a high 
quantum yield (brightness) and low background uptake1,36. Currently, multiple 
fi rst-in-human trails are ongoing to allow broad clinical implementation of this new 
generation of dyes.
OUTLINE OF THE THESIS
Th is thesis is dived in three parts. Th e fi rst part focusses on the intraoperative 
evaluation of surgical margins using NIR fl uorescence imaging in both preclinical 
and clinical settings. Th e second part of this thesis focusses on the clinical imple-
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mentation of fl uorescence guided Sentinel Lymph Node Biopsy. In part three, NIR 
fl uorescence imaging is used to visualize vital structures during abdominal surgery.
Part I: Intraoperative evaluation of surgical margins
Chapter 2 describes the use of a novel fl uorophore (ZW800-1) that is conjugated to 
the ligand cRGD that targets integrins. Th e aim of the current study was to intra-
operatively identify both colorectal tumors and ureters in orthotopic animal models 
using cRGD-ZW800-1 Moreover, as cRGD-ZW800-1 is cleared renally, minimal 
background uptake in the gastrointestinal tract was observed and ureteral visualiza-
tion was feasible aft er a single injection. Th e characteristics of this NIR probe allow 
fl uorescence guidance within 2 hours aft er administration to detect the extent of the 
primary tumor as well as the sites of disseminated disease whilst minimizing the risk 
of damage to ureters. Chapter 3 describes the intraoperative identifi cation of breast 
cancer using NIR fl uorescence and the intravenous administration of methylene blue. 
Chapter 4 gives an overview of the preclinical development and clinical applications 
of NIR fl uorescence imaging during open and laparoscopic hepatopancreatobiliary 
surgery.
Part II: Sentinel lymph node imaging
Chapter 5 evaluates the diagnostic accuracy of NIR fl uorescence for SLN mapping 
in breast cancer patients when used in addition to conventional techniques. Th is 
study describes a multicenter experience with the Fluorescence-Assisted Resection 
and Exploration (FLAREtm) imaging system, developed by the group of professor 
Frangioni (Harvard Medical School, Boston, MA, USA). Patients were enrolled in 
the Dana-Farber / Harvard Cancer Center (Boston, MA, USA) and the Leiden Uni-
versity Medical Center (Leiden, the Netherlands). In Chapter 6 the ability to combine 
both radioactive and NIR fl uorescence guidance for SLN mapping is breast cancer is 
demonstrated. A hybrid radioactive and fl uorescence tracer was used which permits 
both preoperative imaging and intraoperative guidance aft er a single injection. In 
Chapter 7 the same hybrid tracer is used for SLN mapping in melanoma patients. 
Chapter 8 describes feasibility of SLN mapping using NIR fl uorescence and ICG in 
patients undergoing radical cystectomy with lymphadenectomy for bladder cancer. 
In Chapter 9 the application of NIR fl uorescence imaging using diff erent tracers for 
SLN mapping in vulvar cancer patients was investigated.
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Part III: Vital structure imaging
Chapter 10 demonstrates the fi rst successful clinical use of NIR fl uorescence imag-
ing using low dose methylene blue for the identifi cation of the ureters during lower 
abdominal surgery. In Chapter 11 ICG dose and timing for NIR cholangiography 
were optimized during open hepatopancreatobiliary surgery. Subsequently, these 
results were validated during laparoscopic cholecystectomies using a laparoscopic 
fl uorescence imaging system. Th is study clearly shows that a prolonged interval be-
tween ICG administration and surgery permits optimal NIR cholangiography with 
minimal liver background fl uorescence.
Finally, in Chapter 12 results of the studies performed in this thesis are summa-
rized and future perspectives are described.
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Irradical tumor resections and iatrogenic ureteral injury remain a signifi cant problem 
during lower abdominal surgery. Th e aim of the current study was to intraoperatively 
identify both colorectal tumors and ureters in subcutaneous and orthotopic animal 
models using cRGD-ZW800-1 and NIR fl uorescence.
Methods
Th e zwitterionic fl uorophore ZW800-1 was conjugated to the tumor specifi c peptide 
cRGD (targeting integrins) and to the a-specifi c peptide cRAD. One nmol cRGD-
ZW800-1, cRAD-ZW800-1, or ZW800-1 alone was injected in mice bearing subcuta-
neous HT-29 human colorectal tumors. Subsequently, cRGD-ZW800-1 was injected 
at dosages of 0.25 and 1 nmol in mice bearing orthotopic HT-29 tumors transfected 
with luciferase2. In vivo biodistribution and ureteral visualization were investigated 
in rats. Fluorescence was measured intraoperatively at several time points aft er probe 
administration using the FLARE imaging system.
Results
Both subcutaneous and orthotopic tumors could be clearly identifi ed using cRGD-
ZW800-1. A signifi cantly higher signal-to-background ratio (SBR) was observed in 
mice injected with cRGD-ZW800-1 (2.42 ± 0.77) compared to mice injected with 
cRAD-ZW800-1 or ZW800-1 alone (1.21 ± 0.19 and 1.34 ± 0.19, respectively) when 
measured at 24 h aft er probe administration. Th e clearance of cRGD-ZW800-1 
permitted visualization of the ureters and also generated minimal background fl uo-
rescence in the gastrointestinal tract.
Conclusions
Th is study appears to be the fi rst to demonstrate both clear tumor demarcation and 
ureteral visualization aft er a single intravenous injection of a targeted NIR fl uoro-
phore. As a low dose of cRGD-ZW800-1 provided clear tumor identifi cation, clinical 
translation of these results should be possible.
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INTRODUCTION
In cancer surgery, positive resection margins remain one of the biggest problems, 
resulting in a high number of recurrences and poor prognosis. In contrast to the 
many imaging modalities that can be used preoperatively for diagnosis, staging, and 
surgical planning (CT, MRI, SPECT, PET), real-time, intraoperative imaging modali-
ties to assess the extent of disease and to determine adequate resection margins are 
lacking. In most cases, surgeons still have to rely only on palpation and visual inspec-
tion to discriminate between tumor tissue and normal tissue1. Since this situation has 
not been changed for many decades, there remains a need for a diagnostic tool that 
can discriminate tumor tissue from normal tissue in real time during surgery.
In addition, iatrogenic ureteral injury is a rare, but serious complication of lower 
abdominal surgery, with a reported incidence rate varying from 0.7% up to 10%2-4. 
Ureteral identifi cation can be challenging, especially in patients with previous surgery 
or infl ammation, and during minimally invasive procedures. Early identifi cation of 
ureteral damage permits direct repair and is of paramount importance to reduce 
morbidity and preservation of renal function.
Near-infrared (NIR) fl uorescence guided surgery is a novel technique that enables 
real-time visualization of tumors and vital structures (i.e. ureters) using light in the 
NIR spectrum5-7. Th e use of NIR light has the advantages of being less absorbed by 
tissue and being invisible to the human eye. Th is results in high tissue penetration 
without altering the look of the surgical fi eld. By conjugating NIR fl uorescent dyes to 
tumor specifi c ligands, intraoperative NIR fl uorescent tumor detection and demarca-
tion can be achieved. During the last decade, many tumor-specifi c ligands, such as 
antibodies, nanobodies, and peptides have been used for this purpose, all with their 
own advantages and disadvantages8-11. Furthermore, multiple fl uorescent dyes have 
been tested to optimize fl uorescent intensity, biodistribution, and clearance12-15. In 
addition, Metildi et. al. recently showed the ability to visualize sub-millimeter tumor 
deposits along the cecal wall in a patient-derived orthotopic nude mouse model us-
ing a chimeric CEA antibody and visible fl uorescence16.
Th e present study evaluates the use of a low dose fl uorescent dye ZW800-1 con-
jugated to the cyclic RGD peptide (cRGD) targeting integrin for colorectal tumor 
imaging and ureteral visualization15. RGD is a small peptide that targets integrin 
α5β1, α8β1, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and αIIbβ317-20. Integrins are cell-surface 
transmembrane heterodimeric glycoproteins that are involved in cell adhesion, 
matrix interaction, and cell signaling pathways21; integrin αvβ3 plays a key role in 
the early phase of tumor angiogenesis, tumor cell migration, and is overexpressed 
in various cancer types, including colorectal and breast cancer22. Moreover, an 
intermediate to high expression of αvβ3 is observed on the (neo)vasculature of 
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colon carcinoma in about 75% of patients with colon cancer23,24. cRGD-ZW800-1 
has recently been developed and validated by our group using in vitro and in vivo 
assays with melanoma, breast, liver and lung cancer cell lines15. In addition, recent 
preclinical studies demonstrated successful identifi cation of breast, colon, lung, ovar-
ian, and glioblastoma cancers by targeting αvβ3 integrin25-29. Furthermore, a number 
of clinical studies successfully showed integrin αvβ3 targeting using 18F-galacto-RGD 
and PET imaging in breast cancer and malignant gliomas28,30-32.
ZW800-1 is a recently developed zwitterionic fl uorescent dye which is cleared 
rapidly by the kidneys, has a high quantum yield, and was engineered for high hy-
drophilicity33. ZW800-1 has a net charge of 0 aft er conjugation to a targeting ligand 
with a net charge of -1 prior to conjugation, an absorption peak of approximately 
772 nm, and an emission peak of 788 nm in fetal bovine serum. ZW800-1 is freely 
fi ltered by the kidney and is exclusively eliminated from the body by the kidneys. 
As such, non-specifi c background signal in the intestines is low, making it valuable 
for colorectal tumor imaging, and simultaneously, ureteral visualization is enabled. 
To maximize renal clearance of the conjugate, the hydrophilic variant RGDyK was 
chosen for conjugation to ZW800-134.
Th e aim of the current study was to evaluate the ability to visualize both colorectal 
cancer and ureters using NIR fl uorescence and a single injection of cRGD-ZW800-1.
METHODS
Ethical standards and animal care
All animal experiments were approved for animal health, ethics, and research by the 
Animal Welfare Committee of Leiden University Medical Center, the Netherlands. 
All animals received humane care and maintenance in compliance with the ‘‘Code 
of Practice Use of Laboratory Animals in Cancer Research’’ (Inspectie W&V, July 
1999). All animals were housed in the animal facility of the Leiden University Medi-
cal Center. Pellet food and fresh tap water were provided ad libitum. Th e weight of 
the animals was followed throughout the experiment to monitor their general 
health state. Th roughout tumor inoculation, imaging, and surgical procedures, the 
animals were anesthetized with 5% isofl urane for induction and 2% isofl urane for 
maintenance in oxygen with a fl ow of 0.8 L/min and placed on an animal bed with 
an integrated nose mask.
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Tumor models
Subcutaneous colon tumors were induced in 6 week-old CD1-Foxn1nu female mice 
(Charles River Laboratories, Wilmington, MA, USA) weighing 25 - 35 g by subcuta-
neous injection at 4 sites with 5 x 105 HT29-luc2 cells in 40 µL RPMI1640 medium 
per site. Tumor growth was monitored longitudinally using a digital caliper and with 
bioluminescence imaging (BLI) aft er an intraperitoneal injection of 150 mg/kg of 
D-luciferin solution (SynChem, Inc., Elk Grove Village, IL) in PBS in a total volume 
of 50 µL 10 minutes prior to imaging using the IVIS Spectrum imaging system 
(Caliper LifeSciences, Hopkinton, MA, USA). In order to induce orthotopic tumors, 
subcutaneously growing HT29-luc2 colon tumors were harvested and subsequently 
transplanted onto the cecum of a healthy mouse, according to the model described 
by Tseng et al.35 (fi g. 4a). Briefl y, the cecal wall was slightly incised to facilitate tumor 
cell infi ltration and small tumor fragments (approximately 2 mm) were transplanted 
on the cecal wall using a 6-0 suture. Tumor growth was monitored using BLI.
In Vivo biodistribution and ureteral visualization
Th e ability to visualize gastrointestinal tumors in close proximity to other organs was 
investigated in nude mice bearing orthotopic HT29 tumors. As cRGD-ZW800-1 is 
cleared renally, a single intravenous injection could potentially also permit ureteral 
visualization. However, it showed to be challenging to visualize the ureter in nude 
mice weighing only 25-35 g. Th erefore, to validate in vivo biodistribution and ureteral 
visualization, cRGD-ZW800-1 was also administered to male WAG/Rij rats (Harlan, 
Horst, Th e Netherlands) weighing approximately 300–350 g.
NIR fl uorescence imaging
When tumors were measured 5 mm in diameter, the fl uorescent probe was injected. 1 
nmol cRGD-ZW800-1 (N = 3), 1 nmol cRAD-ZW800-1 (N = 3), or 1 nmol ZW800-
1 (N = 3) was injected intravenously in mice bearing subcutaneous tumors. NIR 
fl uorescent signal was measured at 0.3, 0.5, 1, 2, 4, 8, 24, and 48 h aft er injection 
using the FLARE imaging system and signal-to-background ratios were calculated. 
Subsequently, cRGD-ZW800-1 was injected at dosages of 1 and 0.25 nmol in mice 
with orthotopically transplanted cecal tumors (N = 6). To observe in vivo biodistribu-
tion and ureteral visualization, 30 nmol cRGD-ZW800-1 was injected intravenously 
in 3 Wag/Rij rats. Aft er injection, NIR fl uorescent signal of the liver, small bowel, 
colon, kidney, and bladder was measured over time. NIR fl uorescence measurements 
were performed using the FLARE imaging system as described before36.
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Histological analysis
Subcutaneous tumors were surgically removed and processed. Snap frozen tissue 
was sectioned at 6 µm and was scanned on the Odyssey Infrared Imaging System 
(LI-COR Biosciences, Lincoln, NE) using the 800 nm channel. Subsequently sections 
were stained using a hematoxylin and eosin to make an overlay.
Statistical Analysis
For statistical analysis, SPSS statistical soft ware package (Version 17.0, Chicago, 
IL) was used. To generate graphs, GraphPad Prism Soft ware (Version 5.01, La Jolla, 
CA) was used. Signal-to-background ratios (SBR) were calculated by dividing the 
fl uorescent signal of the tumor by fl uorescent signal of surrounding tissue. SBR was 
reported in mean and standard deviation. To compare SBRs between dose groups 
and time points, and to assess the relation between dose and time, a mixed model 
analysis was used. When a signifi cant diff erence was detected, a one-way ANOVA 
was used to post-test for diff erences between separate dose groups and/or time 
points. Th e one-way ANOVA was corrected using the Bonferroni correction. P < 
0.05 was considered signifi cant.
RESULTS
NIR fl uorescent probe
cRGD and cRAD were conjugated to ZW800-1 as described in the supplementary 
data (Fig. 1). Purity (> 98%) was confi rmed by analytical reversed-phase HPLC (770 
nm absorbance) and MALDI-TOF.
Intraoperative NIR Fluorescence Imaging Mice with Subcutaneous tumors
Th ree weeks aft er inoculation, mice were injected intravenously with cRGD-
ZW800-1, cRAD-ZW800-1, or ZW800-1 alone. All subcutaneous tumors of mice 
could be clearly identifi ed aft er injection of cRGD-ZW800-1 using NIR fl uorescence 
(SBR at 24 h aft er injection was 2.42 ± 0.77; Fig. 2). No adequate tumor-to-background 
ratios were observed in the control mice injected with cRAD-ZW800-1 (SBR was 
1.21 ± 0.19 at 24 h aft er injection) or ZW800-1 alone (SBR was 1.34 ± 0.19 at 24 h 
aft er injection). Using a mixed-model analysis, diff erences in SBRs between 3 study 
groups and between time points were signifi cant (P = 0.006 and P < 0.0001, respec-
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tively; Fig. 2). Post-testing using a one-way ANOVA showed signifi cant diff erences 
between the cRGD-ZW800-1 and the cRAD-ZW800-1 (P < 0.0001) study groups 
and between the cRGD-ZW800-1 and ZW800-1 alone (P < 0.0001) study groups. No 
signifi cant diff erence was found between cRAD-ZW800-1 and ZW800-1 alone (P = 
1.0). Th e highest SBRs were measured at 8 (2.33 ± 0.68) and 24 h (2.42 ± 0.77) aft er 
administration of cRGD-ZW800-1.
Histological analysis
Using the Odyssey Infrared Imaging System, clear diff erences were observed between 
3 study groups. An increased fl uorescent signal was observed in tumors harvested 
from mice in which cRGD-ZW800-1 was injected and a weak fl uorescent signal was 
measured in tumors harvested from mice in the control groups (cRAD-ZW800-1 










































































































Figure 1 - Structure formulas and optical properties:
a: Chemical structures and formulae of cRGDyK and cRADyk before and aft er conjugation to ZW800-1. b: 
Optical property measurements of cRGD-ZW800-1 and cRAD-ZW800-1.
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Intraoperative NIR Fluorescence Imaging in Mice with Orthotopic Tumors
In 6 mice with orthotopically transplanted colon tumors, tumor growth was assessed 
using BLI (Fig. 4b). Aft er 30 days, BLI measurements showed approximately 5.0 x 
106 counts and cRGD-ZW800-1 was administered intravenously. cRGD-ZW800-1 
was administered at dosages of 1 (N = 3) and 0.25 nmol (N = 3) (Fig. 4c). In all mice, 
tumors could be adequately diff erentiated from surrounding healthy bowel tissue 
(Fig. 4c and d). Average SBR in these mice was 2.62 ± 0.17 and 1.75 ± 0.36 for the 1 
and 0.25 nmol dose groups respectively.
In vivo Biodistribution and Ureteral Visualization in Rats
To assess the potential use of cRGD-ZW800-1 for both intraoperative detection of 
gastrointestinal tumors and ureteral identifi cation, the NIRF intensity of abdominal 





P < 0.001 










































Figure 2 – In vivo NIR fl uorescence imaging of mice bearing subcutaneous tumors:
a: NIR fl uorescence imaging of mice bearing subcutaneous HT-29-Luc2 tumors 2 h aft er administration of 1 
nmol cRGD-ZW800-1 (upper row), 1 nmol RAD-ZW800-1 (middle row), and 1 nmol ZW800-1 (lower row). 
b: NIR fl uorescence imaging of the same cRGD-ZW800-1 mice 24 and 48 h aft er dye administration. Scale 
bars represent 1 cm. b: Tumor-to-background ratios over time. Plotted are the tumor-to-background ratios 
(mean, SEM) of cRGD-ZW800-1 (blue line), cRAD-ZW800-1 (yellow), and ZW800-1 alone (green). d: Signal-
to-background ratio (mean, SEM) 24 h aft er administration of 1 nmol of fl uorophore.
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cRGD-ZW800-1 intravenously, medial laparotomy was performed and signal in liver, 
small bowel, colon, kidney, and bladder was measured. Time points were 0, 0.1, 0.5, 
1, 2, 3, 4, 8, and 24 h aft er intravenous administration (fi g. 5). Average fl uorescence 
intensities (normalized arbitrary units, AU) at t = 2 hour, were: 594 (± 163), 599 (± 
65), 443 (± 169), 6172 (± 3250) and 21714 (± 2102) for the liver, small bowel, colon, 
kidney, and bladder respectively. Figure 5a shows an example in which the ureters 
could clearly be visualized, 30 minutes aft er injection of cRGD-ZW800-1.
Figure 3 – Fluorescence microscopy:
Shown are hematoxylin and eosin (H&E) staining (left  column) with a pseudo-colored green NIR fl uorescence 
overlay (Odyssey, right column) of a 5 μm tissue section of a subcutaneously growing colon tumor using a 5 
X objective. A high fl uorescent signal was observed aft er cRGD-ZW800-1 administration using the Odyssey 
compared to cRAD-ZW800-1 and ZW800-1. Scale bars represent 500 μm.
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DISCUSSION
Th e present study reports the use of a ligand (cRGD) conjugated to ZW800-1 that 
targets integrins in low dosage range for NIR fl uorescence imaging during surgery. 
cRGD-ZW800-1 was successfully used in both subcutaneous and orthotopic mouse 
models to identify malignant cells. Because contrast agents can accumulate in tu-
mors via enhanced permeability and retention (EPR)37-41, 2 negative control groups 
(cRAD-ZW800-1 and ZW800-1 alone) were included to confi rm specifi city of the 
fl uorescent signal in tumors.
With regards to an oncologic resection, in which all tumor cells need to be resected, 
a specifi c NIR fl uorescent signal is vital. We aimed to develop a fl uorescent agent with 
a low non-specifi c tumor accumulation component and high specifi c targeting. Choi 
et al. recently published the use of the targeted zwitterionic near-infrared fl uoro-




Figure 4 – Intraoperative imaging of orthotopic colon tumors:
a: Schematic overview of the induction of an orthotopic tumor model. Subcutaneously growing HT29-luc2 
colon tumors were resected and transplanted onto the cecum of a healthy mouse. b: tumor growth monitoring 
using noninvasive bioluminescence imaging. c: Shown are 2 examples of cRGD-ZW800-1 administered intra-
venously, which allowed clear tumor identifi cation using NIR fl uorescence in orthotopic colon tumor bearing 
mice. cRGD-ZW800-1 was injected at dosages of 1 nmol and 0.25 nmol. Scale bars represent 1 cm. d: H&E and 
fl uorescence overlay of the border between tumor and normal colon tissue.
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It was shown that cRGD-ZW800-1 outperformed the commercially available dyes 
in vitro for immunocytometry, histopathology and immunoblotting and in vivo for 
image-guided surgery. However, as this was not the design of the study, no negative 
controls were used in in vivo image-guided surgery models. Th erefore, the current 
study aimed to test the specifi city of cRGD-ZW800-1. Mice injected with cRAD-
ZW800-1 or ZW800-1 alone showed no tumor signal both during in vivo imaging 
using the FLARE imaging system and ex vivo imaging using the Odyssey imaging 
system. Since cRGD-ZW800-1 and cRAD-ZW800-1 are comparable with regards to 
size, charge, and solubility, it can be stated that it’s highly probable that the cRGD-
ZW800-1 signal is specifi c.
Imaging in the peritoneal cavity can be challenging, mostly due to high levels of 
background fl uorescence when tracers are cleared by the liver. In this study, high 
tumor-to-background ratios were observed in the orthotopic tumor model due to the 
low hepatic clearance and the resulting low fl uorescent signal in the gastrointestinal 
tract.
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Figure 5 – In vivo biodistribution and ureteral visualization in rats:
a: Both ureters (arrowheads) could clearly be observed aft er injection of cRGD-ZW800-1 using NIR fl uores-
cence imaging. b: Fluorescence intensity of abdominal organs was measured using the Mini-FLARE camera 
system in 3 rats at several time points. c: Signal-to-background ratio of both kidney and ureter is shown over 
time. Based on these curves the ideal window for ureter visualization appears to lie between 10 min and 8 h. 
Bars represent mean ± SEM.
32 Chapter 2
Since cRGD-ZW800-1 is cleared renally, it permits ureteral visualisation in ad-
dition to tumor imaging. Noninvasive detection of the ureters using NIR fl uores-
cence has several advantages over conventional ureteral stent placing as it can be 
used within minutes aft er dye administration during both open and laparoscopic 
surgery. Besides, placement of ureteral stents is an invasive procedure that harbors 
an increased risk of complications such as ureteral perforation, urinary tract infec-
tion, and acute renal failure. Clinical feasibility to identify the ureters using NIR 
imaging has recently been demonstrated42. Using cRGD-ZW800-1 for both tumor 
and ureter imaging during lower abdominal procedures, surgical outcome could be 
greatly improved, while reducing morbidity. Furthermore, this technique will be of 
even greater value in laparoscopic surgery as no tactile information can be used. 
To date, several laparoscopic imaging systems are commercially available, however, 
further technical developments are in progress to facilitate optimal real-time NIR 
fl uorescence guidance in relation to surgical anatomy43,44.
Since cRGD has been extensively used for clinical imaging studies45,46, toxicity and 
safety data are more available when compared to newly synthesized ligands. In these 
clinical studies, galacto-cRGD was conjugated to fl uorodeoxyglucose (18F). However, 
as cRGD (yK) is more hydrophilic compared to galacto-RGD, the cRGDyK variant 
was used in this study and will be used for clinical translation.
Another advantage of cRGD-ZW800-1 is that it permits clear tumor and ureteral 
visualization at low dosages compared to current FDA/EMA approved NIR fl uoro-
phores (ICG and Methylene blue). When the dosages used in mice and rats are con-
verted by body surface area, 0.25, 1, and 30 nmol is equivalent to a total human dose 
of 0.096, 0.39, and 1.33 mg respectively. Th ese dosages are much lower compared to 
the commonly used amounts of ICG (10-25 mg) and methylene blue (15-60 mg). In 
addition, a dose of 0.25 nmol in mice corresponds to a human equivalent dose of < 
100 µg, which is below the FDA threshold for micro-dosing and portends more rapid 
clinical translation47,48.
In conclusion, the present study reports the use of a recently developed fl uorescent 
probe with minimal background uptake in the gastrointestinal tract. cRGD-ZW800-1 
showed clear uptake in both a subcutaneous and an orthotopic colon cancer mouse 
model. Moreover, as cRGD-ZW800-1 is cleared renally, ureteral visualization is 
feasible aft er a single injection. As a low probe dose was used, clinical translation of 
these results is possible.
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Real-time intraoperative detection 
of breast cancer using near-infrared 
fl uorescence imaging and methylene blue
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Despite recent developments in preoperative breast cancer imaging, intraoperative 
localization of tumor tissue can be challenging, resulting in tumor-positive resection 
margins during breast-conserving surgery. Based on certain physicochemical simi-
larities between Technetium(99mTc)-sestamibi (MIBI), a SPECT radiodiagnostic with 
a sensitivity of 83-90% to detect breast cancer preoperatively, and the near-infrared 
(NIR) fl uorophore Methylene Blue (MB), we hypothesized that MB might detect 
breast cancer intraoperatively using NIR fl uorescence imaging.
Methods
Twenty-four patients with breast cancer, planned for surgical resection, were in-
cluded. Patients were divided in 2 administration groups, which diff ered with respect 
to the timing of MB administration. N = 12 patients per group were administered 1.0 
mg/kg MB intravenously either immediately or 3 h before surgery. Th e mini-FLARE 
imaging system was used to identify the NIR fl uorescent signal during surgery and 
on post-resected specimens transferred to the pathology department. Results were 
confi rmed by NIR fl uorescence microscopy.
Results
20/24 (83%) of breast tumors (carcinoma in N=21 and ductal carcinoma in situ in 
N=3) were identifi ed in the resected specimen using NIR fl uorescence imaging. Pa-
tients with non-detectable tumors were signifi cantly older. No signifi cant relation to 
receptor status or tumor grade was seen. Overall tumor-to-background ratio (TBR) 
was 2.4 ± 0.8. Th ere was no signifi cant diff erence between TBR and background sig-
nal between administration groups. In 2/4 patients with positive resection margins, 
breast cancer tissue identifi ed in the wound bed during surgery would have changed 
surgical management. Histology confi rmed the concordance of fl uorescence signal 
and tumor tissue.
Conclusions
Th is feasibility study demonstrated an overall breast cancer identifi cation rate us-
ing MB of 83%, with real-time intraoperative guidance having the potential to alter 
patient management.
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INTRODUCTION
Breast cancer is the most common malignancy in women worldwide and is a leading 
cause of cancer-related mortality1. More than 1.2 million cases are diagnosed every 
year, aff ecting 10–12% of the female population and accounting for 500,000 deaths 
per year worldwide.
In early breast cancer, breast-conserving surgery (BCS) is the preferred standard 
of care. Despite preoperative imaging modalities such as CT and MRI, intraoperative 
identifi cation of breast cancer tissue can be challenging. Previous studies reported that 
the incidence of tumor cells at or near the cut edge of the surgical specimen ranged 
from 5% to 82%, with the majority of studies indicating positive resection margins 
in 20% to 40% of patients aft er resection of the primary tumor2. Positive margins 
may lead to additional surgical procedures, delays in adjuvant treatment, increased 
morbidity, poor aesthetic results, and increased healthcare costs. Th erefore, there is 
an urgent need for new technology to identify breast cancer tissue intraoperatively.
Technetium(99mTc)-sestamibi (MIBI) is a lipophilic cation used for preoperative, 
non-invasive identifi cation of malignant tissue via SPECT imaging3. Using 99mTc-MI-
BI, preoperative identifi cation of breast cancer is possible in approximately 83-90% 
of patients3-5. Based on the lipophilic, cationic structure of Methylene Blue (MB), 
and the fact that like 99mTc-MIBI, MB can function as a perfusion tracer in vivo6,7, we 
hypothesized that it too might be able to detect breast tumors. Importantly, MB is a 
clinically available tracer that can be used at relatively low dose (0.5-1 mg/kg) as a 
fl uorescent tracer during NIR fl uorescence imaging. NIR fl uorescence imaging is a 
promising technique to assist in the intraoperative identifi cation of sentinel lymph 
nodes, tumors, and vital structures8.
During 99mTc-MIBI SPECT imaging, early (within 30 min aft er tracer administra-
tion) and delayed (3 h post tracer administration) imaging is performed in succes-
sion5,9. Th e reason for this is to diff erentiate more accurately between malignant and 
benign lesions because it is presumed that tracer uptake in malignant lesions might 
persist, whereas clearance from benign lesions would be more rapid. Delayed imag-
ing could thereby result in higher tumor-to-background ratios (TBR) from lower 
background signal.
Th e aim of this study was to determine the feasibility of using MB as a NIR fl uo-
rescent tracer for the identifi cation of breast tumor intraoperatively, and to compare 




Breast cancer patients planning to undergo breast surgery were eligible for par-
ticipation in the trial. Patients planned for either breast conserving surgery (BCS) or 
modifi ed radical mastectomy (MRM) were included. Consent was performed at the 
department of Surgery. Exclusion criteria were pregnancy or lactation, and various 
contraindications to MB including the use of serotonin reuptake inhibitors, serotonin 
and noradrenalin reuptake inhibitors and/or tricyclic antidepressants, severe renal 
failure, a G6PD-defi ciency or a known allergy to MB. All patients gave informed 
consent and were anonymized.
Clinical Trial
Th is clinical trial was approved by the Medical Ethics Committee of the Leiden Uni-
versity Medical Center and was performed in accordance with the ethical standards 
of the Helsinki Declaration of 1975.
Patients were divided in 2 administration groups, which diff ered with respect to the 
timing of MB administration. 12 patients per group were administered 1.0 mg/kg MB 
intravenously over 5 minutes either immediately before surgery, or 3 h before surgery. 
Distribution between groups was based on the logistics of the operating room time 
on a particular day. Patients scheduled to be fi rst on the day’s surgical program were 
administered MB immediately before surgery (early imaging). Patients scheduled 
later in the day were administered MB 3 hours before surgery (delayed imaging).
Th e mini-FLARE imaging system was used to identify the fl uorescent signal dur-
ing surgery and on post-resected specimens transferred to the pathology department. 
During surgery images were obtained from the surgical fi eld, resected specimen, 
and wound bed aft er resection. When fl uorescent signal was observed, the operat-
ing surgeon could decide whether to resect the fl uorescent tissue or not, based on 
clinical judgment of the tissue. Th e resected specimen was sliced at the pathology 
department, where images from the bisected tumor were obtained. When possible, 
snap frozen tissue was collected for fl uorescence microscopy images.
Intraoperative Near-Infrared Imaging System (Mini-FLARE)
Imaging procedures were performed using the Mini-Fluorescence-Assisted Resec-
tion and Exploration (Mini-FLARE) image-guided surgery system, as described 
earlier10. Briefl y, the system consists of 2 wavelength isolated light sources: a “white” 
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light source, generating 26,600 lx of 400 to 650 nm light, and a “near-infrared” light 
source, generating 1.08 mW/came of ≈ 670 nm light. Color video and NIR fl uorescence 
images are simultaneously acquired and displayed in real time using custom optics 
and soft ware that separate the color video and NIR fl uorescence images. A pseudo-
colored (lime green) merged image of the color video and NIR fl uorescence images 
is also displayed. Th e imaging head is attached to a fl exible gooseneck arm, which 
permits positioning of the imaging head at extreme angles virtually anywhere over 
the surgical fi eld. For intraoperative use, the imaging head and imaging system pole 
stand are wrapped in a sterile shield and drape (Medical Technique Inc., Tucson, AZ).
Ex vivo Imaging and Fluorescence Microscopy of Resected Lesion
Aft er slicing of the resected lesion at the Pathology department, fl uorescent imaging 
was again performed with the mini-FLARE imaging system. Fluorescence micros-
copy images were obtained with the Odyssey Infrared Imaging System (LI-COR, 
USA).
Statistical Analysis
For statistical analysis, SPSS statistical soft ware package (Version 20.0, Chicago, IL) 
was used. Graphs were generated using GraphPad Prism Soft ware (Version 5.01, La 
Jolla, CA). TBRs were calculated by dividing the fl uorescent signal of the tumor by 
fl uorescent signal of surrounding tissue. Patient age and body mass index (BMI) were 
reported in median and range and TBR was reported in mean and standard devia-
tion. To compare patient characteristics, independent samples t-test and chi-square 
tests were used. To compare TBR and background signal between dose groups, 
independent samples t-test was used. P < 0.05 was considered signifi cant.
RESULTS
A total of 24 patients were included in this study. Patient and tumor characteristics 
are detailed in Table 1. Mean patient age was 60 years (range 44 - 82 years); 21 patients 
were planned for BCS, 3 patients received a MRM. Histopathological analysis showed 
14 patients with infi ltrating ductal adenocarcinoma, 4 patients with infi ltrating lobu-
lar adenocarcinoma, 3 patients with ductal carcinoma in situ, 1 patient with a primary 
mucoepidermoid carcinoma, 1 patient with a mucinous adenocarcinoma, and in 1 
patient, no tumor was found in the resected specimen even though a preoperative 
biopsy showed infi ltrating adenocarcinoma. Although patients were not assigned to 
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a specifi c administration group by randomization, groups were comparable as no 
signifi cant diff erences in patient or tumor characteristics were found (Table 1). All 
patients received preoperative ultrasound, and 9 patients also underwent preopera-
tive MRI scan.









N = 12 P
Mean Range Mean Range Mean Range
Age 60 (44-82) 59 (44-82) 60 (46-71) 0.97
Body mass index 24 (19-37) 24 (19-37) 27 (22-37) 0.16
Pathological tumor size (mm) 15 (6-33) 14 (7-27) 16 (6-33) 0.58
N % N % N %
Clinical Stage 0.22
Stage 0 3 13 3 25 0 0
Stage 1A 13 54 7 58 6 50
Stage 1B 1 4 0 0 1 9
Stage 2A 4 17 2 17 2 17
Stage 2B 2 8 0 0 2 17
Stage 3C 1 4 0 0 1 9
Type of operation 0.54
Mastectomy 3 13 1 9 2 17
Wide local excision 21 87 11 92 10 84
Histological type 0.22
Infi ltrating ductal type adenocarcinoma 15 63 6 50 9 75
Infi ltrating lobular type adenocarcinoma 4 17 2 17 2 17
Mucinous adenocarcinoma 1 4 1 9
Primary mucoepidermoid carcinoma 1 4 1 4
Ductal carcinoma in situ 3 12 3 25
Receptor status
ER positive 19 79 8 67 11 92 0.83
PR positive 11 46 6 50 5 42 0.26
HER2/NEU positive 1 4 0 0 1 9 0.38
Triple Negative 2 8 1 9 1 9 0.95
Histological grade (Bloom-Richardon) 0.34
I 5 21 1 9 4 34
II 9 38 5 42 4 34
III 4 16 2 17 2 17
No grading possible 6 25 4 34 2 17
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In 20 out of 24 patients (83%), breast tumors (carcinoma in N=21 and ductal car-
cinoma in situ in N=3) were identifi ed in the resection specimen with NIR fl uores-
cence imaging aft er bisection in the Pathology department. Tumors were identifi ed 
as a bright fl uorescent spot in the sliced specimen (Figure 1). Table 2 shows patient 
and tumor characteristics related to detectability of the tumor. Patients with non-
detectable tumors were signifi cantly older (mean age 68 years old versus 58 years old; 
P=0.03). Both infi ltrating ductal type adenocarcinoma and infi ltrating lobular type 
adenocarcinoma were detectable. In patients with mucinous adenocarcinoma or pri-
mary mucoepidermoid carcinoma, no fl uorescent tumor was found. No signifi cant 
relation was found regarding receptor status or tumor grade.
Th e overall TBR was 2.4 ± 0.8 (Figure 2A). Th ere was no signifi cant diff erence be-
tween administration groups in TBR (2.5 ± 0.9 vs. 2.3 ± 0.5; P=0.50) or background 
signal in arbitrary units (333 ± 215 vs. 262 ± 134; P = 0.37, data not shown) in the 
sliced specimens.







Figure 1 – NIR fl uorescence imaging of a tumor resection with negative margins:
A. Resected specimen aft er wide local excision. No fl uorescent signal was seen at resection margins. B. Inspec-
tion of wound bed aft er resection. No fl uorescent signal was seen at resection margins. C. Sliced resection speci-
men at Pathology department. A clear fl uorescent spot (arrow) was seen at the location of the tumor. Tumor was 
an infi ltrating ductal adenocarcinoma, grade 2, ER+ PR+ Her2/neu-.
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Four patients (17%) were found to have positive resection margins. In case 1, 
tumor tissue was identifi ed both on the surface of the resected specimen (Figure 3A) 
and intraoperatively in the wound bed using NIR fl uorescence imaging (Figure 3B). 
Direct re-resection was performed, and histopathological analysis confi rmed that the 
fl uorescent resected tissue was tumor (data not shown). Both primary resected and 
re-resected tumor tissue was an infi ltrating lobular adenocarcinoma, grade 2, ER+ 
PR- Her2/neu -. In case 2, no fl uorescent tumor signal was seen on the surface of 
the resected specimen. In the bisected specimen, no fl uorescent signal was seen at 






Mean Range Mean Range
Age 58 (44-71) 68 (56-82)
Body mass index 26 (19-37) 24 (22-26)
Pathological tumor size (mm) 16 (6-33) 10 (7-12)
N % N %
Clinical Stage
Stage 0 2 8 1 4
Stage 1A 10 42 3 13
Stage 1B 1 4 0 0
Stage 2A 4 17 0 0
Stage 2B 2 8 0 0
Stage 3C 1 4 0 0
Histological type
Infi ltrating ductal type adenocarcinoma 14 59 1 4
Infi ltrating lobular type adenocarcinoma 4 17 0 0
Mucinous adenocarcinoma 0 0 1 4
Primary mucoepidermoid carcinoma 0 0 1 4
Ductal carcinoma in situ 2 8 1 4
Receptor status
ER positive 17 71 2 8
PR positive 9 38 2 8
HER2/NEU positive 1 4 0 0
Triple Negative 2 4 0 0
Histological grade (Bloom-Richardon)
I 4 17 1 4
II 9 37 0 0
III 3 13 1 4
No grading possible 4 17 2 8
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location of the tumor. Th is could have been because of lack of uptake or intracel-
lular conversion of MB to its leuco11, non-fl uorescing form, but either way explains 
the lack of fl uorescent signal in the tumor-positive resection margin. Tumor was 
a DCIS grade 3. In case 3, only images of the sliced specimen were available due 
to logistics, so no intraoperative fl uorescent images were available. In case 4, clear 
fl uorescent spots were identifi ed in the wound bed intraoperatively, however, the 
operating surgeon believed that they were a false positive and did not resect them. 
Histopathology, though, confi rmed positive margins at the location of the fl uorescent 
spots. Aft erwards, patient underwent a mastectomy in which the residual lobular 
infi ltrating adenocarcinoma was found near the lumpectomy cavity.
In the patients with negative resection margins, median minimal distance of 
tumor tissue to resection margin was 3 (range 1-20).
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Figure 2 – Tumor-to-Background Ratio and microscopic images of resected lesion:
A. Overall Tumor-to-Background Ratio (TBR) and TBR per administration group are shown. No diff erences 
in TBR between administration groups were observed (P = 0.50; 95% CI -0,49 – 0,96). B. Microscopic images 
of Hematoxylin and Eosin staining of the resected lesion and fl uorescent signal (Odyssey Infrared Imaging 
System, LI-COR). At the NIR fl uorescent image, fl uorescent signal is seen as white, where surrounding breast 
tissue remains black. A clear overlay between fl uorescent signal and tumor tissue was seen. Normal breast tissue 
was indicated by an asterisk (*). Tumor (indicated by arrowhead) was an infi ltrating ductal adenocarcinoma, 
grade 2, ER + PR + Her2/neu -.
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Histological validation of MB positive tumors with fl uorescence microscopy 
showed a clear overlay between fl uorescent signal and tumor tissue (Figure 2B).
Th ree patients in the early administration group experienced transient mild pain 
of the lower arm during administration of MB, which disappeared aft er fl ushing the 
intravenous cannula with saline. No other adverse reactions associated with the use 
of MB or the Mini-FLARE™ intraoperative NIR fl uorescence camera were observed.
DISCUSSION
Th e current study demonstrated feasibility of real-time identifi cation of breast cancer 
using NIR fl uorescence imaging and MB. In 83% of patients, tumor demarcation 
as identifi ed by NIR fl uorescence imaging corresponded to histological presence of 
tumor. In addition, in one case surgical management was changed based on intraop-
erative NIR fl uorescence fi ndings, which avoided the need for re-resection.
During breast cancer surgery, the distinction between healthy and malignant tissue 
is oft en not evident, resulting in positive resection margins in up to 40% of patients 
undergoing breast conserving surgery12,13. Despite major improvements in preop-
erative imaging, real-time intraoperative imaging modalities are lacking2. Th erefore, 
breast cancer surgeons oft en still have to rely on palpation and previously obtained 





Figure 3 – NIR fl uorescence imaging of a tumor resection with positive margins:
A. Resected specimen aft er wide local excision. Fluorescent signal was seen at the deep margin of the resection 
specimen, indicated by arrows. B. Inspection of wound bed aft er resection. Fluorescent signal was seen at resec-
tion margins indicated by arrows. Direct re-resection of the fl uorescent tissue was performed, which contained 
malignant tumor tissue. Tumor was an infi ltrating lobular adenocarcinoma, grade 2, ER+ PR- Her2/neu -.
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mammography or MRI to determine the extent of resection. Optical imaging using 
exogenous contrast agents could usher in a new era in surgical oncology. However, 
to successfully use this modality both a clinical-grade intraoperative fl uorescence 
imaging system and a tumor-specifi c NIR probe are obligatory. To date multiple 
camera systems have become clinically available, however FDA/EMA approved 
tumor-specifi c probes are still lacking. Th erefore, it is important to exploit clinically 
available contrast agents, such as indocyanine green and MB14 whenever possible.
Several papers have reported the intraoperative use of MB for identifi cation of 
various tumors. As early as 1971, MB was used at high concentration as a visible blue 
dye to stain parathyroid adenomas aft er systemic administration15. Th ereaft er, it was 
shown that there was a high uptake of the tracer in various kinds of neuroendocrine 
tumors16-18. One of the disadvantages of using MB is that the high dose (7.5 mg/kg) 
used in these prior studies, which was needed for visualization of the blue colored 
dye the human eye, brings substantial risk of serious adverse events, such as toxic 
metabolic encephalopathy19.
NIR fl uorescence imaging permits visualization of MB at low concentration 
because MB fl uoresces at 700 nm. In transgenic mice, Winer et al20 showed intraop-
erative identifi cation of insulinoma, a pancreatic neuroendocrine tumor, using NIR 
fl uorescence imaging and MB. In a clinical setting, this technique has been used for 
the intraoperative identifi cation of parathyroid adenomas and a solitary fi brous tu-
mor of the pancreas21,22. In these prior studies, a dose of only 0.5 - 0.1 mg/kg MB was 
used, which resulted in clear fl uorescent signal in the identifi ed lesions. Although 
we did not explore dose in this feasibility study, our results suggest that a formal 
study of dose, which includes higher doses than 1.0 mg/kg, is warranted. Such a study 
could answer defi nitively if the 17% of tumors that were not identifi ed using MB were 
because the dose was too low.
Th e exact mechanism of tracer uptake in these tumors is unclear. Th e physico-
chemical similarities of MB and 99mTc-MIBI, both lipophilic and cationic, suggest a 
possible common mechanism. Lipophilic captions were originally developed as myo-
cardial perfusion agents, and subsequently used as tumor-seeking agents in a variety 
of tumors23. Th ey emerged as suitable tools to explore specifi c cellular processes and 
functions in malignant tumors. In several studies, it was shown that lipophilic cations 
show passive infl ux into cells with large negative plasma membrane and mitochon-
drial membrane potentials23,24, with infl ux being reversible. Cellular processes that 
are associated with uptake of these tracers are apoptosis, proliferation, P-glycoprotein 
expression, and neoangiogenesis. However, it has to be further explored whether any 
of these mechanisms result in MB accumulation in breast cancer tissue.
Using 99mTc-MIBI, a breast tumor identifi cation rate of 83-90% has been reported. 
Although our present study was small (N = 24 subjects), our identifi cation rate is 
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in agreement with the sensitivity of 99mTc-MIBI described in the literature. Based 
on clinical experience with 99mTc-MIBI in breast cancer, early and delayed imaging 
is used to discriminate between malignant and benign lesions, as tracer accumula-
tion is prolonged in malignant lesions. Th is is in contrary to MR imaging of breast 
malignancies, where malignant lesions tends to enhance but also washout quicker 
than benign lesions25. Th is is caused by endothelial fenestration in microvasculature, 
which leads to increased capillary leakage, and connections between the arteriolar 
and venular systems (arteriovenous shunting), which leads to less perfusion of the 
capillary bed. Complicating the understanding of mechanism even further is the fact 
that MB can be converted to a non-fl uorescent leuco form under certain intracellular 
redox and pH conditions11. Because the exact mechanism of 99mTc-MIBI and MB 
uptake in breast tumors is still unclear, future studies have to be done regarding this 
eff ect. In the present study, though, no diff erence was seen between diff erent admin-
istration groups in TBR and background signal, suggesting that the more convenient 
early imaging protocol could be used in future studies.
As NIR fl uorescence imaging is a surface technology (≈ 5 mm penetration depth), 
it is important to understand its capabilities and limitations. To date, research and de-
velopment of new imaging modalities for oncology mainly focus on the detection of 
small tumor deposits in the human body. In breast cancer, these small tumor deposits 
can change surgical decision making, but do not provide such prognostic relevance in 
breast conserving surgery, as postoperative radiation eliminates microscopic tumor 
deposits in most cases26. For example, the rate of small tumor deposits is 2 to 3 times 
higher than the incidence of local recurrence using preoperative MR imaging, result-
ing in mastectomies that may not be benefi cial to patient survival27. On the other 
hand, adequate visualization of tumor margins intraoperatively would be benefi cial 
to lower the number of R1 resections and to avoid the need for re-resections and 
radiotherapeutic boost therapy28. Using intraoperative NIR fl uorescence imaging, it 
is not possible to image the whole breast for small tumor deposits due to the limited 
penetration depth. However, the optical properties of NIR fl uorescence are very well 
suited for the visualization of possible residual tumor cells at the resection margin. 
Additionally, NIR fl uorescence has an exceptionally high spatial resolution compared 
to conventional imaging techniques.
To benefi t from the full potential for NIR fl uorescence imaging several factors 
are of paramount importance and need to be optimized: 1) the concentration of the 
NIR fl uorophore in the target tissue, 2) minimizing photon absorption and scattering 
in the tissue, 3) maximizing excitation power of NIR excitation without inducing 
photobleaching or photo damage to tissue, and 4) the sensitivity of the CCD chip on 
the detector. Methylene blue becomes a moderate-strength fl uorophore when used at 
low concentrations, with an excitation maximum of 670 nm. Contrast agents with an 
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emission peak of ≈700 nm have several limitations compared to 800 nm fl uorophores 
with respect to quantum yield, penetration depth, and autofl uorescence. It is hoped 
that new tumor-specifi c “800 nm” contrast agents will become widely available dur-
ing the next few years, although MB could fi ll the gap in the meantime. Improved 
laser or LED light sources and cameras are under constant development to overcome 
the imaging system associated factors.
Another important consideration is extraneous NIR fl uorescence generated from 
other drugs in the surgical fi eld. During this study we found that Patent Blue, used 
for sentinel lymph node mapping, exhibited a weak NIR fl uorescence at 700 nm 
that could confound the MB results (data not shown). Because we have previously 
demonstrated that blue dye can be omitted from sentinel lymph node mapping when 
indocyanine green (ICG) is used29], and the FLARE imaging system is capable of 
imaging 2 independent channels of NIR fl uorescence, e.g., NIR Channel 1 for MB-
guided breast cancer resection and NIR Channel 2 for ICG-guided sentinel lymph 
node mapping, it should be possible to eliminate Patent Blue from future protocols 
and thus eliminate this potential confounder.
Th e primary endpoint of this study was the identifi cation ratio of breast cancer 
using NIR fl uorescence and MB and optimization of injection timing. As it was the 
fi rst feasibility study with MB in breast cancer, no outcomes data were collected to 
correlate with intraoperative NIR fl uorescence fi ndings. Th erefore, is not possible 
to draw conclusions on the prognostic relevance of the technology, although one 
might ponder that true negative MB uptake selected for tumors of low perfusion and 
relatively low metastatic potential. Th ereby only one patient directly benefi tted from 
this technique with respect to direct resection of residual tumor tissue due to the 
reasons mentioned above. Future studies will need to address this and other remain-
ing questions.
In conclusion, this is the fi rst study to demonstrate the use of low dose MB for 
the real-time identifi cation of breast cancer using NIR fl uorescence and MB. No dif-
ference was seen between diff erent administration groups in TBR and background 
signal, suggesting that the more convenient early imaging protocol could be used in 
future studies. Although larger studies are necessary to determine patient benefi t, 
results with MB are promising and improved contrast agents will likely become avail-
able in the future.
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Image-guided hepatopancreatobiliary 
surgery using near-infrared fl uorescent 
light
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Improved imaging methods and surgical techniques have created a new era in 
hepatopancreatobiliary (HPB) surgery. Despite these developments, visual inspec-
tion, palpation, and intraoperative ultrasound remain the most utilized tools 
during surgery today. Th is is problematic, though, especially in laparoscopic HPB 
surgery, where palpation is not possible. Optical imaging using near-infrared (NIR) 
fl uorescence can be used for the real-time assessment of both anatomy (e.g., sensi-
tive detection and demarcation of tumours and vital structures) and function (e.g., 
assessment of luminal fl ow and tissue perfusion) during both open and minimally 
invasive surgeries.
Methods
Th is article reviews the published literature related to preclinical development and 
clinical applications of NIR fl uorescence imaging during HPB surgery.
Results
NIR fl uorescence imaging combines the use of otherwise invisible NIR fl uorescent 
contrast agents and specially designed camera systems, which are capable of detect-
ing these contrast agents during surgery. Unlike visible light, NIR fl uorescent light 
can penetrate several millimetres through blood and living tissue, thus providing 
improved detectability. Applications of this technique during HPB surgery include 
tumour imaging in liver and pancreas, and real-time imaging of the biliary tree.
Conclusions
NIR fl uorescence imaging is a promising new technique that may someday improve 
surgical accuracy and lower complications.
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INTRODUCTION
Over the last few decades, imaging technologies such as ultrasonography (US), com-
puted tomography (CT), magnetic resonance imaging (MRI), and positron emission 
tomography (PET) have become indispensable tools for preoperative planning in he-
patopancreatobiliary (HPB) surgical procedures1. However, translating preoperative 
images to the surgical theatre still remains a major challenge. During HPB surgery, 
the surgeon mainly has to rely on visual inspection and palpation to discriminate 
between vital anatomical structures and, in case of a malignancy, between tumour 
and healthy tissue. Although in some cases intraoperative imaging modalities such as 
ultrasound or cholangiography can be applied1,2, irradical (R1) oncologic resections 
and iatrogenic surgical trauma are still major issues in HPB surgery.
Intraoperative imaging using near-infrared (NIR) fl uorescence light is a novel 
technique that can provide real-time visualisation of tumour tissue and vital anatomi-
cal structures. It can also exploit physiological clearance of exogenous fl uorescence 
contrast agents by the liver and biliary system to provide functional images of these 
structures. Th is makes NIR fl uorescence imaging especially suitable for intraopera-
tive imaging during HPB surgery.
Th is review describes the development, current applications, and future prospects 
of NIR fl uorescence imaging for HPB surgery.
Near-infrared fl uorescence imaging
For intraoperative imaging, NIR fl uorescent light has several advantages. Th e wave-
length of NIR fl uorescence lies between 700 to 900 nanometres, which is invisible to 
humans, and therefore does not alter the look of the surgical fi eld. Further advantages 
of NIR light include high tissue penetration (up to 5 mm) and low autofl uorescence. 
NIR fl uorescence imaging is an inherently safe technique, as there is no ionizing 
radiation and no direct tissue contact. Image acquisition occurs within a few mil-
liseconds, which allows the surgeon to operate under real-time image guidance. Th e 
introduction of minimally invasive techniques has increased the need for additional 
intraoperative imaging modalities. For example, NIR fl uorescence imaging has been 
used to optimize sentinel lymph node dissection during robot-assisted laparoscopic 
surgery3.
Several intraoperative NIR fl uorescence camera systems have been developed for 
both open and laparoscopic surgery, some of which are commercially available. A 
description of the capacities of each of these systems is beyond the scope of this 
review, but is summarized by Gioux et al4. State-of-the-art cameras can acquire a 
real-time overlay of the NIR channel with a normal colour channel4-6. Th is utility 
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facilitates the surgeon with anatomical orientation within the surgical fi eld, which is 
combined with the NIR fl uorescent signal to allow image-guided surgery.
NIR fl uorescent contrast agents
In addition to an appropriate camera system, a NIR fl uorescent contrast agent is also 
needed to visualise specifi c structures intended to be resected (e.g. tumour tissue) 
or to be spared (e.g. bile ducts). Such contrast agents contain a fl uorescent moiety, 
which emits NIR fl uorescent light aft er being excited with a NIR light source; and 
depending on the application, a targeting ligand that directs the fl uorophore to the 
structure under study. Visualization of the tissue is based on the signal of the contrast 
agent in the region of interest relative to the background signal, known as signal-to-
background ratio (SBR).
Indocyanine green (ICG) and methylene blue (MB) are the only NIR fl uorophores 
that are registered with the Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for clinical use, albeit for other indications. ICG has been 
registered for several decades to measure cardiac output, hepatic function, and 
ophthalmic perfusion. ICG emits fl uorescent light at ≈ 800 nm, a property that has 
allowed its use in clinical NIR fl uorescence imaging studies7. ICG is safe to use, as 
complications following administration are rare8,9. For intraoperative imaging, ICG 
dose generally lies between 1 and 10 mg, but intravenous injection up to 25 mg has 
been reported to be safe7. Circulating ICG is cleared rapidly by the liver and almost 
exclusively excreted into the bile.
MB has been used for over 120 years for several medical applications10. It is used 
to treat sepsis and has been used at high dosages (>7.5 mg/kg) as a visible blue dye 
to stain the parathyroid glands during surgery10-13. When diluted to levels that are 
almost undetectable to the human eye, MB becomes a fl uorophore emitting at ≈ 
700 nm14. Th is phenomenon is known as “unquenching”4. At high dye concentra-
tion, fl uorescence emission from MB is reabsorbed intermolecularly. When diluted, 
fl uorescence emission becomes unquenched. At lower concentration, MB has a more 
favourable toxicity profi le, although when used at high dosages ( > 7.5 mg/kg) seri-
ous adverse reactions have been reported, particularly in patients taking serotonin 
reuptake inhibitors (SSRI’s)15. MB is cleared equally by both the liver and kidney, 
permitting imaging of both bile ducts and ureters16,17.
Th e chemical structures of both ICG and MB do not allow these agents to be con-
jugated to tissue-specifi c ligands. As such, they are nonspecifi c NIR contrast agents. 
To permit targeted imaging, such as tumour imaging, novel NIR fl uorescent probes 
are being developed, as recently reviewed by Luo et al.18. Th ese fl uorophores can be 
conjugated to a tumour-specifi c ligand to target tumour cells19. For instance, they 
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can be conjugated to tumour-specifi c antibodies20, nanobodies21, small peptides,20 
or they can be activated by enzymatic cleavage in order to become fl uorescent22. A 
major drawback in the development of new NIR fl uorescence contrast agents is that 
each fl uorophore-target conjugate needs separate regulatory approval, which is an 
expensive and time-consuming process.
Th e following section of this review will focus on the diff erent applications of NIR 
fl uorescence imaging during HPB surgery.
Tumour imaging
Liver cancer and colorectal metastases
Liver cancer accounted for an estimated 748,300 new cases and 695,900 cancer 
deaths worldwide in 200823. Colorectal cancer is the second cause of cancer death 
worldwide24 and the survival of colorectal carcinoma patients mainly depends on the 
occurrence of distant metastases, which occur most frequently in the liver. Improve-
ments in surgical techniques, preoperative imaging, and neoadjuvant chemotherapy 
have led to an increase in the percentage of patients eligible for resection of liver 
tumours. For intraoperative identifi cation of liver tumours, visual inspection, palpa-
tion, and intraoperative ultrasound (IOUS) are used routinely. Still, recurrence rates 
of colorectal liver metastases (CLM) vary between 11% to 37.5%, of which 65% to 
85% appear within 2 years following surgery25-29. A possible explanation for this high 
recurrence rate is the presence of small malignant lesions that are missed by current 
preoperative and intraoperative detection methods.
NIR fl uorescence imaging using ICG is a promising technique to assist in the 
identifi cation of primary liver tumours and CLM30-36 during surgery. Due to the 
hampered visibility and inability to palpate the liver surface during laparoscopy, 
NIR fl uorescence imaging could also be of great value during minimally invasive 
liver surgery. It has been shown that ICG passively accumulates in hepatocellular 
carcinomas (HCC) and in a rim around CLM when intravenously administered 1 
to 14 days before surgery30 (fi gure 1 also shows an example of this phenomenon). 
However, it is important to realise that accumulation of ICG in liver tumours is based 
the pharmacokinetic clearance of ICG and is therefore most likely subject to liver 
perfusion, ICG clearance and bile drainage.
Several clinical studies describe the use of NIR fl uorescence imaging to visualise 
HCC (Table 1)31,32,34,37. In these studies combined, a total 32 patients were included. In 
all patients 0.5-mg/kg ICG was administered intravenously 1 to 8 days before surgery. 
All superfi cially located tumours could be clearly identifi ed using NIR fl uorescence. 
However, due to the limited penetration depth tumours located deeper than ap-
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proximately 5 mm under the liver capsule could only be identifi ed aft er resection 
and sectioning. Importantly, Gotoh et al. reported identifi cation of additional occult 
HCC nodules in 4 out of 10 cases that were not detected by use of any preoperative 
examinations32. However, Ishizawa et al. reported in a group of 63 HCCs 5 false posi-
tive nodules30. Th e fi rst successful case of liver tumour imaging during laparoscopic 
surgery in a patient suff ering from a HCC was recently reported (Figure 2)31.
A number of clinical studies have described the use of ICG for visualization of CLM 
(Table 1). Th ese studies combined included a total of 68 patients30,33,35,36. Ishizawa et 
al. described demarcation of both HCC and CLM using intravenous administration 
of ICG30. With intraoperative imaging, 21 of the 41 HCCs were detected and all 
CLM (which were all superfi cially located). Aft er resection and sectioning, all liver 
tumours could be identifi ed by both gross examination and fl uorescence imaging, 
resulting in a sensitivity and positive predictive value of 100% of this technique on 
surgical specimens ex vivo. ICG (0.5 mg/kg) was injected ranging from 1 to 14 days 
prior to surgery. Th e macroscopically confi rmed CLM metastases were identifi ed by 
a rim fl uorescent pattern surrounding the lesion. It was hypothesized that this could 
be due to compromised biliary excretion by the surrounding noncancerous liver tis-
sues, which are compressed by the tumour. It has also been reported that in patients 
with a poor ICG retention rate (i.e. decreased clearance function of the liver), the 
fl uorescence signal of the noncancerous liver parenchyma was higher. Th is makes it 
more challenging to obtain an adequate tumour to liver contrast, in particular in case 
of cirrosis, steatosis or chemotherapy pretreatment.
Colour NIR Fluorescence Colour-NIR Merge 
In vivo 




Figure 1 – NIR fl uorescence imaging of colorectal liver metastases:
A colorectal liver metastasis (arrow) is clearly identifi ed by a NIR fl uorescent rim around the tumour in vivo 
(top row), 24 h aft er injection of 10-mg ICG. Normal liver tissue (arrowhead) shows minimal retention ICG. Af-
ter resection and slicing of the specimen, the rim around the tumour is better visualized ex vivo (bottom row).

































































































































































































































































































































































































































































































































































































































































































































Uchiyama et al. showed similar results in 32 CLM patients33. Th e use of intraop-
erative ultrasound in combination with NIR fl uorescence improved the diagnostic 
sensitivity compared to the use of CT and MRI from 46/52 (88.5%) to 51/52 metas-
tases (98.1%, P = 0.050). With the use of NIR fl uorescence, 2 additional malignant 
lesions could be identifi ed that otherwise would have been missed. Van der Vorst 
et al. performed a NIR fl uorescence study for the identifi cation of CLM metastases 
using ICG in 22 consecutive patients (manuscript under review) and found similar 
results; additionally, Van der Vorst et al. optimized ICG dosing and timing.
Another study investigated the potential of this technique to detect small he-
patic metastases in pancreatic cancer patients. Consecutive patients (n = 49) with 
pancreatic cancer who were eligible for surgical resection with curative intent were 
Figure 2 – Laparoscopic NIR fl uorescence imaging of a hepatocellular carcinoma:
(a) Colour image (left ) and fl uorescent image (right) of the visceral surface of the left  liver before mobilization. 
Fluorescent imaging clearly delineated the hepatocellular carcinoma located in segment II, with the surround-
ing structures. (b) Th e left  liver was fully mobilized and the lesser omentum was sectioned, using NIR fl uores-
cence imaging to confi rm the appropriateness of the resection margin of the tumour. Adapted from Ishizawa et 
al. (2010) 31 and reprinted with permission from John Wiley & Sons, Inc.
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examined. In these patients, no hepatic tumours were identifi ed on either preopera-
tive imaging, intraoperative inspection, or US. Following injection of 25-mg ICG38, 
NIR fl uorescence imaging detected abnormal hepatic lesions in 13 patients. In 8 out 
of 13 lesions, micrometastases were found (8 out of 49 included patients: 16%). Th is 
suggests that NIR fl uorescence imaging has the potential to detect hepatic pancre-
atic cancer micrometastases that were not found using currently existing imaging 
techniques, and could help surgeons select patients for either curative or palliative 
surgery.
It has also been demonstrated that NIR fl uorescence imaging can be used to 
identify hepatic segments and subsegments for anatomical hepatic resection39. Aoki 
et al. performed a study in 35 patients with malignant liver disease who underwent 
hepatectomy. ICG (5mg) was administered into the portal vein branch, and subse-
quently, NIR images were obtained. Stained subsegments and segments of the liver 
were identifi ed in 33 of the 35 patients. Th e procedure was unsuccessful in 2 patients; 
however this was probably due to diffi  culties with ICG administration. Segmental 
mapping with NIR fl uorescence seems a promising technique to assist the surgeon 
during anatomic resections of the liver. Uchiyama et al. combined intraoperative 
fl uorescent imaging with contrast-enhanced ultrasonography in 22 patients for 
intraoperative liver resection40. Following portal pedicle ligation, 0.5 mg/kg ICG was 
injected intravenously. Subsequently the negative-brightness area of the liver without 
blood fl ow was detected on the liver surface using the PDE system. Demarcation 
line of the liver surface aft er the portal pedicle ligation was apparent in 17 patients; 
however the resection line using PDE was clearly detected in all patients. Segmental 
mapping with NIR fl uorescence seems a promising technique to assist the surgeon 
during anatomic resections of the liver.
Preoperative administration of ICG was also used to visualise cholestatic liver 
parenchyma during surgery35. In a pilot study, 2 patients diagnosed with intrahe-
patic cholangiocarcinoma and 1 patient with CLM metastases and a suspected bile 
duct thrombus were included. NIR fl uorescent imaging could clearly demarcate the 
cholestatic regions on the surface of the liver caused by bile duct tumour invasion 
or thrombi in all 3 patients35. One study reported the use of percutaneous injection 
of ICG mixed with ethanol (dilution: 1:100) for hepatic tumour resection36. De-
marcation of the target area with ICG-ethanol using real-time virtual sonography 
and fl uorescence based resection was successful in 1 patient. Th e technique could 
potentially be helpful for resection of hepatic tumours which cannot be identifi ed by 
routine ultrasonography.
Several preclinical studies assessed the use of NIR probes for intraoperative detec-
tion of liver tumours. To optimize dose and timing of ICG for detection of CLM, 
van der Vorst et al. performed a preclinical study in 18 rats bearing CLM. Th is study 
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reported that the optimal timing of ICG administration was 72 h before surgery and 
that the optimal dose was 0.25-mg/kg ICG41. Tumour-to-liver ratios of approximately 
3 were reported in this study. In an attempt to improve tumour-to-liver ratios, NIR 
fl uorescence imaging using lactosome nanocarriers labelled with ICG in a hepa-
tocellular carcinoma (HCC) bearing mouse model was performed42. Th e ability to 
visualize liver tumours was based on the enhanced permeation and retention (EPR) 
eff ect of the lactosome. EPR is caused by leaky blood vessels and hampered lymphatic 
drainage in the tumour43,44. Tumour targeted NIR fl uorescence imaging of CLM was 
shown in an orthotopic rat model using an integrin αvβ3 targeting NIR probe. Inte-
grin αvβ3 plays a key role in tumour angiogenesis, tumour cell migration and is over 
expressed in various cancer types45. All CLM could be clearly visualized and clinically 
relevant tumour-to-liver ratios of approximately 2 were reported in this study20.
In conclusion, several studies showed that NIR fl uorescence imaging is feasible for 
liver tumour imaging and segmental demarcation. Due to passive accumulation of 
ICG, superfi cial liver metastases can be identifi ed with high sensitivity. A pitfall of 
this technique is the limited tissue penetration of NIR light, which is approximately 
5 mm. Th is can be problematic for tumours located deeper beneath the liver capsule. 
Nevertheless, this technique could be of great value for the detection of small super-
fi cial lesions, and newer optical techniques are being developed to interrogate 1 cm 
or more.
Pancreatic tumours
Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death in the 
Western world46. Th e overall 5-year survival rate is less than 5%, showing no substan-
tial improvement over the past 30 years46. Th e main prognostic factor in pancreatic 
cancer patients that are eligible for resection is the involvement of tumour-positive 
resection margins. Reported median survival rates aft er a R0 resection for pancreatic 
adenocarcinoma are twice as high as compared to a R1 resection47. Irradical resec-
tion of pancreatic cancers still occurs in 34.7% to 42% of patients48-50. Advances in 
preoperative imaging modalities have improved the ability to estimate respectability 
and to diff erentiate pancreatic carcinoma from other pancreatic diseases51. However, 
as mentioned before, translating these images to the operating room remains chal-
lenging.
NIR fl uorescence imaging off ers new opportunities for intraoperative pancreatic 
tumour visualization. Th us far, only 1 clinical study has attempted to visualize pan-
creatic tumours using this technique. Based on previous studies that showed that 
solid tumour accumulation is achievable using a nontargeted probe based on EPR 
eff ect, Hutteman et al. attempted to use this concept for pancreatic cancer imaging 
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with ICG. However, the results were disappointing52. Aft er intravenous injection 
of ICG, a pancreatic tumour could be visualized in only 1 of 8 patients. Th is could 
possibly be explained by the lower perfusion of adenocarcinomas of pancreas in 
comparison with healthy pancreatic tissue, which might decrease availability of ICG 
for a potential EPR eff ect of the tumour53,54.
Several preclinical studies have shown adequate tumour identifi cation in diff erent 
pancreatic tumour animal models using NIR fl uorescence. Von Bursin et al. showed 
the use of a tumour targeted protease activatable NIR probe to obtain tumour iden-
tifi cation in a mouse model of early-stage pancreatic cancer55. Using this technique 
it was possible to discriminate between normal pancreatic tissue, infl ammation, and 
early-stage malignancy. Tran Cao et al. described successful fl uorescence laparoscopy 
to image green fl uorescent protein (GFP)-expressing tumours in an orthotopic mouse 
model of human pancreatic adenocarcinoma using a GFP-specifi c NIR fl uorescent 
probe. Th ey argued that fl uorescence laparoscopy of tumours labelled with GFP or 
fl uorescent antibodies could be used for diagnosis and staging of pancreatic cancer 
in the future56.
NIR fl uorescence imaging of neuroendocrine pancreatic tumours have also been 
investigated in animal models. Winer et al. showed the ability to clearly visualise 
pancreatic insulinomas using MB57. Intravenous administration of MB permitted 
high-sensitivity, real-time localization of primary, multicentric, and metastatic in-
sulinoma and permitted diff erentiation among tumour, normal pancreas, and other 
abdominal structures. At doses > 1 mg/kg, high signal-to-background ratios up to 3 
were observed for up to 1 h aft er administration57. MB is a phenothiazine derivative 
that acts as a perfusion tracer. As such, it is likely that hypervascular tumours, such 
as insulinomas can be visualised using MB, although the complete mechanism of this 
phenomenon still remains unclear.
In conclusion, although the identifi cation of pancreatic tumours was successful in 
preclinical models, clinical NIR fl uorescence imaging of these tumours is still to be 




During laparoscopic cholecystectomy, common bile duct (CBD) injury is a rare but 
severe complication with a postoperative mortality of 11%58. It has been stated that 
intraoperative cholangiography can reduce the risk of CBD injury from 0.58% to 
0.39%58. However, recent literature questions the advantage of routine cholangiog-
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raphy59. Futhermore, intraoperative cholangiography is time consuming and the 
introduction of a catheter into the common bile duct can induce leakage60. Laparo-
scopic ultrasonography is a less invasive and safe method to identify CBD stones and 
anatomical abnormalities, but its use has not been deployed broadly.
NIR fl uorescence imaging provides new opportunities for safe exploration of bili-
ary anatomy and function during hepatobiliary surgery. Th e most common method 
is to intravenously inject a fl uorophore like ICG, which is excreted into the bile, 
resulting in fl uorescence cholangiography (Figure 3). Some studies also reported 
retrograde injection of an NIR probe into the bile duct, however, introduction of a 
catheter could result in iatrogenous damage.
A total of 9 clinical studies report the use of ICG as a NIR fl uorescent dye for bile 
duct imaging aft er intravenous administration (Table 2)34,37,61-67. Seventy-fi ve patients 
undergoing laparoscopic and 27 patients undergoing open bile duct imaging were 
included. In general, ICG was injected intravenously 30 min prior to surgery, and 
most studies used a dose of 2.5 mg (with the exception of one study that reported 
the use of 12.5 mg ICG64). Using fl uorescence cholangiography during laparoscopic 
cholecystectomy, Aoki et al. showed identifi cation of the common bile duct and 
cystic duct in 10 of 14 patients64. Th e authors stated that unsuccessful identifi cation 
of the bile ducts was due to obesity. In these patients, fatty tissue surrounding the bile 
ducts limited visualization.
For dose optimization and biodistribution purposes, Hutteman et al. visualized 
the common bile duct and cholangiojejunostomy during open pancreaticoduode-
nectomy aft er intravenous injection of ICG in 8 patients. Between 10 and 90 min 
aft er administration of 5- and 10-mg ICG, the common bile duct could clearly be 
identifi ed by NIR fl uorescence imaging in all patients. No diff erence was observed 
between the 5- mg and 10-mg groups (P = 0.849). Highest signal-to-background 
Colour NIR Fluorescence Colour-NIR Merge 
1 cm 
* * 
Figure 3 – NIR fl uorescence imaging of the bile duct during liver surgery
Colour video (left  panel), NIR fl uorescence (middle panel), and a colour-NIR overlay (right panel) of intraop-
erative imaging of the cystic duct (arrowhead) and common bile duct (arrow) in a patient who underwent liver 
resection for colorectal metastases, 24 h aft er administration of 10-mg ICG. Th e asterisk indicates the position 
of the gallbladder.
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ratios were found between 30 and 90 min postinjection, with a maximum mean 
signal-to-background ratio of 6.2 ± 1.3 at 60 min postinjection52.
A total of 5 preclinical studies reported the use of NIR fl uorescence imaging to 
visualize the biliary anatomy in animal models16,65,66,68,69. Four of these studies used 
ICG. Aft er surgical exposure and intravenous injection of ICG, bile duct imaging 
was successful in all experiments. Due to hepatic clearance of ICG, timing of ICG 
injection is crucial to minimize background signal of the liver. One study tested both 
ICG and IRDye® 800CW fl uorophore (LI-COR, biosciences, Lincoln, Nebraska.)68. 
A single intravenous injection of IRDye® CW800-Carboxylate at doses greater than 
0.0015 mmol/kg resulted in a high SBR (+/-3) of the CBD for at least 30 min post-
injection, with a dose of 0.0075 mmol/kg being optimal. Due to the quick excretion 
of IRDye® 800CW, liver background signal was low, which can be an advantage over 
ICG. Another study used MB and ICG for biliary imaging in pigs16. Bile duct imaging 
was successful in all animals. Contrast-to-background ratio for MB and ICG were 
roughly equivalent at later time points aft er injection. Th e use of ICG’s fl uorescence 
at 800 nm has the advantage of lower autofl uorescence from the surrounding bowel 
and tissue, but the disadvantage of longer retention in the liver resulting in higher 
background. As a consequence, ICG required a long lag time (>90 min) before ad-
equate contrast could be observed relative to the liver. Th e ICG signal lasted for up to 
240-min postinjection. MB signal intensity in the common bile duct became visible 
within minutes, and remained adequate for imaging for up to 120 min. Advantages 
of MB include low liver uptake and rapid excretion into bile. Disadvantages include a 
700-nm rather than an 800-nm emission and a relatively low quantum yield.
A recent study tested a novel NIR lipophilic probe VM674 (VisEn Medical, Bedford, 
MA). Th is probe allows rapid biliary excretion aft er intravenous administration69. It 
was tested in mice with chronic biliary obstruction, acute biliary obstruction, bile 
duct perforation and choledocholithiasis65. Bile duct visualisation was successful 
aft er intravenous administration of 10 nmol and it was feasible to visualize bile duct 
obstruction, perforation, and choledocholithiasis. Optimal signal-to-background 
ratio of 6.4 ± 0.8 was observed aft er 25 min post intravenous injection and a clear 
signal was visible for up to 60 min.
In conclusion, to perform fl uorescence cholangiography, dose and timing of con-
trast agent administration is crucial. According to the available clinical literature, the 
most optimal parameters to perform clinical NIR fl uorescence bile duct imaging are 
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Bile leakage imaging
Bile leakage is a serious complication aft er HPB surgery70. Th ere is a strong associa-
tion between bile leakage aft er hepatic resection and a high risk for liver failure and 
surgical mortality70. Early detection of bile leakage could potentially prevent late 
complications, such as liver failure. To identify bile leakage during surgery, diff erent 
approaches have been described71,72. A randomized trail in 103 patients investigated 
the value of intrabiliary injection of saline to identify bile leakage, but found no 
signifi cant diff erence.71 A trial that investigated injection of a fat emulsion reported 
a reduction in bile leakage; however, complete prevention of bile leakage was not 
achieved72.
Two clinical studies have demonstrated the use of NIR fl uorescence for bile leakage 
identifi cation aft er hepatic resection73,74. ICG was injected intrabiliary aft er hepatic 
resection through a transcystic catheter. Th e common bile duct was clamped distal 
to the cystic duct and fl uorescent imaging was performed. In a group of 102 patients 
undergoing hepatic resection, 5 patients developed postoperative bile leakage in 
the control group versus no patients in the group in which NIR fl uorescence was 
used (P = 0.019)73. Th is suggests an additive value of NIR fl uorescence imaging for 
intraoperative detection of bile leakage.
DISCUSSION AND FUTURE PROSPECTS
Image-guided HPB surgery using invisible NIR fl uorescent light has been intensely 
explored over a relatively short time. Th e technique has shown potential to improve 
intraoperative identifi cation and demarcation of tumours and vital structures. It 
could potentially be a useful tool to reduce the number of positive resection margins 
and to prevent re-interventions. Applications include the identifi cation and demarca-
tion of HPB tumours, identifi cation of pancreatic liver metastases during pancreatic 
surgery, real-time bile duct imaging and bile leakage detection. In addition, it is also 
possible to acquire functional images of the liver and bilary system by physiologi-
cal clearance of exogenous fl uorescence contrast agents that are almost completely 
cleared by the liver (i.e. ICG).
Th e clinical availability of ICG and MB allowed NIR fl uorescence image-guided 
surgery to be introduced into clinical trials. However, for tumour imaging to make 
the next step into development and acceptance of this new technique, tumour tar-
geted contrast agents will be essential. As described in this review, many preclinical 
studies showed promising results using tumour specifi c probes. However, the most 
important drawback in the clinical implementation of these probes is that each probe 
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has to go through a separate expensive and time-consuming regulatory approval 
processes.
Development of new imaging systems will off er new prospects for image-guided 
surgery, as most current imaging systems are still in the experimental phase. Major 
improvements are to be expected concerning image resolution, sensitivity, and 
fl uorescence-guided laparoscopy. Th e use of laparoscopy in HPB surgery is steadily 
increasing, which makes it a particularly interesting fi eld for the development and 
improvement of laparoscopic fl uorescence imaging systems. To date, quantifi cation 
in optical imaging remains challenging. As tissue absorbance and probe concentra-
tion at the site of the tumour will vary among patients, the contrast between target 
tissue (tumours, vital structures or lymph nodes) and surrounding tissue is impor-
tant and will be the basis of clinical decision making. Current research is focused on 
new methods to improve signal quantifi cation, for example by means of time domain 
imaging and spatial frequency domain imaging75,76.
One of the major challenges of NIR fl uorescence imaging is its limited penetra-
tion depth. To date, the available literature reports a penetration depth ranging from 
several millimetres to, at most and in rare circumstances, one centimetre. A future 
goal is the development of novel fl uorophores and camera systems to improve these 
numbers.
Finally, to validate the use of NIR fl uorescence imaging, and more importantly 
to quantify patient benefi t, large clinical trials will be essential. Despite the very 
promising results already obtained, the next decade will defi ne the true effi  cacy of 
NIR fl uorescence imaging during HPB surgery.
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ABSTRACT
NIR fl uorescence imaging using indocyanine green (ICG) has the potential to 
improve the SLN procedure by facilitating percutaneous and intraoperative iden-
tifi cation of lymphatic channels and SLNs. Previous studies suggested that a dose 
of 0.62 mg (1.6 ml of 0.5 mM) ICG is optimal for SLN mapping in breast cancer. 
Th e aim of this study was to evaluate the diagnostic accuracy of near-infrared (NIR) 
fl uorescence for sentinel lymph node (SLN) mapping in breast cancer patients when 
used in conjunction with conventional techniques. Study subjects were 95 breast 
cancer patients planning to undergo SLN procedure at either the Dana-Farber/
Harvard Cancer Center (Boston, MA, USA) or the Leiden University Medical Center 
(Leiden, the Netherlands) between July 2010 and January 2013. Subjects underwent 
the standard-of-care SLN procedure at each institution using 99Technetium-colloid 
in all subjects and patent blue in 27 (28%) of the subjects. NIR fl uorescence-guided 
SLN detection was performed using the Mini-FLARE imaging system. SLN identifi -
cation was successful in 94 of 95 subjects (99%) using NIR fl uorescence imaging or a 
combination of both NIR fl uorescence imaging and radioactive guidance. In 2 of 95 
subjects, radioactive guidance was necessary for initial in vivo identifi cation of SLNs. 
In 1 of 95 subjects, NIR fl uorescence was necessary for initial in vivo identifi cation 
of SLNs. A total of 177 SLNs (mean = 1.9, range = 1-5) were resected: 100% NIR 
fl uorescent, 88% radioactive, and 78% (of 40 nodes) blue. In 2 of 95 subjects (2.1%), 
SLNs containing macrometastases were found only by NIR fl uorescence, and in 1 
patient this led to upstaging to N1. Th is study demonstrates the safe and accurate ap-
plication of NIR fl uorescence imaging for the identifi cation of SLNs in breast cancer 
patients, but calls into question what technique should be used as the gold standard 
in future studies.
Sentinel lymph node mapping in breast cancer using NIR fl uorescence 79
INTRODUCTION
Sentinel lymph node (SLN) biopsy is regarded as standard-of-care in staging the ax-
illa in breast cancer patients with clinically negative lymph nodes1. Th ree methods of 
mapping the sentinel lymph node are currently standard of care: 1) radioactive tracer 
alone, 2) blue dye, and 3) a combination of both. Th e combination of both radioac-
tive tracer and blue dye currently report the highest identifi cation rates (>95%) and 
lowest false negative rates (<10%)2-6. However both modalities have certain disad-
vantages. For example, blue dyes cannot be seen through skin and fatty tissue, blue 
staining results in tattooing of the breast lasting for several months, skin necrosis can 
occur with subdermal injections, and allergic reactions with rare anaphylaxis have 
been reported7,8. Radioactive colloids are expensive, require involvement of a nuclear 
physician, and do not provide real-time visual guidance. Moreover, many hospitals 
worldwide are limited to the use of blue dye only to perform SLN biopsy because 
of the lack of access to radioactive isotopes or suffi  cient funding, although blue dye 
alone is associated with higher false negative rates9.
As a result of these issues, near-infrared (NIR) fl uorescence (700-900 nm) imaging 
has recently been introduced for SLN mapping and tested in several cancer centers 
worldwide10-23. NIR fl uorescence imaging has several characteristics that are advanta-
geous for the SLN procedure, which include a relatively high penetration into living 
tissue (up to 5 mm) and real-time, high-resolution optical guidance24,25. Indocyanine 
green (ICG) is currently the only FDA and EMEA approved NIR fl uorescent probe 
that can be used (off -label) in clinical trials as a lymphatic tracer. Th is tracer has out-
performed blue dye staining for SLN identifi cation in 4 clinical trials10,19,22,26. Previous 
studies indicated that a dose of 0.5 mM (1.6 ml) ICG is optimal for SLN mapping in 
breast cancer19,21,22.
A signifi cant advantage of NIR imaging is that it can provide real-time guidance. 
However, to enable the surgeon to work under direct image guidance, navigation in 
relation to the surgical anatomy is obligatory. In contrast to most camera systems used 
worldwide, the system used in this study is capable of displaying NIR fl uorescence 
signal simultaneously with surgical anatomy, using a hands-free design. Moreover, 
the real-time, high resolution images allow clear detection of fl uorescent lymphatic 
channels, which has shown to be benefi cial in the visualization of the lymphatic 
drainage pathway and position of the SLN21,27.
Th e primary objective of this multicenter experience was to validate the diagnostic 
accuracy of fl uorescence guided SLN biopsy when used with conventional techniques. 
Th e secondary objective was to evaluate the safety of intraoperative NIR fl uorescence 
SLN mapping using 0.5 mM (1.6 ml) ICG.
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METHODS
Preparation of Indocyanine Green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
or Akorn (Decatur, IL, USA). Directly before surgery, it was resuspended in 10 cc 
of supplied diluent (sterile water) for injection to yield a 2.5 mg/ml (3.2 mM) stock 
solution. To obtain the desired 0.5 mM (0.39 mg/ml) dilution of ICG, 7.8 mL of the 
3.2 mM ICG solution was diluted in 42.8 mL of sterile water (NL) or 9.2 mL of the 
stock solution was diluted in 50 mL of sterile saline (US). In previous studies, we 
determined that the optimal dose of ICG lies between 1.6 mL of 0.4 mM and 0.8 mM; 
therefore, a dose of 0.5 mM was chosen21,22.
Intraoperative Near-Infrared Imaging System
SLN mapping was performed using 2 identical versions of the Mini-Fluorescence-
Assisted Resection and Exploration (Mini-FLARE™)21 image-guided surgery 
system at each institution. Briefl y, the system consists of 2 wavelength isolated light 
sources: a “white” light source, generating 26,600 lx of 400 to 650 nm light, and a 
“near-infrared” light source, generating 7.7 mW/cm2 of 760-nm light. Color video 
and NIR fl uorescence images are simultaneously acquired and displayed in real time 
using custom optics and soft ware that separate the color video and NIR fl uorescence 
images. A pseudo-colored (lime green) merged image of the color video and NIR 
fl uorescence images is also displayed in real time. Th e imaging head is attached to a 
fl exible gooseneck arm, which permits positioning of the imaging head at extreme 
angles virtually anywhere over the surgical fi eld. For intraoperative use, the imaging 
head and imaging system pole stand are wrapped in a sterile shield and drape (Medi-
cal Technique Inc., Tucson, AZ).
Clinical Trial
Th e data in this paper are combined from 2 Phase 2 trials approved separately by 
the Medical Ethics Committees of the Dana-Farber/Harvard Cancer Center (Boston, 
MA USA) and the Leiden University Medical Center (Leiden, Netherlands) and per-
formed in accordance with the ethical standards of the Helsinki Declaration of 1975. 
All patients planning to undergo a SLN procedure for invasive breast cancer or high-
risk carcinoma in situ were eligible for participation in the trials between July 2010 
and January 2013. Study subjects had clinically negative axillary nodes as assessed by 
palpation and ultrasonography. Exclusion criteria were pregnancy, lactation, or an 
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allergy to iodine, shellfi sh, or indocyanine green. All subjects gave informed consent 
and were anonymized. Subjects received the standard-of-care sentinel node procedure 
without interference from the Mini-FLARE imaging system. In the Netherlands, this 
implied the periareolarly administration of approximately 100 MBq 99mTechnetium-
nanocolloid the day before surgery, followed by a lymphoscintigraphy 15 min and 
180 minutes aft er injection. In addition, in 27 subjects, 1 mL total of patent blue 
(Bleu Patenté V, Guerbet, Brussels, Belgium) was injected intradermally and peri-
areolarly in multiple deposits directly before the start of surgery. Usage of patent blue 
was performed in concordance with the Dutch guidelines. However, a randomized 
controlled trial published during this study showed no benefi t of using patent blue; 
therefore, it was omitted in the latter part of the current trial19. In the United States 
this implied the subareolar injection of approximately 0.8 mCi 99mTechnetium-sulfur 
colloid 1-3 hours before surgery.
Immediately before surgery, the attending surgeon injected 1.6 mL total of 0.5 mM 
ICG at multiple sites periareolarly (NL) or intradermally and peritumorally (US). 
Aft erwards, the injection site was massaged to assess lymphatic drainage. Aft er surgi-
cal scrub and sterile draping of the operative fi eld, NIR fl uorescence imaging was 
performed using the Mini-FLARE camera system at approximately 30 cm distance to 
the surgical fi eld. Th e surgical fi eld was also illuminated using the white light source 
of the Mini-FLARE imaging system. NIR camera exposure times were between 5 to 
500 ms.
Before incision, the surgical fi eld was inspected for percutaneous lymphatic chan-
nels and potential SLNs using NIR fl uorescence. With respect to detection of the 
SLN, surgeons had direct access to both the gamma probe and the NIR fl uorescence 
images. Th e “hands-free” design of the Mini-FLARE permitted continuous image 
acquisition during the SLN procedure. Th e method used for fi rst detection of the all 
SLNs was noted. Whether a SLN was deemed fl uorescent or radioactive was depen-
dent on the signal-to-background ratio (SBR) or radioactive counts, respectively. A 
region of interest (ROI) from adjacent skin, identical in size and shape to that over the 
SLN, was chosen as background. A SLN exhibiting a SBR ≥ 1.1 in situ was considered 
positive by NIR fl uorescence. Th e NIR fl uorescence and radioactive signatures of all 
SLNs were also inspected ex vivo using Mini-FLARE and a handheld gamma probe, 
respectively. When multiple SLNs were found, a SLN was deemed radioactive when 
the radioactive counts were more than 10% of the SLN with the highest radioactive 
counts.
All subjects underwent routine histopathological analysis of the SLNs according to 
the Dutch and US guidelines.
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Table 1 – Characteristics of study subjects (n = 95)
Characteristic n %
Age (median, range) 57 (30-75)













Upper outer 54 57
Lower outer 6 6
Lower medial 7 7
Upper medial 16 17
Central 12 13
Previous treatment
Neoadjuvant chemotherapy 4 4
Neoadjuvant hormone therapy 5 5




Wide local excision 82 86
Wide local excision and lymph node dissection 3 3
Sentinel lymph node biopsy only 2 2
Pathological tumor size (median, range) 12 (3-50)
Histological type
Infi ltrating ductal type adenocarcinoma 66 69
Infi ltrating lobular type adenocarcinoma 11 12
Mixed ductal and lobular type 10 11






No grading possible 5 5
Study subject SLN tumor status
Negative 79 83
Positive (micrometastases or macrometastases) 16 17
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Statistical Analysis
For statistical analysis, SPSS statistical soft ware package (Version 20.0, Chicago, IL) 
was used. Correlation between values was determined using the Spearman’s rank 
correlation coeffi  cient, in case of nonparametric values. To compare BMI between 
subject groups, the independent-sample t-test was used. To test diff erences between 
identifi cation time in BMI subgroups, the Kruskal-Wallis one-way analysis of vari-
ance test and the Dunn’s Multiple Comparison Test (only computed if overall P < 
0.05) were used. P < 0.05 was considered signifi cant.
RESULTS
Subject and Tumor Characteristics
Ninety-fi ve breast cancer patients who underwent SLN mapping using both radioac-
tive and fl uorescence guidance (Table 1) were included in the study. Median age of 
study subjects was 57 years (range: 30-75) and median BMI was 25 kg/m2 (range: 19 
- 47). Tumor characteristics are shown in Table 1. Th e majority of subjects underwent 
a wide local excision (90%); the remainder underwent a mastectomy or SLN biopsy 
only. Nine subjects were treated with neoadjuvant hormonal or chemotherapy. Th e 
average time between injection of ICG and the skin incision was 19 ± 7.1 min. No 
adverse reactions associated with ICG or the Mini-FLARE imaging system occurred.
SLN Detection
In 94 of 95 subjects, at least one SLN was identifi ed using NIR fl uorescence or radio-
activity (identifi cation rate = 99%; Figure 1 and 2A). A total of 177 sentinel lymph 
nodes (mean = 1.9, range = 1-5) were resected: 155 (88%) were radioactive and 177 
(100%) were fl uorescent (Figure 2B). In 1 subject, all SLNs were only NIR fl uorescent 
and not radioactive. In 2 subjects, the gamma probe was necessary for initial localiza-
tion of SLNs (2/95 = 2.1%, Figure 2A and 3). However, aft er detection, these nodes 
were found to be NIR fl uorescent in vivo (mean SBR = 2.5). Of note, the BMI of these 
subjects was higher compared to the other subjects (mean BMI = 35.5 vs. 27.3; t = 
1.72, p = 0.09; Figure 3). In 4 subjects (Figure 3), additional SLNs could be located 
using the gamma probe aft er initial identifi cation of 1 or more NIR fl uorescent SLNs. 
Again, these nodes were fl uorescent in vivo (n = 6, mean SBR = 6.27). Th e mean BMI 
of these subjects was not signifi cantly diff erent from the rest of the subjects (mean 
BMI = 25.0 vs. 27.3; t = 0.75, p = 0.45). In 1 of these 4 subjects, an additional SLN 
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located by radioactivity (but also NIR fl uorescent in vivo at the time of resection) 
contained a micrometastasis. Th e BMI of this subject was 23. In summary, in 6 of 
95 subjects (6.3%), radioactive guidance was necessary for the initial or additional 
localization of SLNs, though 100% of those nodes were NIR fl uorescent at the time 
of resection.
Lymph node involvement was found in 22 (12%) of the resected lymph nodes in-
cluding 18 nodes with macrometastases and 4 nodes with micrometastases. Isolated 
tumor cells were found in 7 nodes (4%). All tumor-positive SLNs were fl uorescent, 
however only 20 (91%) were also radioactive. In 2 subjects (2.1%), macrometastases 
were found in SLNs that could only be found using NIR fl uorescence (Table 2, Figure 
3). Even during ex-vivo inspection with the gamma probe, radioactivity counts of 
those nodes were very low (less than 5% of other nodes). One of those 2 subjects also 
had other fl uorescent/radioactive nodes that were tumor-positive. More importantly, 
in the other patient, tumor-positive SLNs could only be detected using NIR fl uo-
rescence, and resulted in upstaging to N1. Furthermore, in 1 other patient isolated 
tumor cells were found in a SLN that could only be detected using fl uorescence.












Figure 1 – NIR fl uorescence guided sentinel lymph node (SLN) mapping
Top row, percutaneous NIR identifi cation of aff erent lymphatic channels fl owing away from the injection site 
(Inj.). Th e planned incision site, based on the presumed location of the SLN, is shown as a dashed line. Middle 
row, real-time fl uorescence identifi cation of the SLN directly aft er incision. Bottom row, ex vivo image of the 
SLN. Scale bars = 1 cm. Camera exposure times were: 150 msec (upper row), 55 msec (middle row), and 50 
msec (bottom row).
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In the subgroup that also received patent blue, 31 out of 40 SLNs (78%) were 
blue. In subjects that received patent blue, only 3 out of 5 tumor-positive SLNs were 
stained blue.
NIR fl uorescence enabled visualization of the percutaneous lymphatic channels in 
81% of subjects, which was inversely correlated to BMI (R = -0.36; P < 0.001). In 42% 
of subjects, the complete lymphatic channel could be followed percutaneously from 
injection site to area in which the SLN was identifi ed. In addition, percutaneous NIR 
fl uorescence revealing the location of the SLN could be observed in 31% of subjects. 
Average brightness of exposed SLNs, expressed as signal-to-background ratio (SBR), 
was 10.5 ± 6.7. Average time between skin incision and SLN identifi cation was 7 ± 
6 min and was also inversely correlated to BMI (R = 0.46; P < 0.001). Time between 
skin incision and SLN identifi cation was signifi cantly higher in subjects with BMI 
> 35 compared to subjects with a BMI ≤ 25 (P < 0.001). In 1 subject, the interval 
between skin incision and SLN detection was 42 min. Th is subject received neoadju-
vant chemotherapy, and the SLN was located in the area next to the latissimus dorsi 
muscle.
a b 
Initial in vivo Identification of SLNs  
in All Patients 
Source(s) of Contrast  
in All SLNs 
Source(s) of Contrast  
in Tumor-Positive SLNs 
Figure 2 – Method of identifi cation of initial SLN and SLN sources of contrast
A: Th e method of initial identifi cation of the SLN in all patients (n = 95) is shown as a percentage of total. B: Th e 
source(s) of contrast for all SLNs (left ; N = 177) and tumor-positive SLNs (right; N = 22) aft er in vivo localiza-
tion by fl uorescence and/or radioactivity. F = Fluorescence, R = Radioactivity.
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Estimation of Diagnostic Accuracy
Th ere are two key performance metrics for SLN mapping: 1) identifi cation of all 
SLN(s) and 2) identifi cation of tumor-positive SLN(s) that will change patient man-
agement. Using both NIR fl uorescence and radioactivity, the false negative rate for 
SLN mapping was only 1%. Using radioscintigraphy as the gold standard, the sensi-
tivity of NIR fl uorescence for initial localization of SLNs in all subjects was 98%. Aft er 
initial localization, though, the sensitivity of NIR fl uorescence was 100% whereas 
radioscintigraphy was only 88%. With respect to identifying the 22 tumor-positive 




Identification of macrometastases only by NIR fluorescence 
Radioactivity necessary for identification of initial SLNs 
Identification of SLN only by NIR fluorescence 
Figure 3 – SLN identifi cation in study subjects
Shown is the eff ect of Body Mass Index (BMI) (abscissa) on skin incision to SLN identifi cation time (ordinate) 
in the context of SLN detectability and study site. Points represent individual patients. Red circles represent 
patients enrolled at Dana-Farber/Harvard Cancer Center (Boston); blue circles represent patients enrolled at 
the Leiden University Medical Center (Leiden). Magenta rims indicate patients in which radioactivity was nec-
essary for initial identifi cation of SLNs. Green rim represents the single patient in which the SLN was only NIR 
fl uorescent. Dotted green rims indicate patients with tumor-positive SLNs that could only be found using NIR 
fl uorescence. In 1 patient (BMI = 29) the SLN could be identifi ed aft er 42 min using NIR fl uorescence (outside 
table limit). Dotted line represents the median for each group.
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DISCUSSION
Th e primary endpoint of this study was measurement of the eff ectiveness of intraop-
erative NIR fl uorescence imaging using ICG for SLN mapping in breast cancer. Based 
on our data and those from several other large trials (Table 3), it appears that NIR 
fl uorescence is, at the least, complementary to radioactivity, but might also lead to a 
new standard of care in the future.
Th e use of NIR fl uorescence for SLN mapping has several advantages over con-
ventional modalities, such as superior depth penetration compared to blue dyes, 
Table 2 – SLN outcome
Characteristic N %
Number of SLNs identifi ed 177










Blue (n= 27 study subjects / 40 SLNs) 31 78
SLN status
Negative 148 84
Isolated tumor cells 7 4
Micrometastases 4 2
Macrometastases 18 10
Signature of tumor-positive SLNs
Radioactive 20 91
Fluorescent 22 100
Blue (n = 5 study subjects / 5 SLNs) 3 60
Signal-to-background ratio (mean, SD) 10.5 6.7




Average time between injection and skin incision (minutes, SD) 19 7
Average time between skin incision and SLN resection (minutes, SD) 7 6
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real-time visual guidance, as well as broad availability compared to radioactive 
tracers. Table 3 summarizes all NIR fl uorescence breast cancer SLN clinical studies 
with 50 or more study subjects each. To the best of our knowledge, all large studies 
performed worldwide have used the Photo Dynamic Eye (PDE; Hamamatsu, Japan) 
camera system10,11,13-18,28. Th is hand-held fl uorescence camera system is easy to use 
and commercially available; however, no color overlay is possible. Moreover, most 
studies only compared fl uorescence to patent blue and only 1 study made a large (i.e., 
n > 50) comparison between radioactive to fl uorescence guidance15. In that study, 
Wishart et al. observed that fl uorescence imaging using ICG was not associated with 
harvesting of an excessive number of nodes compared to radioactive guidance, which 
is concordant with our data15. In addition, the sensitivity of fl uorescence and blue dye 
was 95% in their study. Th is suggests that a combination of blue dye and fl uorescence 
is a potential alternative to radioactivity, although the present study, as well as previ-
ous studies, suggests that blue dye is itself unnecessary19.
As shown in Table 3, most large clinical studies on this topic have utilized a dose of 
ICG almost ten-fold higher than that used in our study. In a series of controlled tri-
als, we demonstrated that the concentration and volume of ICG was of considerable 
importance. Counterintuitively, higher injected ICG concentrations actually lead to 
worse detectability because of fl uorophore “quenching.” Th at is, at too high a concen-
tration, photons emitted by ICG are reabsorbed and are therefore not detectable29. 
Even 0.5 mM (used in our study) is a concentration that exhibits quenching, but by 
the time the ICG is diluted in lymph fl uid, the fi nal concentration in the SLN is such 
that NIR fl uorescence is maximal. A high concentration can also lead to increased 
fl ow to second-tier nodes, as refl ected in the higher number of “SLNs” seen with 
higher injected doses (Table 3). Careful attention to concentration and dilution is 
one factor that enables improved performance of the technology, especially because 
identifi cation of a higher number of SLNs does not increase patient survival and 
harbors the risk of increased morbidity. Retrospective analysis of 1530 consecutive 
patients with negative SLNs (detected using radioactivity and blue dye) showed an 
axillary recurrence of only 0.26%30.
Th e second factor is the imaging system used. Our study employed hands-free 
imaging using the Mini-FLARE imaging system, which is capable of displaying NIR 
fl uorescence images simultaneously with surgical anatomy. Th is enabled the surgeon 
to perform surgery under direct image guidance. In addition, a signifi cant advantage 
of fl uorescence-guided SLN mapping is the introduction of real-time visualization 
of lymphatics and, in some cases, also lymph nodes through the skin. In the current 
study, we were able to visualize percutaneous lymphatic channels in 81% and axillary 
lymph nodes in 31% of cases. Even when the SLN itself is not visible through the skin, 
its location can still be inferred with reasonable accuracy by projecting downward 












































































































































































































































































































































































































































































































































































































































































































































































































and slightly away from the point at which the lymphatic channel dives deep and 
becomes invisible. Exploiting this feature is an important part of the learning curve 
for the technique. Pre-incision SLN detection, when it occurs, is a major advantage 
because it can minimize both surgical incision length and the exploration time 
needed to fi nd the SLN.
No adverse events related to fl uorescence imaging were reported in this study, 
which confi rms safe application of NIR fl uorescence and ICG. Moreover, the esti-
mated incidence of adverse events using ICG is considerably lower (< 1:10,000 cases) 
than that of Patent Blue (~ 1:150 cases)31-33.
It should also be pointed out that the hydrodynamic diameters of ICG (≤ 1 nm) 
and radioactive colloid (≥ 50 nm) are vastly diff erent and can have a major impact 
on performance34. ICG fl ows much faster (seconds to minutes) and potentially has 
access to smaller lymphatic channels, but can also pass through the SLN into second 
tier nodes. Colloid requires hours to fl ow but has excellent retention in the SLN. It 
is unclear what role hydrodynamic diameter and timing played for the SLNs found 
only using NIR fl uorescence. Another parameter not addressed in this study is the 
optimal formulation of ICG, which is known to be unstable over time in aqueous 
environments35.
Our study calls into question what should be considered the “gold standard” in 
SLN mapping. By one metric, initial SLN identifi cation, NIR fl uorescence identi-
fi ed the SLN in 1 patient that could not be detected using radioactivity. However, 
radioactivity was necessary for initial SLN identifi cation in 2 cases. In NIR failures, 
BMI did not appear to be a discriminating factor. It is unclear at present if NIR 
fl uorescence failures could have been avoided by improved intraoperative techniques 
and greater experience, or whether those failures would have resulted in a clinically 
poorer outcome. By understanding the limitations of NIR fl uorescence (e.g., ≈ 5 mm 
penetration depth), it might be possible to modify exploratory techniques to improve 
detectability. It is equally possible, however, that the superior depth of radioactive 
detection will be required in some cases. A well-designed, properly powered, ran-
domized controlled clinical trial could answer this critical question.
By a second metric, though, identifi cation of tumor-positive SLNs, NIR fl uores-
cence identifi ed N+ SLNs with macrometastases in two patients that could not be 
identifi ed using radioactivity. It could be argued that this is a more important metric 
because upstaging changes patient management, as it did in 1 study subject. Th is also 
calls into question whether radioactivity can be safely omitted from SLN mapping of 
breast cancer under certain conditions. Defi nitive conclusions await a much larger 
clinical trial.
A key aspect of NIR fl uorescence SLN mapping is that it can be readily translated 
to breast cancer centers worldwide. Aspects supporting implementation of NIR fl uo-
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rescence SLN mapping include: 1) it utilizes a contrast agent already FDA-approved 
for other indications, 2) multiple imaging systems are now commercially available, 
and 3) unlike radioactive tracers, no extensive infrastructure is needed to implement 
the technology.
In conclusion, this multi-center experience validates the safe and accurate applica-
tion of NIR fl uorescence imaging for the identifi cation of SLN in breast cancer patients 
using 1.6 mL of 0.5 mM ICG and the Mini-FLARE camera system. In the context of 
fi nding tumor-positive SLNs, NIR fl uorescence outperformed both radioactivity and 
blue dye staining. We believe that fl uorescence guided SLN mapping using ICG is a 
safe and accurate method that can be used in combination with radioactivity and/or 
blue dye, but would be of special value in breast cancer centers that currently have 
access to only blue dye.
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Combining radioactive colloids and a near-infrared (NIR) fl uorophore permit pre-
operative planning and intraoperative localization of deeply located sentinel lymph 
nodes (SLNs) with direct optical guidance by a single lymphatic tracer. Th e aim of 
this clinical trial was to evaluate and optimize a hybrid NIR fl uorescence and radio-
active tracer for SLN detection in breast cancer patients.
Method
Patients with breast cancer undergoing SLN biopsy were enrolled. Th e day before 
surgery, indocyanine green (ICG)-99mTc-Nanocolloid was injected periareolarly and 
a lymphoscintigram was acquired. Directly before surgery, blue dye was injected. 
Intraoperative SLN localization was performed by a gamma probe and the Mini-
FLARETM NIR fl uorescence imaging system. Patients were divided into two dose 
groups, with one group receiving twice the particle density of ICG and nanocolloid, 
but the same dose of radioactive 99mTechnetium.
Results
Th irty-two patients were enrolled in the trial. At least one SLN was identifi ed pre- and 
intraoperatively. All 48 axillary SLNs could be detected by gamma tracing and NIR 
fl uorescence imaging, but only 42 of them stained blue. NIR fl uorescence permitted 
detection of lymphatic vessels draining to the SLN up to 29 hours aft er injection. 
Increasing the particle density by two-fold did not yield a diff erence in fl uorescence 
intensity, median 255 (range 98 – 542) vs. median 284 (90 – 921; P = 0.590), or signal- 
to-background ratio, median 5.4 (range 3.0 – 15.4) vs. median 4.9 (3.5 – 16.3; P = 
1.000), of the SLN.
Conclusion
Th e hybrid NIR fl uorescence and radioactive tracer ICG-99mTc-Nanocolloid permit-
ted accurate pre- and intraoperative detection of the SLNs in patients with breast 
cancer.
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INTRODUCTION
Sentinel lymph node (SLN) biopsy is standard of care for nodal staging in breast 
cancer patients with clinically negative axillary lymph nodes1. To locate the SLNs, 
a combination of radioactive lymphatic tracers and blue dye staining is oft en pre-
ferred2-5. Radioactive tracers, permit preoperative planning and retention in the fi rst 
echelon nodes, whereas blue dyes permit direct intraoperative visualization of the 
lymphatics and SLNs.
Optical imaging using near-infrared (NIR; 700-900 nm) fl uorescence has been 
tested extensively for SLN detection in breast cancer and in other cancers, such as 
melanoma6-15. Th e fl uorescent tracer indocyanine green (ICG) is used for detection 
of SLNs up to several millimetres deep in tissue16-18. Th is tracer has outperformed 
blue dye staining for SLN identifi cation in multiple clinical trials7,8,18,19. Nevertheless, 
radioactive colloids are still considered the standard of care for preoperative plan-
ning. Radioactive colloids are essential for localization of deeper located SLNs, for 
example in patients with a higher body mass index (BMI)8,20.
To combine radioactive and NIR fl uorescence guidance in one “package”, the 
hybrid tracer ICG-99mTc-Nanocolloid has been developed21. Th e fl uorescent label 
ICG and the radioactive label 99mTechnecium (99mTc) are integrated into the same 
colloidal particle. Unlike “free” ICG, this nanoparticle provides long retention in 
the SLN22. Feasibility and validity of this tracer has been shown in various tumour 
types23-25. However, this hybrid tracer has not been studied in SLN biopsy procedures 
in patients with breast cancer.
Th e aim of this study was to evaluate the hybrid tracer for SLN detection in patients 
with breast cancer and to assess nodal accumulation of the tracer and the fl uorescent 
signal intensity in the SLN by increasing the particle density of the tracer.
METHODS
Th is clinical trial was approved by the medical ethics committee of the Leiden Uni-
versity Medical Center and was performed in accordance with the ethical standards 
of the Helsinki Declaration of 1975. All patients with breast cancer scheduled for SLN 
biopsy in the period from August 2011 to July 2012 were eligible for participation in 
the study. Patients had clinically negative axillary nodes as assessed by palpation and 
ultrasonography. Exclusion criteria were pregnancy, lactation, or an allergy to iodine 




99mTc-Nanocolloid was prepared by adding sodium pertechnetate (approximately 
1000 MBq) in 2 mL saline to a vial of 0.5 mg human serum albumin nanocolloid 
(GE Healthcare, Eindhoven, the Netherlands). Aft er 30 min of incubation at room 
temperature, 50 µL of 6.4 mM (0.25 mg) ICG (Pulsion Medical Systems, Munich, 
Germany) was dissolved in water for injection to obtain ICG-99mTc-Nanocolloid at a 
fi nal ICG concentration of 160 µM and a fi nal pH of 6,0 – 7,024,25. To obtain a two-fold 
higher concentration ICG-Nanocolloid, 99mTc-Nanocolloid was prepared by adding 
pertechnetate (approximately 500 MBq) in 1 mL saline to 0.5 mg Nanocolloid, while 
the amount of ICG (0.25 mg) was kept the same, resulting in a fi nal ICG concen-
tration of 320 µM. Th is preparation resulted in doubling of the ICG and Nanocol-
loid concentration, but the same radioactivity dose (approximately 100 MBq). All 
procedures were performed under current good manufacturing practice and under 
supervision of the institution’s pharmacist.
Study design
Th e day before surgery, ICG-99mTc-Nanocolloid was injected intracutaneously 
periareolar in the quadrant in which the tumour was localized (one deposit; total 
volume 0.2 mL; 100 MBq). Patients were divided into the low and high ICG-99mTc-
Nanocolloid particle density groups; the fi rst consecutive half of the patients were 
assigned to the low dose, and the second half of the patients to received a two fold 
higher dose. Anterior, lateral, and anterior oblique planar images were obtained at 
15 minutes and approximately three hours aft er injection, by a detector of a single 
or two-headed gamma camera (Symbia T6, Siemens, Erlangen, Germany or Toshiba 
GCA-7200PI/7200DI/7100UI, Toshiba, Tokyo, Japan). Th e percentage of tracer in 
the SLN was calculated using the anterior oblique images by dividing the counts in 
the SLN(s) by the sum of counts in the injection site and all lymph nodes. Simultane-
ously with the gamma camera images, percutaneous NIR fl uorescence images were 
acquired using the Mini-FLARETM NIR fl uorescence imaging system, as described 
previously26. A SLN was defi ned as a lymph node on a direct lymphatic drainage 
pathway from the primary tumour as detected by lymphoscintigraphy27. Intraopera-
tively, lymph nodes with a gamma count of 10 per cent or more compared to the most 
radioactive SLN, were also designated as SLNs28.
Directly before surgery, 1 mL total of patent blue (Bleu Patenté V, Guerbet, Brussels, 
Belgium) was injected periareolarly in multiple deposits. Gentle pressure was applied 
to the injection site for 1 min. Th e surgical fi eld was illuminated using the white light 
luminary of the Mini-FLARETM imaging system. During surgical exploration, the 
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combined radioactive and fl uorescent signature of the preoperatively defi ned SLNs 
were visualized by a hand-held gamma probe (Europrobe, Euromedical Instruments, 
Le Chesnay, France) and the Mini-FLARETM.
Th e primary endpoint of the study was the SLN identifi cation rate. Secondary 
endpoints were the number of SLN identifi ed per patient, the percentage of the tracer 
accumulated in the SLN based on the scintigraphy, the fl uorescent intensity, and the 
fl uorescent signal- to- background ratio (SBR) of the SLNs. Th e SBR of the SLN 
was calculated by dividing the fl uorescence intensity of the SLN by the fl uorescence 
intensity of the fatty tissue directly surrounding the SLN. Blue dye staining was used 
to provide additional optical guidance.
SLNs were fi xed in formalin and embedded in paraffi  n for routine hematoxylin 
and eosin staining and immunohistopathological staining for cytokeratin (AE1/AE3) 
at three levels, with an interval of 150 to 250 µm, according to the Dutch guidelines 
for SLN analysis in breast cancer.
Statistical analysis
For statistical analysis, SPSS statistical soft ware package (Version 20.0, Chicago, IL) 
was used. To compare categorical characteristics between the two groups of patients, 
the Fisher’s Exact test was used for binary data and the chi-square test for non-binary 
data. Continuous data was tested for normal distribution using the Shapiro-Wilk 
test. Normal distributed continuous data (age and tumour size) was tested using the 
independent-sample t- test and not normally distributed data was tested using the 
Mann-Whitney test. Continuous data is presented as median and range. P < 0.05 was 
considered signifi cant.
RESULTS
Th irty-two consecutive patients with breast cancer undergoing SLN biopsy were 
included in this study (Fig. 1). Th e median age was 56 (range 34 - 82) years, median 
BMI was 24 (18 - 39) kg/m2. Of the 32 patients, the fi rst 16 were assigned to the low 
ICG-99mTc-Nanocolloid dose and the following 16 received the two-fold higher dose. 
No diff erences were observed between the two treatment groups concerning patient, 
tumour, and treatment characteristics (Table 1). Th e median time between injection 
of ICG-99mTc-Nanocolloid and surgery were 24 (19 – 29) hours and 22 (20 – 25) 
hours for the low dose and higher dose treatment groups, respectively. Similar to 
the use of “free” ICG7,8,26, no adverse reactions associated with the use of ICG-99mTc-
Nanocolloid were observed.
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Sentinel lymph node detection
Preoperative scintigraphy identifi ed at least one SLN in all patients, with a median 
of one (1 – 2) SLN per patient. All SLNs were located in the axilla. In 22 patients 
superfi cial lymph drainage could at least partially be visualized percutaneously by 
NIR fl uorescence at the time of preoperative scintigraphy or prior to surgery (Fig. 2).
Surgical excision of the SLNs was performed guided by a combination of radio-
activity and fl uorescence. Aft er initial guidance by the preoperative scintigraphy 
and the gamma probe, the axilla was explored using NIR fl uorescence imaging. 
Only in patients where NIR fl uorescence did not directly point to the SLN, was the 
gamma probe used for additional intraoperative guidance. Th e results of the SLN 
biopsy procedures are presented in Table 2. Th e NIR fl uorescence based detection of 
lymphatic vessels that drained to the SLN contributed to their identifi cation (Fig. 3). 
In all patients, at least one SLN was identifi ed and resected. In addition to the SLNs 
detected by lymphoscintigraphy, an additional ten lymph nodes were intraoperatively 
considered as SLN, with a median of one (1 – 3) SLN harvested from each patient. All 
48 radioactive SLNs were detected by NIR fl uorescence and the gamma probe, but 
only 42 out of 48 SLNs stained blue. In all patients the NIR fl uorescence signal in the 
SLN was detected before patent blue was visualized.
Figure 1 – Patient enrolment
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Histological analysis of the SLNs showed lymph node metastases in 13 of 32 pa-
tients. Macrometastases (larger than 2 mm) were found in eight patients and isolated 
tumour cells (ITCs) or micrometastases (equal to or smaller than 2 mm) in fi ve 
patients.
Comparison between treatment groups
Th e number of preoperative identifi ed SLNs by radioscintigraphy was not diff erent 
between the low dose group, median one (1 – 2), and high dose group, median one 
(1 – 2), P = 0.564. Despite doubling the particle density, the percentage of the amount 
of injected tracer accumulated in the SLN per patient based on the scintigraphy did 







Age in years (median; range) 59 (44 – 82) 55 (34 – 77) 0.322
Body mass index, kg/m2 (median; range) 25 (21 – 39) 23 (18 – 37) 0.043
Previous breast procedure 0.635
- Breast augmentation 1 1
- Lumpectomy 0 1
- Neoadjuvant hormonal /
 Chemotherapy 4 2
- Previous axillary surgery 0 0
Multifocality 1 5 0.172
Type of Operation 0.458
- Mastectomy 7 4
- Wide local excision 9 12
Hours between injection and surgery (median; 
range) 24 (19 - 29) 22 (20 - 25) 0.196
Pathological tumour size in mm (median; range) 14 (3 – 34) 15 (4 – 30) 0.681
Histological type 0.717
- Infi ltrating ductal adenocarcinoma 13 13
- Infi ltrating lobular adenocarcinoma 2 1
- Ductal Carcinoma In Situ (DCIS) 1 2
Histological grade 0.058
- I 2 3
- II 10 4
- III 1 7
- No grading possible (DCIS) 3 2
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not improve, median 1.7 (0.2 – 7.3) per cent vs. median 2.6 (0.4 – 30.4) per cent, P = 
0.402. Nevertheless, the higher particle density group had SLNs that showed a higher 
accumulation of the tracer (Fig. 4). Between the groups no diff erence was observed 
in the amount of higher echelon nodes during lymphoscintigraphy.
Intraoperatively, the number of identifi ed SLNs did not diff er between the low 
dose group, median one (1 – 2), and high dose group, median one (1 - 3), P = 0.323. 
No signifi cant diff erence was found for the fl uorescence intensity, median 255 (98 – 
542) vs. median 284 (90 – 921), P = 0.590 or signal-to-background ratio of the SLN, 
median 5.4 (3.0 – 15.4) vs. median 4.9 (3.5 – 16.3), P = 1.000, between the low dose 
group and higher dose group, respectively (Fig. 4).







1 Day before  
surgery 
Directly prior  
to incision 
SLN detection 
Figure 2 – NIR fl uorescence imaging during SLN mapping in breast cancer
Th e periareolar injection site (inj.) and an aff erent lymphatic channel (arrowhead) are clearly visualized the 
day before surgery (upper panel). Directly before surgery, patent blue is injected periareolarly. Th e lymphatic 
channels (arrowhead) can still be visualized percutaneously using NIR fl uorescence (middle panel). Th e sen-
tinel lymph node (SLN) (arrow) is identifi ed by NIR fl uorescence and blue staining. Th e black cross indicates 
the presumed position of the SLN. Camera exposure times were 100 ms (upper and middle panels) and 40 ms 
(lower panel).
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DISCUSSION
Th e present study shows that the use of ICG-99mTc-Nanocolloid for SLN biopsy is 
feasible in patients with breast cancer. Th is tracer permits preoperative imaging and 
intraoperative guidance. By combining NIR fl uorescence and radioactivity in one 
tracer, discrepancies between the two imaging modalities used for SLN localization 
are less likely to occur. In the current study all SLNs could be surgically detected by 
both gamma radiation and NIR fl uorescence imaging. Lymphatic vessels draining 
to the SLN were fl uorescent the day aft er tracer administration and contributed to 
detection of the SLN.
In an attempt to optimize nodal accumulation of the tracer and the NIR fl uores-
cence signal, a two-fold higher particle density of ICG and Nanocolloid was admin-
istered. In the higher dose group, multiple outliers with higher tracer accumulation 
in the SLN were observed, though not yielding a statistically signifi cant increase in 
tracer accumulation. Th e results were similar for the fl uorescence based identifi ca-
tion (Fig. 4). In contrast to intratumoural tracer deposition29, an increase in particle 
density does not appear to have a signifi cant infl uence on the SLN identifi cation 









Preoperative SLN identifi cation
-Identifi cation rate 32 / 32 16 / 16 16 / 16
-Number of SLNs detected per patient 
(median; range) 1 (1 – 2) 1 (1 – 2) 1 (1 – 2) 0.564
-Percutaneous fl uorescence lymph 
drainage visualization 22 / 32 10 / 16 12 / 16 0.704
Intraoperative SLN identifi cation
-Identifi cation rate 32 / 32 16 / 16 16 / 16
-Total number of SLNs removed 48 21 27
Method of intraoperative detection
- Radioactive 48 / 48 21 / 21 27 / 27
- Blue 42 / 48 17 / 21 25 / 27 0.383
- Fluorescent 48 / 48 21 / 21 27 / 27
Histology sentinel lymph node 0.686
- Negative 19 / 32 10 / 16 9 / 16
- Micrometestases / ITC 5 / 32 3 / 16 2 / 16
- Macrometastases 8 / 32 3 / 16 5 / 16
ITC; Isolated tumour cells, SLN; Sentinel lymph node
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when periareolar administrations are used. In the current study the dose of 99mTc was 
kept the same for both groups (100 MBq). Globally diff erent doses of 99mTc varying 
from 10 up to 370 MBq are used for SLN detection30. As the lymphatic distribution 
of ICG-99mTc-Nanocolloid is mainly determined by the large Nanocolloid particles, 
no signifi cant diff erences in sensitivity of the fl uorescence signal are expected when 
varying the amount of 99mTc while maintaining the Nanocolloid dose.
In previous studies using ICG alone, 25-times more ICG was injected during 
surgery7,8. In addition, the volume of these injections was eight times higher, thereby 
increasing the interstitial fl uid pressure and lymphatic drainage. Th ese two factors 
contributed to a SBR of approximately nine7,8. In this study a lower SBR (approxi-
mately six) was observed using ICG-99mTc-Nanocolloid. Th is decrease is relatively 
small because the lower dose and smaller injection volume of ICG is likely off set by 
the longer time between injection and imaging, which aids in the concentration of 
ICG in the SLN. Importantly, this decrease did not infl uence surgical guidance, as 
in all these patients ICG-99mTc-Nanocolloid permitted accurate SLN identifi cation 
during surgery and lymphatic vessels were still clearly visible.
In the current study 42 out 48 SLNs stained blue, which is comparable to the iden-
tifi cation rate of blue dye in large multi-centre studies3. NIR fl uorescence identifi ed 
more SLNs compared to blue dye staining and detected SLNs that were deeper located 
in the tissue. Similar results were obtained in previous studies7,26, showing no benefi t 
of blue dye when NIR fl uorescence imaging was used8. When ICG-99mTc-Nanocolloid 
is used and blue dye is omitted, no lymphatic tracer has to be injected directly prior 
to surgery, and in combination with the enhanced detection by NIR fl uorescence 
compared to blue dyes, this can improve logistics and shorten the time of surgery.
Various techniques are being evaluated to improve depth penetration of NIR fl uo-
rescence contrast agents31,32 and to study when radioactivity can be omitted8. If in the 
Color NIR Color-NIR Merge 
1 cm 
Figure 3 – Intraoperative detection of lymphatic vessels using NIR fl uorescence:
Th e lymphatic vessel (arrowhead) draining to the sentinel node (arrow) located deeper into the tissue, is clearly 
identifi ed by NIR fl uorescence.
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future depth penetration of NIR fl uorescence contrast agents increases, radioactive 
colloids may possibly be omitted, thereby improving logistics and costs. At present, 
NIR fl uorescence is mainly used in addition to radioactive colloids. Widespread 
clinical dissemination of this technique requires a cost-eff ective approach. ICG–
99mTc-Nanocolloid is based on a regularly used lymphatic tracer in Europe and only 
needs addition of a small amount (0.025 mg) of ICG with a cost of approximately 
50-80 Euro for 25 mg. A variety of relatively low-cost commercial camera systems are 
already available for clinical use33.
Th e hybrid optical/nuclear agent ICG–99mTc-Nanocolloid has shown to be a 
successful tracer for image-guided SLN biopsy in patients with breast cancer. ICG–
99mTc-Nanocolloid provides fully integrated pre- and intraoperative radioactive and 
NIR fl uorescence guidance, no injection directly prior to surgery is necessary and the 
intraoperative fi ndings are comparable to those when using ICG alone. As no diff er-
ence was observed between the two ICG-99mTc-Nanocolloid dose groups, a particle 
density of 160 µM ICG-99mTc-Nanocolloid injected in 200 µL the day before surgery 
could be recommended.
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 Chapter 7
Sentinel lymph node biopsy in melanoma 
patients using combined radioactive and 
fl uorescence guidance
Verbeek FP1, Tummers QR1, Rietbergen DD, Schaafsma BE, Boonstra MC, 
Liefers GJ, Frangioni JV, van de Velde CJ, van Leeuwen FW, Vahrmeijer AL





Recently, near-infrared (NIR) fl uorescence has been introduced for sentinel lymph 
node (SLN) biopsy. NIR fl uorescence imaging outperforms blue dye, however ra-
dioactive guidance remains essential for preoperative planning and deeply located 
SLNs. Th e main aim of is study is to validate the use of a dual-modality fl uorescence 
and radioactive tracer for SLN detection in melanoma patients using a “hands free” 
imaging system.
Methods
Th is prospective study included patients planning to undergo SLN mapping for 
cutaneous melanoma. Th e day before or on the day of surgery, the dual-modality 
radioactive and NIR fl uorescence tracer ICG-99mTc-Nanocolloid was injected around 
the primary excision scar. Preoperative lymphoscintigraphy was acquired. Directly 
before surgery, blue dye was injected. Intraoperative SLN localization was performed 
using a handheld gamma probe and the Mini-FLARETM imaging system.
Results
Fourteen patients with cutaneous melanoma undergoing SLN biopsy were included. 
Preoperative lymphoscintigraphy allowed detection of the SLN in all patients, with 
a total of 19 nodes. Moreover, in 9 out of 14 patients lymphatic channels draining 
from the injection site to the SLN could be observed percutaneously using NIR 
fl uorescence allowing real time surgical guidance. Intraoperatively, all SLNs could be 
identifi ed using both radioactive and fl uorescence guidance, whereas only 13 out of 
19 stained blue.
Conclusions
Th is study is the fi rst to demonstrate the added value of continuous visualisation of 
lymphatic vessels and SLNs in relation to the surgical anatomy using a dual modality 
fl uorescent and radioactive probe.
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INTRODUCTION
Sentinel lymph node (SLN) biopsy is currently regarded as standard-of-care in nodal 
staging of cutaneous melanoma patients1. SLN biopsy in melanoma patients is con-
ventionally performed using a combination of radioactive colloids and blue dye2. Th e 
use of this combination facilitates high detection rates (>95%).
Over the last few years, near-infrared (NIR) fl uorescence imaging has been in-
troduced for SLN biopsy3. NIR fl uorescence imaging has several characteristics that 
are advantageous in the SLN procedure compared to blue dye. NIR fl uorescence 
imaging has a relatively high penetration into living tissue (several millimetres) and 
there is no interference with the surgical fi eld as NIR light is invisible to the human 
eye4. Recent studies showed that NIR fl uorescence imaging outperformed blue dye 
staining for SLN identifi cation5-10. However, radioactive colloids are still essential for 
preoperative planning and to identify aberrant drainage profi les and deeply located 
SLNs11.
To combine both radio guidance and NIR fl uorescence, a dual-modality radio-
active and NIR fl uorescence tracer has been developed . Both the fl uorescent label 
indocyanine green (ICG) and radioactive label 99mTechnecium (99mTc) are bound by 
nanocolloid, which provides optimal retention of both signatures within the SLN. 
Th e aim of this study was to evaluate this tracer using a “hands free” fl uorescence im-
aging setup for the visualisation of lymphatic vessels and SLNs in melanoma patients.
MATERIALS AND METHODS
Th e trial was approved by the Medical Ethics Committee of the Leiden University 
Medical Center and was performed in concordance with the ethical standards of the 
Helsinki Declaration of 1975. Patients planned for therapeutic re-excision and SLN 
biopsy for cutaneous melanoma were included in this prospective study. Exclusion 
criteria were pregnancy, lactation, or an allergy to iodine, shellfi sh, or ICG. Th e trial 
has been registered in the Dutch trial registry as NTR3850. All patients gave informed 
consent and were anonymized.
Tracer preparation
99mTc-nanocolloid was prepared by adding sodium pertechnetate (approximately 
1000 MBq) in 2 mL saline to a vial of 0.5 mg human serum albumin nanocolloid 
(Nanocall, GE Healthcare, Eindhoven, the Netherlands). Aft er 30 min of incubation 
at room temperature, 50 µL of 6.4 mM (0.25 mg) ICG (Pulsion Medical Systems, 
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Munich, Germany) dissolved in water for injection was added to obtain ICG-99mTc-
nanocolloid at a fi nal ICG concentration of 160 µM and a fi nal pH of 6.0 – 7.0 (fi g. 
1A)12,13. All procedures were performed under current good manufacturing practice 
(cGMP) and under supervision of the institution’s pharmacist.
Clinical trial
Th e day before surgery (n = 12) or the day of surgery (n = 2), 60-100 MBq ICG-99mTc-
nanocolloid was injected at 4 quadrants around the primary excision scar (fi g. 1B). 






B. Tracer administration 
C. Pre-operative scintigraphy  
ICG-99mTc-Nanocolloid  
D. Intraoperative SLN mapping 
A. Tracer preperation 
Figure 1 – Clinical Trial Protocol:
A: Aft er preparation of 99mTc-nanocolloid, ICG dissolved in water for injection is added to obtain ICG-99mTc-
nanocolloid at a fi nal ICG concentration of 160 µM. B: Th e tracer ICG-99mTc-nanocolloid is administered at 4 
quadrants around the primary excision scar. C: Preoperative lymphoscintigraphy is acquired at the department 
of Nuclear Medicine to determine the position of the injection site (arrowhead) and SLN (arrow). D: Surgical 
resection of the SLNs is performed using a combination of radioactivity and fl uorescence. Th e surgeon is con-
tinuously provided with real-time NIR fl uorescence image guidance. When desired, an acoustic gamma probe 
can be used as well. Th e mini-FLARE imaging system allows “hands free” visualisation of lymphatic vessels and 
lymph nodes in relation to surgical anatomy.
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images at 15 minutes and 3 hours post injection, using one detector of a single or two-
headed gamma camera (Symbia T6, Siemens, Erlangen, Germany or Toshiba GCA-
7200PI/7200DI/7100UI, Toshiba, Tokyo, Japan). Before the start of the operation, 
1 ml Patent Blue V (Guerbet, Brussels, Belgium) was injected in multiple deposits 
surrounding the primary excision scar. Aft er surgical scrub, the Mini-FLARE imag-
ing system, as described earlier, was positioned at approximately 30 cm above the 
surgical fi eld14. Th e NIR fl uorescence signal was measured percutaneous prior to skin 
incision. Subsequently, during surgical exploration, the surgeon was continuously 
provided with real-time NIR fl uorescence image guidance and radioactive guidance 
using a hand-held gamma probe (Europrobe, Euromedical Instruments, Le Chesnay, 
France) (fi g. 2). Lymphatic vessels draining the injection site towards the SLN were 
visualized using fl uorescence. When visible, the blue dye was also used to provide 
optical guidance.
SLNs were fi xed in formalin and embedded in paraffi  n for haematoxylin, eosin, 
and immunohistopathological staining using the S-100 and MART-1 markers at six 
levels, with an interval of 50-150 μm.












Inj. site  
Figure 2 – NIR fl uorescence imaging during sentinel lymph node mapping:
Top row, percutaneous near-infrared identifi cation of aff erent lymphatic channels and the SLN. Th e off -page 
connector symbol indicates the position of the injection site (Inj. site; off -screen) and the marked cross indicates 
the presumed position of the SLN (arrow) as marked by the nuclear medicine physician. Middle row, real-time 
fl uorescence guidance of the SLN (arrow) directly aft er incision. Bottom row, resection of the SLN (arrow) un-
der NIR fl uorescence guidance, two minutes aft er incision. Blue dye staining becomes also visible. Scale bars = 
1 cm. Camera exposure times were: 200 ms (upper row), 100 ms (middle row) and 20 ms (bottom row).
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RESULTS
Patient and Tumour Characteristics
Fourteen patients with cutaneous melanoma undergoing SLN biopsy were included. 
Seven patients were male. Median body mass index was 25 kg/m2 (range 19 - 29), 
median age was 51 years (range 27 - 74 years), and median Breslow’s depth was 1.8 
mm (range 0.3 – 4.5 mm). In 6 patients, the melanoma was located at the upper 
extremities, in 5 patients on the trunk and in 3 patients at the lower extremities.
Table 1 – Sentinel Lymph Node Identifi cation Results
Characteristic N %
SLN Detection
- Number of SLNs Identifi ed 19
- Median Number of SLNs Identifi ed (Range) 1 (1 - 3)
Method of Detection
- Radioactive 19 100
- Fluorescent 19 100
- Blue 13 68
Median Time between tracer Injection and Skin Incision (hours), (Range). 23 (5 – 29)
Median Time between Skin Incision and SLN Resection (minutes), (Range) 12 (2 – 24)
Percutaneous identifi cation
- Lymphatic vessels (no. of patients) 9 64
- SLNs (no. of patients) 4 2
SLN localization
- Axilla 13 68
- Groin 6 32
Histology
- Negative 17 89
- Micrometastases 2 11
- Macrometastases 0 0
Adjuvant treatment (no. of patients)
- None 12 86
- Axillary Lymph Node Dissection 2 14
SLN, sentinel lymph node
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Sentinel Lymph Node Detection
Preoperative lymphoscintigraphy allowed detection of at least one SLN in all patients 
with a total of 19 SLNs. Th e median time of ICG-99mTc-nanocolloid injection to 
surgery was 23 hours (range, 5 – 29). In 9 out of 14 patients (64%) lymphatics drain-
ing the injection site towards the SLN were observed percutaneously. Moreover, in 4 
patients SLNs could be observed percutaneously (fi g. 2).
Surgical resection of the SLNs was performed using a combination of radioactiv-
ity, continuous fl uorescence-imaging, and blue guidance. All 19 resected SLNs were 
both radioactive and fl uorescent (Table 1). However, only 13 out of 19 SLNs (68%) 
were stained blue. Lymphatic vessels draining the SLN were still fl uorescent up to 29 
hours aft er tracer injection (fi g. 2). Median SLN fl uorescence signal-to-background 
ratio was 5.6 (range, 2.5 – 13.8). Median time between skin incision and resection of 
the fi rst SLN was 12 minutes (range, 2 – 24). In 2 patients one resected SLN contained 
micrometastases. No adverse reactions or complications occurred.
COMMENT
Th e used dual-modality tracer allowed both preoperative planning and real-time 
intraoperative radioactive and fl uorescence guidance for SLN detection, and aided in 
the intraoperative detection of fl uorescent lymphatic vessels up to 29 h aft er injection.
Recently, our group have demonstrated feasibility of accurate SLN mapping using 
NIR fl uorescence and ICG in melanoma patients15. However, radioactive guidance 
appeared to be still obligatory for preoperative planning and for the identifi cation of 
deeply located SLNs. ICG-99mTc-nanocolloid permits both fl uorescence and radioac-
tivity guidance aft er a single injection and has already been tested in various cancer 
types16,17. And, unlike patent blue, ICG does not alter the look of the surgical fi eld 
or tattoo the skin of the patient. In addition, this tracer maintains the properties of 
99mTc-nanocolloid, which is a commonly used lymphatic tracer in Europe and only 
needs addition of a small amount (0.025 mg) of ICG.
An advantage of NIR imaging is that is has the ability to provide real-time guid-
ance. However, to enable the surgeon to apply this guidance effi  ciently, navigation in 
relation to the surgical anatomy is obligatory. Th e camera system used in this study is 
capable of displaying NIR fl uorescence signal in relation to the surgical anatomy, and 
especially designed for hands free operation. Moreover, this allowed clear detection 
of fl uorescent lymphatic vessels, which especially aided in the detection of the SLN.
In conclusion, this study demonstrates the added value of direct lymphatic guid-
ance towards the SLN in relation to the surgical anatomy by combining the use of 
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a “hands free” camera system and a dual modal NIR probe. Th is technique has the 
potential to shorten time of surgery and to reduce surgical manipulation.
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Unlike other cancers, the Sentinel Lymph Node (SLN) procedure in bladder cancer 
requires special attention to the injection technique. Th e aim of this study was to 
assess feasibility and to optimize tracer injection technique for SLN mapping in blad-
der cancer patients using NIR fl uorescence imaging.
Methods
Twenty patients with invasive bladder cancer scheduled for radical cystectomy were 
prospectively enrolled. Indocyanine green (ICG) bound to human serum albumin 
(complex ICG:HSA; 500 µM) was injected peritumourally to permit SLN mapping. 
ICG:HSA was fi rst administrated serosally (n=5), and subsequently mucosally by 
cystoscopic injection (n=15). In the last cohort of 12 patients treated with cystoscopic 
injection, the bladder was kept fi lled with saline for at least 15 minutes.
Results
Fluorescent lymph nodes were observed only in the patient group with cystoscopic 
injection of ICG:HSA. Filling of the bladder post-injection was of added value to 
promote drainage of ICG:HSA to the lymph nodes, and in 11 of these 12 patients 
(92%) one or more NIR fl uorescent lymph nodes were identifi ed.
Conclusions
Th e current study demonstrates proof-of-principle of using NIR fl uorescence imag-
ing for SLN identifi cation in bladder cancer. Cystoscopic injection with distension of 
the bladder appears optimal for SLN mapping.
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INTRODUCTION
Pelvic lymph node dissection is the standard-of-care for surgical management of 
muscle-invasive bladder cancer. Lymph node dissection is both of therapeutic and 
prognostic value as patients with tumour involvement in the lymph nodes have a 
higher risk of developing disease progression1,2. Over the last few decades, the sen-
tinel lymph node (SLN) concept has been introduced to provide as a less invasive 
technique for nodal staging compared to lymphadenectomy. SLN biopsy has proven 
to be feasible and safe in breast cancer, penile cancer, and melanoma for selecting 
patients who would benefi t from lymphadenectomy3-5. Moreover, SLN mapping has 
also been suggested as a tool to improve nodal staging by selecting lymph nodes for 
ultrastaging using serial sectioning and additional immunohistochemistry or reverse 
transcriptase (RT)-PCR6. Th ough, to date little evidence is available concerning the 
value of SLN mapping in the management of bladder cancer patients.
Th e feasibility of the SLN procedure in bladder cancer has been assessed in only 
a few clinical studies7-12. Th e largest study was able to detect the SLN in 65 out of 75 
patients (87%), with a false-negative rate of 6 out of 32 patients (19%)7. Th ese results 
are lagging behind results obtained with SLN biopsy in patients with penile cancer or 
melanoma3,4. In studies exploring SLN mapping in bladder cancer, only conventional 
SLN tracers were used, such as radioactive colloids, blue dye, or a combination of 
both. However, radioactive colloids require the involvement of a nuclear physician 
and blue dye has been found less sensitive in bladder cancer and fl ows rapidly to 
2nd-tier lymph nodes7.
More recently, fl uorescence guided surgery has been introduced, and is a rapidly 
emerging intraoperative imaging modality in the fi eld of urology for identifi cation 
of tumour tissue, vital structures (e.g. ureters), and for SLN mapping13-16. Th e use of 
near-infrared (NIR) fl uorescence imaging has several advantages, such as a relatively 
high tissue penetration and low autofl uorescence, which makes it possible to detect 
low concentrations of tracer deeper (i.e., millimetres) into tissue17-19. As NIR light, 
with a wavelength between 700-900 nanometres, is invisible to the human eye, NIR 
fl uorescence does not alter the surgical fi eld. Using the clinically-available NIR fl uo-
rescence tracer Indocyanine green (ICG), this technique has been successfully used 
in the clinic for several types of cancer20-22.
In bladder cancer, NIR fl uorescence imaging has been evaluated in large animals 
in which diff erent tracers and injection techniques were assessed to optimize fl uores-
cence SLN mapping23. Th ough, the fl uorescent lymphatic tracers used (HSA800 and 
fl uorescent quantum dots) are currently not clinically available, and results overall 
were not as promising as in other cancers. Th e aim of current study is to assess the 
feasibility of NIR fl uorescence SLN mapping in bladder cancer patients and to opti-
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mize tracer injection by testing various administration techniques in a clinical trial 
setting.
MATERIALS AND METHODS
Th is study was approved by the Medical Ethics Committee of the Leiden University 
Medical Centre and was performed in accordance with the ethical standards of the 
Helsinki Declaration of 1975. Th is study is registered in the Dutch Trial Register as 
NTR3657. All patients with invasive bladder cancer planned for radical cystectomy 
at the Leiden University Medical Center were eligible for inclusion. Exclusion criteria 
were pregnancy, lactation, or an allergy to iodine or ICG. Th e trial was performed 
between May 2010 and February 2014. All enrolled patients gave informed consent 
and were anonymized.
Tracer Preparation
ICG (25-mg vials, Pulsion Medical Systems, Munich, Germany) was resuspended in 
10 cc of sterile water. ICG was mixed with human serum albumin (HSA) to form the 
ICG:HSA complex. To obtain a concentration of 500 µM of ICG, 7.8 mL of the 3.2 
mM ICG solution was diluted in 42.8 ml of Cealb (20% HSA, Sanquin, Amsterdam, 
Th e Netherlands) to create the preparation ICG:HSA. A dose of 500 µM was chosen 
based on previous dose optimization studies in other cancers24.
Surgical Technique
In addition to the planned cystectomy, patients received the NIR fl uorescent tracer 
ICG:HSA to permit NIR SLN mapping. To optimize the technique, diff erent injec-
tion methods were assessed in consequetive series. First, ICG was injected around 
the tumour (500 µM, 4 deposits of 0.5 ml) directly into the bladder wall (serosa) aft er 
laparotomy (n = 5). Subsequently ICG (500 µM, 4 deposits of 0.5 ml) was injected 
cystoscopically (n = 15) around the tumour into the bladder wall (mucosa) directly 
before surgery. In the last twelve cases the bladder was fi lled using saline for at least 
15 minutes aft er cystoscopic injection of ICG:HSA to provide moderate bladder 
distension, which could promote lymphatic drainage. Th e study protocol is presented 
schematically in Figure 1.
In all but one patient, extended bilateral exploration of the lymphatic regions 
draining the bladder was performed before cystectomy. Th e one patient in whom 
no lymphadenectomy was performed suff ered from non-muscular invasive papillary 
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urothelial carcinoma and synchronous prostate cancer with clinically low risk for 
positive lymph nodes, which was not an indication for lymphadenectomy. Moreover, 
suspected lymph nodes outside the lymphadenectomy region were also resected and 
sent for pathology.
Directly before and during lymphadenectomy, SLN mapping was performed using 
the Mini-Fluorescence-Assisted Resection and Exploration (Mini-FLARE) camera 
system as described previously24. SLNs were defi ned as fl uorescent lymph nodes 
draining from the bladder that could be identifi ed using the Mini-FLARE camera 
system. Fluorescent hotspots identifi ed intraoperatively or aft er lymphadenectomy 
in the resection specimen were sent separately to pathology. Excised fl uorescent 
hotspots and lymphadenectomy specimens were analysed by the pathologist using 
hematoxylin and eosin staining as per the standard of care.
A. Tracer Injection 
C. Ex Vivo Imaging D. Send for Pathology 
B. Intraoperative Imaging 
ICG:HSA 
SLN 1 SLN 2 LND 




Cystoscopic injection (n = 15) 
     Ɣ Without bladder distension (n = 3) 
     Ɣ With bladder distension (n = 12) 
 
 
Figure 1 – Clinical Trial Protocol
1. Th e tracer ICG:HSA is administered either serosally aft er laparotomy or cystoscopically into the mucosa. In 
one cohort of patients, the bladder was distended with saline aft er cystoscopic injection of ICG:HSA. 2. Dur-
ing lymphadenectomy, the Mini-FLARE imaging system was used for in vivo identifi cation of NIR fl uorescent 
lymphatic vessels and lymph nodes. 3. Aft er resection of NIR fl uorescent lymph nodes (SLN) and further lymph 
node dissection (LND), all tissue was assessed ex vivo using Mini-FLARE to identify possible additional NIR 





Patient characteristics and surgical results are presented in Table 1. In total 20 pa-
tients with invasive bladder carcinoma were included in this study. Fourteen patients 
were male, median age was 72 years (range, 47 - 77), median body mass index (BMI) 
was 26 kg/m2 (range, 18 - 40). All patients were clinically staged with muscle invasive 
disease based on preoperative biopsy. Th ree patients had a history of radiotherapy to 
the pelvic area because of invasive bladder cancer (N = 2) or cervical cancer (N = 1). 
Median tumour size was 38 mm (range, 17 - 93) with tumour invasion stages ranging 
from T2 to T4. In 3 patients, that were staged as a cT2, no residual tumour was found 
aft er resection by pathology. In case a bilateral lymphadenectomy was performed 
an average of 14 ± 9.1 lymph nodes were resected. In 4 patients tumour-positive 
lymph nodes were detected during pathological examination. According to the 
Dutch guidelines, patients did not recieive (neo)adjuvant chemotherapy. No adverse 
reactions associated with the use of ICG:HSA were observed.
Sentinel lymph node mapping
Diff erent injection strategies were consequetevely evaluated in bladder cancer 
patients to fi nd the most promising technique. ICG:HSA was administered using 
abdominal serosal injection in cases 1-5. Th ough, as these procedures were failing, 
cystoscopic muscosal injection was applied in the latter 6-20 cases. From case 9 till 
20, bladder distension using saline was also applied aft er tracer injection.
Abdominal serosal injection (cases 1-5): In none of the fi ve patients receiving 
ICG:HSA by subserosal injection aft er laparotomy a fl uorescent node was observed 
either in vivo or in the resection specimen. In one patient, a possible NIR fl uorescent 
lymphatic vessel was observed. No tumour-positive nodes were detected during 
pathological examination.
Cystoscopic mucosal injection without bladder distension (cases 6-8): In one out of 
three patients a single fl uorescent lymph node was identifi ed and denominated as 
a SLN. However, in this patient the fl uorescent node was tumour-negative whereas 
other resected lymph nodes were tumour-positive. No fl uorescent lymphatic chan-
nels were observed.
Cystoscopic mucosal injection with distension of the bladder (cases 9-20): Aft er 
cystoscopic mucosal injection and fi lling of the bladder, in 11 out of 12 cases (92%) 
a fl uorescent node could be identifi ed and denominated as a SLN in vivo (Figure 2). 
In these patients a median of 2.5 (range 0 – 6) SLN were identifi ed in vivo. Moreover, 
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fl uorescent lymphatic vessels could be followed to the SLN (Figure 3). In two patients, 
SLNs identifi ed using NIR fl uorescence contained a metastasis. No false-negative 
cases were observed in this group.
Table 1 – Patient characteristics and sentinel lymph node detection












Intra-abdominal subserosal ICG injection
1 74 M T3N0 0 6 0
2 77 V T3N0 0 4 0
3 69 M T1N0 0 13 0
4 52 V T2N0 0 15 0
5 67 M T0N0 (cT2)b 0 0a 0 Low grade papillary urothelial carcinoma 
and synchronous prostate cancer
Cystoscopic submucosal ICG injection without fi lling of the bladder
6 61 M T4N1 0 1 1 SLN procedure failed, intraoperatively 
identifi ed positive lymph node,
7 58 M T4N1 1 7 1 False-negative SLN as detected by NIR 
fl uorescence, tumour detected in a 
diff erent resected node
8 66 V T2N0 0 0 0 Previous pelvic lymphadenectomy and 
radiotherapy‡
Cystoscopic submucosal ICG injection with fi lling of the bladder for 15 minutes with saline
9 47 M T0N0 (cT2)b 1 25 0
10 77 V T2N0 3 32 0
11 71 M T2N0 0 9 0 Previous radiotherapy†
12 77 M T3N0 1 5 0
13 76 M T2N0 1 13 0 Previous radiotherapy†
14 74 V T3N1 1 13 1 Tumour positive SLN detected by NIR 
fl uorescence
15 71 V T2N0 3 16 0
16 71 M T4N0 3 7 0
17 72 M T2N0 6 25 0
18 74 M T2N1 2 9 1 Multifocal disease. Tumour positive SLN 
detected by NIR fl uorescence
19 72 M T2N0 4 26 0
20 72 M T0N0 (cT2)b 4 21 0
a No indication for lymphadenectomy
b Preoperative tumour stage of based on cystoscopy biopsy
Medical history of pelvic radiotherapy for † bladder cancer or for ‡ cervical cancer
ICG, indocyanine green
SLN, sentinel lymph node
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DISCUSSION
Th is clinical study assesses diff erent injection techniques and the feasibility of SLN 
mapping in bladder cancer patients using NIR fl uorescence imaging. Several methods 
of tracer administration were consecutively evaluated. Unlike the results obtained in 
large animals, NIR fl uorescence guided SLN mapping aft er abdominal serosal injec-
tion of ICG:HSA failed in all patients. As a consequence, we tested additional admin-
1 cm 






Figure 2 – Intraoperative and ex vivo detection of fl uorescent lymph nodes
Shown are colour video (left ), NIR fl uorescence (middle), and a pseudo-coloured merge of the two (right). 
Th e upper row shows the intraoperative detection of two NIR fl uorescent lymph nodes (arrowheads) along the 
left  external iliac vein. In the lower row, the two NIR fl uorescent lymph nodes are clearly identifi ed using NIR 
fl uorescence imaging aft er excision. Excitation fl uence rate was 7.7 mW/cm2. Camera exposure times were 10 
ms (upper row) and 15 ms (bottom row). Scale bar = 1 cm.
Color NIR Merge 
1 cm 
Figure 3 – NIR fl uorescent identifi cation of lymphatic vessels
Shown are colour video (left ), NIR fl uorescence (middle), and a pseudo- coloured merge of the two (right). 
Aft er exploration, the lymphatic vessel (arrow) draining to the SLN (arrowhead) is clearly identifi ed using NIR 
fl uorescence aft er injection of ICG:HSA. Excitation fl uence rate was 7.7 mW/cm2. Camera exposure times were 
10 ms.
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istration techniques. Cystoscopic injection of ICG:HSA with subsequent distension 
of the bladder was found to be crucial for providing drainage of the lymphatic tracer 
to the lymph nodes and permitted detection of the SLN in 11 out of 12 patients in 
this group. Th e positive infl uence of distension of the bladder on lymphatic drainage 
was also observed in a preclinical study in canines23. Possible explanations could be 
the increased interstitial pressure as result of bladder distension, which facilitates 
lymphatic fl ow. In the current study the bladder was only fi lled with a volume provid-
ing moderate bladder distension, as a surplus of bladder distension can result in com-
pression of the lymphatic vessels that hamper lymph drainage23,25. During distension 
of the bladder no quantifi cation of the bladder pressure was obtained. However, clear 
lymph drainage was visible in most of these patients. Based on these results, future 
studies should focus on the relationship between intraluminal bladder pressure and 
lymphatic fl ow.
Cystoscopic administration of the lymphatic tracer has multiple advantages over 
subserosal administration aft er laparotomy. Cystoscopic injection in the urothelium 
prior to surgery ensures intact lymphatic vessels, which can be disrupted during 
surgical exploration. Additionally, tracer administration during cystoscopy provides 
direct visualization of the location of the tumour compared to only palpation when 
the tracer is injected serosally aft er laparotomy. Moreover, injection prior to surgery 
allows the lymphatic tracer more time to accumulate in the SLN. Th ese advantages 
of cystoscopic injection over serosal tracer injection could also be reasons no SLNs 
were identifi ed in the group in which the tracer was administrated aft er laparotomy.
It is known that the lymphatic drainage pattern of the bladder is complex and 
drainage is heavily infl uenced by tumor location, type of tumor, and extent of the 
disease. Previous studies exploring feasibility of SLN mapping in bladder cancer 
patients used conventional techniques such as radioactive colloids and blue dye7-10. 
Th ese tracers have several limitations when used for bladder cancer. Preoperative 
planning using radioactive colloids and lymphoscintigraphy is more diffi  cult to 
use in patients with bladder cancer, as radioactivity from the primary injection site 
interferes with SLN visualization. Moreover, the lymphatic pattern in the pelvis is 
more complex and SPECT in combination with low dose CT would be necessary to 
transfer the preoperatively identifi ed nodes to corresponding anatomical locations7,9, 
which additionally increases cost. On the other hand, when blue due is administered 
cystoscopically prior to surgery, the long period between the injection and the start 
of nodal exploration allows blue dye to fl ow to the 2nd-tier nodes7. In the present 
study, ICG provided direct optical support and as ICG is bound to the large serum 
proteins in the lymphatic channels, prolonged SLN retention is expected26. Moreover, 
this technique allows visualization of the lymphatic drainage pattern in real-time, 
and can therefore provide more insight in the actual drainage from pathway of the tu-
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mor. In addition, the advantage of depth penetration of NIR light, made it possible to 
detect lymph nodes several millimetres into the tissue without the need for ionizing 
radiation. When preoperative imaging (e.g. SPECT/CT) and intraoperative gamma 
guidance is desirable, ICG can simply be premixed with radioactive nanocolloid27.
Several limitations were observed in the study. In all treatment groups there were 
patients in which only few lymph nodes were resected. Resection of only few lymph 
nodes was most likely mainly due to previous radiotherapy. Moreover, in one patient 
in whom no lymphadenectomy was performed suff ered from non-muscular invasive 
papillary urothelial carcinoma and synchronous prostate cancer with clinically low 
risk for positive lymph nodes, which was not an indication for lymphadenectomy. 
In addition, one patient had a previous pelvic lymphadenectomy as part of surgery 
for cervical cancer; therefore no lymph nodes were found during lymphadenectomy. 
Th ough, SLN mapping was still performed to detect redirected lymphatic fl ow or 
potentially remaining lymph nodes.
One false-negative case occurred. In this case, one of the tumour-positive lymph 
nodes was completely fi lled with tumour, which could explain the impaired uptake 
of ICG in these nodes28. Moreover, although ICG was administered cystoscopically 
in this patient, the bladder was not kept fi lled aft er tracer injection, which could 
have resulted in insuffi  cient lymph drainage of the tracer. In previous studies in SLN 
biopsy in bladder cancer false-negative cases were also observed, with rates as high 
as 19%7. Due to this reported high false-negative rate, SLN biopsy in bladder cancer 
is not to be advised for avoiding a lymphadenectomy. Nevertheless, SLN mapping 
could still be a useful tool to select lymph nodes for ultrastaging (for example using 
RT-PCR) because ultrastaging of lymph nodes can more accurately assess lymph 
node status29. In addition, controversy exists on the extent of lymphadenectomy 
and the minimum number of nodes required for adequate lymphadenectomy1,2,30, as 
single node metastases can be located outside the obturator spaces along the com-
mon iliac and presacral areas12,31,32. At this stage, we believe that SLN mapping using 
NIR fl uorescence imaging is not able to replace the role of the lymph node dissection. 
However, in vivo SLN mapping can be suggested as a tool to improve assessment of 
lymph node status and for identifying SLNs lying outside the pre-operative planned 
resection, which potentially can still carry metastases. In addition, NIR fl uorescence 
imaging can also provide a useful tool for the detection of aberrant lymphatic path-
ways or crossover lymphatic drainage to contralateral lymph nodes33. Furthermore, 
as NIR fl uorescence imaging facilitates real-time visualization of lymphatic vessels 
and SLNs it could also be of added value during laparoscopic lymph node assessment 
in high-risk patients. It is expected that the development of new imaging systems and 
probes, which will improve depth penetration, image sensitivity and increase reten-
tion in the SLN, will further improve NIR fl uorescence image-guided surgery19,34.
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CONCLUSIONS
Th e current study demonstrates proof of principle of using ICG:HSA-based NIR 
fl uorescence imaging for SLN identifi cation in bladder cancer, but also identifi ed 
complex issues regarding the injection technique. Cystoscopic mucosal injection 
with distension of the bladder appears the optimal injection technique. Using this 
technique a fl uorescent node could be identifi ed and denominated as a SLN in vivo in 
11 out of 12 cases (92%). A next step in the development of this technique can be the 
diff use injection of ICG in the bladder mucosa. It is expected this will result in har-
vesting more SLNs, and could potentially provide more insights in actual lymphatic 
drainage pattern and also reduce the number of false negatives cases. Th is feasibility 
study allows initiating larger clinical trials to assess sensitivity more precisely and 
assess which patient groups can benefi t from NIR fl uorescence based SLN mapping.
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Sentinel lymph node biopsy in vulvar 
cancer using combined radioactive and 
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Near-infrared (NIR) fl uorescence imaging using Indocyanine Green (ICG) has 
recently been introduced to improve the SLN procedure. Several optical tracers have 
been successfully tested. However, the optimal tracer formulation is still unknown. 
Th is study evaluates the performance of ICG–99mTc-nanocolloid in relation to two 
most commonly used ICG-based formulas during SLN biopsy in vulvar cancer.
Materials and Methods
12 women planned to undergo SLN biopsy for stage I vulvar cancer were prospectively 
included. SLN mapping was performed using the dual-modality radioactive and NIR 
fl uorescence tracer ICG-99mTc-Nanocolloid. All patients underwent combined SLN 
localization using NIR fl uorescence, and the (current) gold standard using blue dye 
and radioactive guidance.
Results
In all 12 patients at least one SLN was detected during surgery. A total of 21 lymph 
nodes (median 2, range 1 – 3) were resected. Median time between skin incision 
and fi rst SLN detection was 8 (range 1 – 22) minutes. All resected SLNs were both 
radioactive and fl uorescent, though only 13 of 21 SLN (62%) stained blue. Median 
brightness of exposed SLNs, expressed as SBR, was 5.4 (range 1.8 – 11.8). Lymph 
node metastases were found in 3 patients.
Conclusions
NIR fl uorescence guided SLN mapping is feasible and outperforms blue dye staining. 
Premixing ICG with 99mTc-nanocolloid provides real-time intra-operative imaging of 
the SN and appears the optimal tracer combination in terms of intraoperative detec-
tion rate of the SN (100%). Moreover, ICG-99mTc-Nanocolloid allows administration 
of a 5-times lower injected dose of ICG (compared to ICG and ICG:HSA) and can be 
injected the up to 20h before surgery.
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INTRODUCTION
Lymph node involvement remains the most important prognostic factor for survival 
in women with vulvar cancer1,2. Th e introduction of radical wide local excision or 
radical vulvectomy with inguinofemoral lymphadenectomy using separate groin 
incisions has signifi cantly reduced morbidity compared to conventional radical 
vulvectomy with en bloc inguinofemoral lymphadenectomy3. Nevertheless, up to 
two third of patients who underwent inguinofemoral lymphadenectomy suff er 
from lymphedema4-6. Because < 30% of patients with FIGO (International Federa-
tion of Gynecology and Obstetrics, 2009) stage I or II vulvar cancer have positive 
lymph nodes, lymphadenectomy appears unnecessary aft erwards in the majority 
of patients7-9. Th e introduction of the sentinel lymph node (SLN) procedure has 
provided a less invasive algorithm to assess nodal staging10. To date, the use of the 
SLN procedure has been validated in several large studies and is considered both 
safe and accurate in a selected group of patients7,11. Moreover, it appears the most 
cost-eff ective strategy for the management of patients with early-stage vulvar cancer 
due to lower treatment costs and lower costs due to complications12.
To locate the SLN, a combination of both radioactive tracers and blue dye is 
currently the gold standard13. However both modalities have certain disadvantages. 
Despite the need for radiocolloids during preoperative planning, this technology 
gives only acoustic feedback intra-operatively and is unable to provide real-time 
visual guidance. Furthermore, blue dyes cannot be seen through skin and fatty tissue 
and can result in blue staining of the surgical fi eld at the site of injection. Near-
infrared (NIR) fl uorescence imaging using indocyanine green (ICG) has recently 
been introduced to improve optical identifi cation during the SLN procedure14-16. NIR 
fl uorescence imaging using Indocyanine green (ICG) has several characteristics that 
can be advantageous during the SLN procedure, including a relatively high tissue 
penetration and real-time optical guidance17. ICG is approved for clinical use by 
the US Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) and can be used off -label as a lymphatic tracer14.
Feasibility of NIR fl uorescence guided SLN biopsy in vulvar cancer has been previ-
ously demonstrated using several ICG-based tracer formulas18-21. In these studies, 
multiple methods of tracer administration and dosages of ICG have been investi-
gated. Crane et al. used ICG alone for SLN mapping in vulvar cancer (645 nmol 
ICG administered in 1 mL) and Hutteman et al. used several concentrations of ICG 
absorbed to human serum albumin (ICG:HSA) to improve SLN retention (800, 1200 
and 1600 nmol ICG administered in 1.6 mL)18,19.
Unfortunately, premixing with HSA, thereby increasing the hydrodynamic diam-
eter to 7nm, did not improve performance compared to ICG alone20. It was recently 
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shown that premixing ICG with 99mTc-nanocolloid yields the hybrid tracer ICG-99mTc-
nanocolloid with hydrodynamic diameter 20-80 nm, that retains in SLNs similar 
to the particle which is used as standard-of-care radiotracer 99mTc-nanocolloid22,23. 
Th is tracer has recently shown its value during gynecological SLN resections in the 
groin21, and during the highly similar procedures related to penile cancer24
To summarize, several ICG-based formulations and injected volumes have been 
used, but despite preclinical comparison studies, no comparison between diff erent 
tracers is available from the clinical setting. Th is study evaluates the use of ICG–99mTc-
nanocolloid, a dual-modality radioactive and NIR fl uorescence tracer. Subsequently 
results were compared to a previous performed randomized controlled trial in which 
two other diff erent tracer formulations, ICG alone and ICG:HSA, were used in ad-
dition to the standard-of-care procedure using blue dye and radioactive guidance.
MATERIALS AND METHODS
Clinical Trial
Th is clinical trial was approved by the Medical Ethics Committee of the Leiden Uni-
versity Medical Center and were performed in accordance with the ethical standards 
of the Helsinki Declaration of 1975. Women planned to undergo sentinel lymph 
node biopsy for clinically FIGO stage I vulvar cancer and with clinically negative 
inguinofemoral nodes (determined by palpation and ultrasonography) were eligible 
for participation in the trials25. Patients were enrolled in the study between January 
and October of 2013. Exclusion criteria were pregnancy, lactation, or an allergy to 
iodine or ICG. All patients gave informed consent and were anonymized. Th e 12 
patients included in the present study received ICG-99mTc-nanocolloid and have not 
previously been reported.
Tracer Preparation
ICG (25-mg vials) was purchased from Pulsion Medical Systems (Munich, Germany). 
ICG–99mTc-nanocolloid was purchased from GE Healthcare (Leiderdorp, the Nether-
lands). Aft er tracer preparation ICG–99mTc-nanocolloid had a fi nal activity of 60-100 
MBq. Th e tracer was injected intracutaneously at 3 to 4 depots around the tumor or 
excision scar. In the ICG–99mTc-nanocolloid formulation, the ICG concentration was 
161 µmol/l, leading to an injected ICG dose of 160 nmol in 1 mL (0.12 mg)21,24,26.
All procedures were performed under current good manufacturing practice and 
under supervision of the institutional pharmacist.
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Study Design
Patients received the standard-of-care SLN procedure using a combination of radio-
active (99mTc-nanocolloid), patent blue, and fl uorescence guidance11,27.
Th e day before or the morning prior to surgery the combined tracer ICG-99mTc-
nanocolloid was injected at the department of nuclear medicine. In the operating 
room also 1 mL of patent blue V (Guerbet, France) was injected in all patients. SLN 
localization was also performed with patent blue V, as it is part of the standard-
of-care for SLN mapping in the Netherlands. Th e tracers (radioactive, fl uorescent 
and blue dye) were all injected intracutaneously at 3 or 4 sites around the tumor or 
excision scar in case of earlier excision biopsy of the tumor. In all patients, directly 
aft er injection of the radioactive tracer, a dynamic lymphoscintigraphy was made 
at the department of Nuclear Medicine (Symbia T6, Siemens, Erlangen, Germany 
or Toshiba GCA-7200pi/7200di/7100ui, Toshiba, Tokyo, Japan). Th e sentinel node 
in the groin was marked on the skin using a waterproof marker. Directly following 
injection of the radioactive tracer and approximately 2 hours aft er injection, planar 
images were derived. In some patients SPECT/CT was performed on the two headed 
gamma camera (Symbia T6, Siemens, Erlangen, Germany with 6 slice CT).
SLN mapping was performed using the Mini-Fluorescence-Assisted Resection 
and Exploration (Mini-FLARE™) image-guided surgery system as described previ-
ously27,28. Th e NIR fl uorescence signal was measured percutaneously prior to skin 
incision, and continuously during the surgical procedure. Relative brightness of the 
SLNs was determined by measuring signal-to-background ratios (SBR) using cus-
tomized imaging soft ware29. In all patients the SLN was defi ned on lymphoscintigra-
phy as the fi rst node which received lymphatic drainage from the primary tumor30. 
Intraoperatively, the lymph nodes were identifi ed using acoustic feedback from the 
gamma probe. When the probe gave a gamma count of 10% or more compared to the 
most radioactive SLN, these nodes were also considered SLNs.
Excised SLNs were routinely analyzed by histopathological frozen section analysis. 
SLNs were fi xed in formalin and embedded in paraffi  n for hematoxylin, eosin, and 
immunohistopathological staining for AE1/AE3 at multiple levels, with an interval 
of 250 μm, according to the GROningen INternational Study on Sentinel nodes in 
Vulvar cancer (GROINSS-V) study protocol11. According to the study protocol a full 
inguinofemoral lymphadenectomy was performed in case of tumor-positive frozen 




For statistical analysis, SPSS statistical soft ware (Version 20.0, Chicago, IL) was used. 
Graphs were generated using GraphPad Prism Soft ware (Version 5.01, La Jolla, CA). 
Correlation between Body Mass Index (BMI) and SLN identifi cation time was deter-
mined using the Spearman’s rank correlation coeffi  cient. To compare patient charac-
teristics the 1-way ANOVA and chi-square tests were used. Th e 1-way ANOVA was 
corrected using Bonferroni correction in case of parametric data. For nonparametric 
data the Kruskal-Wallis test was used. Data was tested for normal distribution using 
the Shapiro-Wilk test. P < 0.05 was considered signifi cant.
RESULTS
Patient and Tumor Characteristics
Twelve consecutive patients with vulvar cancer who underwent SLN mapping us-
ing the combined tracer ICG–99mTc-nanocolloid were included in the current study. 
Median age of the patients was 72 years (range: 40 – 90) and median BMI was 24 kg/
m2 (range: 17 - 30). Tumor characteristics are shown in table 1. Th e median tumor 
size and infi ltration depth was 9 (range: 4 – 35) mm and 2.3 (range: 0.6 – 9) mm 
respectively. No adverse reactions associated with lymphatic tracer administration or 
the use of the Mini-FLARE™ imaging system were observed.











Age (median; range) 72 (40 - 90) 77 (47 - 87) 69 (36 - 83) 71 (36 - 90) 0.23
Body mass index (median; range) 24 (17 - 30) 28 (24 - 40) 27 (21 - 35) 27 (21 - 40) 0.08
Primary tumor size in mm 
(median; range)
9 (4 -35) 18 (5 - 48) 20 (5 - 55) 16 (5 – 55) 0.28
Primary tumor infi ltration depth 
in mm (median; range)
2.3 (0.6 – 9) 3.0 (1.5 - 27) 1.9 (1.3 -14) 2.5 (0.6 – 27) 0.24
Previous groin surgery 1 (8%) 2 (17%) 1 (8%) 4 (11%) 0.77
ICG:HSA, indocyanine green (ICG) adsorbed to human serum albumin (HSA)
* Patients were previously reported in BJOG. 2013 May;120(6):758-64.
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SLN Detection
Th e position of the SLN could be located during preoperative lymphoscintigraphy 
in all 12 patients (Figure 1). Th e SLN was located unilaterally in 4 patients and 
bilaterally in 8 patients (Table 2). Median time between ICG tracer injection and 
skin incision was 17 (range: 3 – 21) hours. Before incision, NIR fl uorescence imag-
ing enabled visualization of percutaneous lymphatic channels in 6 of 12 patients. A 
total of 21 SLNs (median of 2 per patient, range: 1 – 3) were resected. Median time 
between skin incision and fi rst SLN detection was 8 (range: 1 – 22) minutes. During 
ex-vivo analysis, all these 21 nodes were all both radioactive and fl uorescent, and 13 
(62%) stained blue (Table 2). Fluorescent SLNs could be clearly identifi ed as a bright 
green signal depicted in the overlay images (Figure 2 and supplementary video). 
Median brightness of exposed SLNs, expressed as SBR, was 5.4 (range: 1.8 – 11.8). 
Lymph node metastases were found in 4 out of 20 groins (3 patients), including 2 
patients with macrometastases (> 2mm) and 1 patient with isolated tumor cells or 
micrometastases.
DISCUSSION
Th e current study evaluates the use of ICG–99mTc-nanocolloid for combined NIR 
fl uorescence- and radio-guided SLN biopsy in vulvar cancer patients. We argue that 
the visual intraoperative detection using ICG combined with radioactive guidance 
(ICG–99mTc-nanocolloid) may help to optimize the SLN procedure, and will locate 
the SLN more precisely (Figures 1 and 2). Th is could reduce the need for an unneces-






FIGURE 1 – Preoperative SLN mapping
Example of SLN mapping using lymphoscintigraphy and SPECT/CT aft er administration of ICG:99mTc-nano-
colloid. A: lymphoscintigraphy showing the injection spot and one SLN in the left  groin. B, C, D and E: fused 
SPECT/CT images showing the position of the SLN in relation to patient anatomy. SLN= Sentinel Lymph node, 
inj.: Injection spot.
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sary full inguinofemoral lymphadenectomy, and thereby reduce anesthesia time and 
decrease the risk of postoperative and long-term complications such as infection or 
dehiscence of the wound and lymphedema.
Th e obtained results were compared to a previous performed and published ran-
domized controlled trial20. Th e current trial was performed using the same camera 
system and identical surgical workup. In the previous trial ICG was prepared using 2 
diff erent protocols to obtain ICG or ICG bound to Human serum albumin (HSA). 1.6 
mL of ICG alone (N=12) or ICG:HSA (N=12) were injected in the operating room 
directly before surgery . Hence in both formulations 0.62 mg of ICG was injected 
eff ectively. Overall, a total of 36 patients who underwent SLN mapping using both 
Table 2 – SLN Identifi cation Results
Characteristic



















0.62 mg in 1.6 mL
Directly before surgery
N % N % N % N %
SLNs detected by lymphoscintigraphy
Unilateral 4 42 8 67 6 50 19 53 0.48
Bilateral 8 58 4 33 6 50 17 47
Intraoperative detection rate per 
patient†
12 100 9 75 10 83 31 86 0.21
Number of SLNs identifi ed 21 12 23 56
Method of SLN detection
Radioactive 21 100 12 100 23 100 56 100 0.19
Fluorescence 21 100 12 100 23 100 56 100
Blue dye 13 62 11 92 16 70 40 71











Time between skin incision and fi rst 
SLN detection in min. (median; range) 8 (1 -22) 12 (2 – 24) 7 (2 – 16) 8 (1 – 24) 0.79
Histology
Negative 9 75 9 75 8 67 26 72 0.77
ITC/micrometastases 1 8 2 17 1 8 4 11
Macrometastases 2 17 1 8 3 25 6 17
H, Hours; ICG:HSA, indocyanine green (ICG) adsorbed to human serum albumin (HSA); SLN, sentinel lymph 
node; ITC, isolated tumor cells
* Patients were previously reported in BJOG. 2013 May;120(6):758-64.
† Detection rate combining NIR fl uorescence imaging, the gamma probe, and blue dye staining
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radioactive, blue, and fl uorescence guidance were evaluated in the current analysis. 
Intraoperative NIR fl uorescence based SLN detection rates were 75%, 83%, and 100% 
for ICG alone, ICG:HSA, and ICG–99mTc-nanocolloid, respectively (P = 0.21). Up to 
25% more SLNs were optically identifi ed using ICG:HSA and ICG–99mTc- nanocol-
loid compared to ICG alone, showing a trend towards signifi cance (P = 0.06). Time 
between skin incision and fi rst SLN detection were not signifi cantly diff erent between 
the diff erent patient populations (P = 0.79). Time between skin incision and SLN 
identifi cation increased with BMI (R = 0.54; P <0.01) (Figure 3). NIR fl uorescence 
imaging enabled visualization of percutaneous lymphatic channels in 39% of patients 
which seemed to be inversely correlated to BMI (R = -0.28; P < 0.10) and could assist 
the skin incision placement during surgery (Figure 2). A comparison between patient 
characteristics and SLN identifi cation results can also be found in tables 1 and 2.
All three ICG-based formulations were able to optically detect SLNs during sur-
gery, but, although not signifi cant, ICG-99mTc-nanocolloid seemed to outperform the 
other two formulations in terms of the intraoperative detection rate, even though it 
Color NIR Fluorescence Color-NIR Merge 















FIGURE 2 – NIR fl uorescence-guided sentinel lymph node (SLN) mapping
Intraoperative NIR fl uorescence guided SLN mapping performed in the same patient as fi gure 1, using 
ICG:99mTc-nanocolloid. Top row, percutaneous NIR identifi cation of aff erent lymphatic channels fl owing away 
from the injection site (Inj.). Th e planned incision site, based on the presumed location of the SLN, is shown as 
a dashed line. Middle row, real-time fl uorescence identifi cation of the SLN directly aft er incision. Bottom row, 
SLN resection under fl uorescence guidance. Scale bars = 1 cm. Camera exposure times were: 100 msec (upper 
and middle row) and 60 msec (bottom row).
144 Chapter 9
uses the lowest amount of ICG (only 160 nmol compared to 800 nmol used for ICG 
alone and ICG:HSA). Moreover, this visualization was achieved with a lower injected 
volume (1.0 mL vs. 1.6 mL) and a signifi cantly longer period between tracer ad-
ministration and surgical resection (up to 20h longer). Th e improved visualization is 
likely related to the superior retention in the SLN and the direct correlation between 
pre- and intra-operative fi ndings in which the SLN can be visualized in real-time31. 
Th e 5-times lower injected dose of ICG (ICG-99mTc-nanocolloid compared to ICG 
and ICG:HSA) and the up to 20h increase in time between injection and NIR-guided 
resection, did result in a signifi cantly lower SBR for ICG-99mTc-nanocolloid. How-
ever, the lower SBR of 5.4 did not limit the surgical guidance and did not result in 
prolongation of the time between skin excision and fi rst SLN identifi cation.
Combining ICG-99mTc-nanocolloid permits both fl uorescence and radioactiv-
ity guidance aft er a single injection. And, unlike patent blue, the use of ICG does 
not alter the surgical fi eld by dark staining or tattooing the skin of the patient32. In 
addition, clinical implementation of this hybrid tracer is simple as it is based on 
99mTc-nanocolloid, which is an approved lymphatic tracer in Europe and only needs 
addition of a small amount (0.05 mg) of ICG, also approved for clinical use (off -
label use for SLN identifi cation)23. In concordance with previous reports where blue 
dye and NIR fl uorescence was compared for drainage sites in the groin20,21,24, NIR 
fl uorescence outperformed blue dye in terms of SLN detection; in the present study 
Time between incision and SLN detection









































FIGURE 3 – Time between skin incision and SLN detection
Shown is the eff ect of Body Mass Index (BMI) (abscissa) on skin incision to SLN identifi cation time (ordinate) 
in the context of ICG preparation method. Points represent individual patients. Green circles represent patients 
that received ICG alone; blue circle represents patients that received ICG:HSA; and red circles represents pa-
tients that received ICG:99mTc-nanocolloid. Dotted line represents the median for each group.
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only 62% of nodes stained blue. Th erefore, blue dye does not appear to add value to 
the SLN procedure compared to NIR fl uorescence imaging, if available. Th erefore, 
we would argue that blue dye staining should not be considered part of the standard 
anymore in future studies.
A signifi cant advantage of NIR imaging is that it can provide real-time surgical 
guidance. To date, most centers that are implementing the use of NIR fl uorescence-
guided SLN biopsy with indocyanine green in an “open” setting are using the Photo 
Dynamic Eye (PDE; Hamamatsu, Japan) camera system19,21. Th is system is commer-
cially available and easy to use; however, no color overlay is possible. To enable the 
surgeon to work under direct image guidance, navigation in relation to the surgical 
anatomy is desirable. Th e camera system used in this study is capable of displaying 
NIR fl uorescence signal in relation to the surgical anatomy by a real-time overlay 
function between color and NIR fl uorescence, using a hands-free setup28.
It should be pointed out that the hydrodynamic diameter of the tracer compounds 
used, ICG (≤ 1 nm), HSA (7nm) and Nanocolloid (20-80 nm), are considerably dif-
ferent, which could have a major impact on the lymphatic migration and retention in 
the SLNs22. A small particle (like ICG) has the potential to travel much faster through 
the lymphatic vessels and could thereby access second tier nodes. However, average 
number of SLN identifi ed in the current study did not diff er between groups.
During the implementation of a novel technique, it is of major importance to 
understand its limitations. NIR fl uorescence imaging has a maximum penetration 
depth of approximately 5 mm into (fatty) tissue17. Th erefore, detectability of SLNs 
in patients with higher BMI can be challenging. In our study we found that the time 
P < 0.02 
Signal-to-Background Ratio



















FIGURE 4 – Signal-to-Background ratios between study protocols
Th e signal-to-background ratios of the diff erent formulations is shown as mean with range: ICG alone (0.62 
mg; 1.6 mL; injected during surgery), ICG:HSA (0.62 mg; 1.6 mL; injected during surgery) and ICG-99mTc-
nanocolloid (0.05 mg; 0.4 mL; injected up to 20h prior to surgery).
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between skin incision and SLN identifi cation increases with an increase in BMI. As 
radioactive guidance has a much higher penetration depth, it could be especially of 
value in patients with higher BMI. Th erefore, radioactive guidance appeared to be 
still obligatory for preoperative planning and for the identifi cation of deeply located 
SLNs14 .
To conclude, this study demonstrates the added value of direct lymphatic guid-
ance towards the SLN in relation to the surgical anatomy by combining the use of 
a radioactive and NIR fl uorescence guidance in a single tracer. In vulvar cancer the 
ICG-99mTc-nanocolloid based SLN procedure seems to outperform ICG, ICG:HSA 
and blue dye based SLN procedures in terms of the intraoperative optical detection 
rate. Th is improvement is achieved with considerably less dye and is also eff ective at 
longer time intervals. Moreover, the ICG-99mTc-nanocolloid compound is extremely 
simple to formulate. Th erefore we would recommend using ICG-99mTc-nanocolloid 
for combined fl uorescence and radio-guided SLN mapping in vulvar cancer patients.
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Intraoperative near-infrared fl uorescence-
guided identifi cation of the ureters using 
low-dose methylene blue: a fi rst-in-human 
experience
Verbeek FP, van der Vorst JR, Schaafsma BE, Swijnenburg RJ, Gaarenstroom KN, 
Elzevier HW, van de Velde CJ, Frangioni JV, Vahrmeijer AL.




Near-infrared (NIR) fl uorescence imaging is a promising technique that off ers, real-
time, visual information during surgery. Th e current study reports the fi rst clinical 
results of ureter imaging using NIR fl uorescence aft er a simple peripheral infusion of 
methylene blue (MB). Furthermore, optimal timing and dose of MB were assessed.
Materials and Methods
A total of 12 patients that underwent lower abdominal surgery were included in this 
prospective feasibility study. NIR fl uorescence imaging was performed using the 
Mini-FLARETM imaging system. To determine optimal timing and dose, MB was 
injected intravenously at doses of 0.25, 0.5 or 1 mg/kg, aft er exposure of the ureters. 
Subsequently imaging was performed for up to 60 min following injection.
Results
In all patients both ureters could be clearly visualized within 10 minutes aft er infu-
sion of MB. Signal lasted at least up to 60 minutes aft er injection. Th e mean signal-
to-background ratio (SBR) of the ureter was 2.27 ± 1.22 (N = 4), 2.61 ± 1.88 (N = 4) 
and 3.58 ± 3.36 (N = 4) for the 0.25, 0.5 and 1 mg/kg groups, respectively. A mixed 
model analysis was used to compare SBRs between dose groups and time points 
and to assess the relation between dose and time. A signifi cant diff erence between 
time points (P < 0.001) was found. However no diff erence between dose groups was 
observed (P = 0.811).
Conclusions
Th is study demonstrates the fi rst successful use of NIR fl uorescence using low-dose 
MB for the identifi cation of the ureters during lower abdominal surgery.
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INTRODUCTION
Iatrogenic ureteral injury is a rare, but serious complication of lower abdominal 
surgery, with a reported incidence rate varying from 0.7% up to 10%.1-5 Early identi-
fi cation of ureteral damage permits direct repair and is of paramount importance to 
reduce morbidity and preservation of renal function.2 Unfortunately, the diagnosis is 
oft en missed during surgery, which can result in severe complications, such as geni-
tourinary fi stula formation or severe renal dysfunction. Identifi cation of the ureters 
can be challenging in the setting of pelvic tumors, infl ammation or aft er radiation to 
the pelvic area.6 Moreover, several anatomical variations can be present, which when 
unrecognized, increase the risk of ureteral damage by the surgeon.
To reduce the risk of injury, several preoperative imaging modalities have been 
developed such as: intravenous pyelography, retrograde pyelography, or urologic 
computed tomography.7 However these techniques are not performed routinely prior 
to most abdominal surgical procedures since they are costly, expose patients to radia-
tion, and are unable to provide real-time guidance during surgery.
If hampered intraoperative ureteral identifi cation is anticipated, double-J stents 
can be placed in the ureter, which can be palpated during open surgery. Recently, 
lighted ureteral stents have become commercially available for laparoscopic surgery.8 
However, preoperative ureteral stent placement is an invasive procedure that harbors 
an increased risk of complications, such as ureteral perforation, urinary tract infec-
tion and acute renal failure.8
An ideal technique should be capable to detect the ureter in the acute setting 
using a noninvasive procedure that is available during both open and laparoscopic 
surgery. Recently, ureteral identifi cation using an intravenously administered radio-
pharmaceutical agent has been described.9 In this study, gamma probe localization 
was successfully performed aft er injection of 99mTc-DTPA in ten patients. However, 
this technique requires involvement of a nuclear physician, requires tissue contact, 
exposes patient and caregivers to ionizing radiation, and lacks visual information.
Intraoperative near-infrared (NIR) fl uorescence imaging is a promising technique 
that off ers, real-time, visual information during surgery.10-13 Th is technique is based 
on the use of exogenous NIR fl uorescent contrast agents that can be detected by intra-
operative imaging systems to visualize specifi c tissues and/or anatomical structures. 
An advantage of this technique is that NIR fl uorescent light has a relatively high 
tissue penetration of several millimeters. As such, it has wide applications, including 
sentinel lymph node mapping in several tumor types and visualization of bile ducts 
during laparoscopic surgery.14-17 Th e clinically available dye methylene blue (MB) has 
the advantageous property that it becomes a moderate-strength fl uorophore emitting 
at ≈ 700 nm when diluted to levels that are almost undetectable to the human eye. 
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MB is cleared renally and has previously been used for macroscopic identifi cation 
of ureteral leakage and parathyroid glands in high dosages.7,18,19 We have recently 
demonstrated feasibility of intraoperative visualization of the ureters by NIR fl uores-
cence imaging using low-dose MB during both open and laparoscopic surgeries in 
Yorkshire pigs.20 Moreover, NIR imaging has recently shown feasibility in diagnosing 
ureteropelvic junction obstruction in a swine model.21 However, to date, no clinical 
data are available. Th e aim of the current study was to assess feasibility of this tech-
nique for detection of the ureters in patients undergoing lower abdominal surgery. 
Furthermore, optimal timing and dosage of MB administration for NIR fl uorescence 
imaging were assessed.
MATERIALS AND METHODS
Intraoperative Near-Infrared Imaging System (Mini-FLARE)
Imaging procedures were performed using the Mini-Fluorescence-Assisted Resec-
tion and Exploration (Mini-FLARE) (fi gure 3) image-guided surgery system, as 
described previously.22 Briefl y, the system consists of 2 wavelength isolated light 
sources: a “white” light source, generating 26,600 lx of 400 to 650 nm light, and 
a “near-infrared” light source, generating 1.08 mW/cm2 of ≈ 670 nm light. Color 
video and NIR fl uorescence images are simultaneously acquired and displayed in 
real time using custom optics and soft ware that separate the color video and NIR 
fl uorescence images. A pseudo-colored (lime green) merged image of the color video 
and NIR fl uorescence images is also displayed. Th e imaging head is attached to a 
fl exible gooseneck arm, which permits positioning of the imaging head at extreme 
angles virtually anywhere over the surgical fi eld. For intraoperative use, the imag-
ing head and imaging system pole stand are wrapped in a sterile shield and drape 
(Medical Technique Inc., Tucson, AZ). Subsequently, the camera head is positioned 
30 cm above the surgical fi eld during image acquisition. Fluorescence intensity was 
calculated using the mini-FLARE soft ware, which allows quantitative measurements.
Clinical Trial
Th is prospective clinical trial was approved by the Medical Ethics Committee of the 
Leiden University Medical Center and was performed in accordance with the ethi-
cal standards of the Helsinki Declaration of 1975. Patients, from the department of 
Gynecology and Urology, were included between December 2010 and April 2012. All 
patients scheduled to undergo open surgery in the lower abdomen in which exposing 
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the ureters was part of the procedure were eligible for participation in the trial. Exclu-
sion criteria were pregnancy or lactation, the use of serotonin reuptake inhibitors, 
serotonin and noradrenalin reuptake inhibitors and/or tricyclic antidepressants, 
severe renal failure, G6PD-defi ciency, or a known allergy to MB. All patients gave 
informed consent and were anonymized. Aft er standard midline laparotomy and 
exposure of the surgical fi eld, the ureters were identifi ed and isolated from surround-
ing tissue. Subsequently, the Mini-FLARE imaging system was positioned above the 
surgical fi eld and 0.25, 0.5 or 1 mg/kg of MB (concentration 10 mg/ml) was infused 
intravenously over 5 min. NIR fl uorescence imaging of each exposed ureter was 
performed at 0-5, 15, 25, 35, 45 and 60 minutes aft er injection.
Statistical Analysis
For statistical analysis, SPSS statistical soft ware package (Version 16.0, Chicago, IL) 
was used. Patient age and body mass index (BMI) were reported in median and range 
and signal-to-background was reported in mean and standard deviation. To compare 
patient characteristics, the one-way ANOVA and chi-square tests were used. To com-
pare signal-to-background ratios (SBR) between dose groups and time points, and to 
assess the relation between dose and time, a mixed model analysis was used. When 
a signifi cant diff erence was detected, a one-way ANOVA was used to post-test for 
diff erences between separate dose groups and/or time points. Th e one-way ANOVA 
was corrected using the Bonferroni correction. P < 0.05 was considered signifi cant.
RESULTS
Study subjects
A total of 12 patients were included in this study. Patient characteristics are listed in 
Table 1. Median patient age was 48 years (range 29-75 years), median BMI was 23 kg/
m2 (range 21-28) and median eGFR was 91 (range 66-125). No patient suff ered from 
severe renal impairment. Eight patients were planned for surgery for cervical cancer, 
of which 4 underwent a radical hysterectomy with pelvic lymphadenectomy and 4 
underwent a radical trachelectomy with pelvic lymphadenectomy. Th ree patients un-
derwent a cystectomy with uretero-ileocutanostomy or Indiana pouch. One patient 
underwent cytoreduction surgery for advanced stage ovarian cancer.
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Intraoperative NIR Fluorescence Imaging
Intraoperative NIR fl uorescence imaging was performed using the Mini-FLARE 
imaging system directly aft er exposure of the ureters and MB infusion. In all patients, 
both ureters could be clearly identifi ed using NIR fl uorescence (Fig. 1). In all cases 
adequate signal of the ureter was obtained within 10 minutes aft er injection. Signal 
lasted up to 60 minutes aft er injection, even in the lowest dose group.
A second objective of this trial was to determine the optimal dose of injected 
MB for NIR fl uorescence imaging, expressed as SBR. To assess the eff ect of the dose 
of injected NIR fl uorescent dye on the SBR, patients were allocated to three dose 
groups ranging from 0.25 to 1 mg/kg MB. SBR ratios were calculated by dividing the 
fl uorescence intensity of a large region of interest of the ureter by the tissue directly 
surrounding the ureter and SBRs were taken from the same part of the ureter over 
time. Th e mean signal-to-background ratio of the ureter was 2.27 ± 1.22 (N = 4), 
2.61 ± 1.88 (N = 4) and 3.58 ± 3.36 (N = 4) for the 0.25, 0.5 and 1 mg/kg groups, 
respectively. Th e calculated overall coeffi  cient of variation was 0.85. A mixed model 
analysis showed a signifi cant diff erence between time points (P < 0.001) and no 
signifi cant diff erence between dose groups (P = 0.811). Furthermore, no signifi cant 
relation between dose groups and time points was found (P = 0.614). Th e highest 
SBRs were observed at 45 minutes aft er injection (Fig. 2). Overall, the average signal-
to-background ratio (SBR) on this time point was 4.59 ± 1.68. However, post-tests 
between SBRs of diff erent dose groups on the 45 minutes time point using a one-way 
Table 1 – Patient Characteristics and Ureter Identifi cation Results
Characteristic









N % N % N % N %
Age (mean, range) 49 (27-75) 53 (27 – 69) 52 (37-75) 42 (29 - 60) 0.70
Body mass index (mean, range) 24 (20-28) 25 (24 - 28) 24 (21-28) 24 (20 - 25) 0.30
eGFR (ml/min/1.73m2)* 
(mean, range)
94 (66-125) 90 (66-125) 92 (68-120) 101 (90-107) 0.72
Procedure
Cystectomy 3 25 1 25 2 50 0 0 0.37
Uterus extirpation/
trachelectomy
8 67 3 75 2 50 3 75
Debulking 1 8 1 25
Intraoperative NIR fl uorescent 
ureters
12 100 4 100 4 100 4 100 1
*: eGFR: estimated Glomerular Filtration Rate, calculated using the MDRD GFR equation.
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ANOVA corrected with the Bonferroni correction method, showed no signifi cant 
diff erences (P = 0.35). No diff erences in overall fl uorescence signal between left  and 
right ureter were found (p = 0.80). No patient suff ered from renal impairment prior 
or during surgery. No adverse reactions associated with the use of MB or the Mini-
FLARE™ intraoperative NIR fl uorescence camera were observed.
DISCUSSION
Th is study describes a novel, non-invasive, technique for ureteral identifi cation 
within 10 minutes aft er infusing of low dose MB. Previously, MB has been used 
extensively in high dosages to macroscopically identify ureteral injury by blue color. 
Th e primary objective of the current study was to test the feasibility to identify the 
ureters using dilute MB and NIR fl uorescence. Th e potential advantages of using NIR 
fl uorescence imaging are the increased tissue penetration of light at 700 nm and the 
fact that MB can be administered via a simple peripheral vein on the operating room 
in signifi cantly lower doses, thereby reducing the risk for adverse events.23 A clear 
identifi cation of the ureters using NIR fl uorescence was found in all patients within 
10 minutes aft er injection, and as shown in fi gure 1, the ureters could be detected 
even if covered superfi cially by the peritoneum. Patients were allocated to three 





Figure 1 – NIR fl uorescence imaging of the ureter during lower abdominal surgery
Color video (left  panel), NIR fl uorescence (middle panel), and a color-NIR overlay (right panel) of intraopera-
tive imaging of the ureters. Th e upper row (A) shows a clear identifi cation of the left  ureter, which was exposed 
45 min aft er administration of 1 mg/kg Methylene Blue. Th e lower row (B) shows clear identifi cation of the right 
ureter with overlying blood and tissue, 15 min aft er administration of 0.5 mg/kg Methylene Blue.
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diff erent dose groups to determine optimal dosage and timing of MB, however no 
signifi cant diff erences in SBR between groups were found. Th erefore, based on this 
study, the lowest dose of 0.25mg/kg MB seems optimal based on logistical and safety 
preferences.
Intraoperative identifi cation of the ureters remains challenging in some cases, 
in particular in patients with severe infl ammation or a history of radiation of the 
lower abdomen. Not surprisingly, injury to the ureter is a common complication 
in these cases. When hampered ureteral identifi cation is anticipated, preoperative 
placed ureteral stents can assist in identifying the ureter by palpation. However stent 
placement comes with a certain risk of complication and can be challenging during 
abdominal surgery. If extra ureteral guidance during surgery is necessary, NIR fl uo-
rescence imaging using MB has the potential to be a eff ective, non-invasive, addition 
to ureteral stents.
Due to the inability to palpate the retroperitoneum during laparoscopy surgery, 
NIR fl uorescence could also be of value to identify the ureters during laparoscopy. 
Fluorescence guided laparoscopy has already been introduced in the clinic for vari-
ous indications and systems are becoming more and more available.24-26
A potential pitfall using the present technology is that MB can only be used in 
patients with adequate renal function. Moreover, as the urine fl ow in the ureter is 
not continuous but pulsatile and the fl uorescent signal is related to urine fl ow, the 
fl uorescent signal in both ureters varies over time. However a preclinical study us-
ing this technique showed that a diuretic, which increased the fl ux of urine through 
the ureters, did not increase NIR fl uorescence.20 In the present study, the ureter was 
exposed prior to injection of MB for dose and timing optimization. During normal 
use, the ureter will be located retroperitoneally and will therefore be covered by 
























Figure 2 – Diff erences between dose groups over time
Signal-to-background ratios of the dose groups (mean ± S.D.) are plotted as a function over time aft er injection 
of 0.25/0.5/1 mg/kg Methylene blue. No diff erences between dose groups were found.
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peritoneum. Since the penetration depth of NIR fl uorescence imaging using 700 nm 
light and MB has a maximum of approximately 3-5 mm, identifi cation of the ureter 
may still be challenging under some circumstances. Improved contrast agents with 
800 nm fl uorescence, a higher extinction coeffi  cient, and a higher quantum yield 
would help in this regard. It is expected that these contrast agents will become widely 
available during the next years.
CONCLUSIONS
Th e current study is the fi rst clinical study to show that low-dose MB and NIR fl uo-
rescence can be used for the intraoperative detection of the ureters aft er a simple 
peripheral infusion. As NIR imaging is extremely sensitive, this technique has the 
potential to decrease the risk of injury during complicated lower abdominal surgery 
and thereby reducing operation time and avoiding the need for reoperation. Th is 
technique can provide valuable additional information during surgery in a safe 
manner, provided that proper exclusion criteria are followed. As in the lowest dose 
group the SBR was amply suffi  cient for early identifi cation of the ureter, we would 
recommend injecting 0.25mg/kg MB intravenous several minutes before ureter 
visualisation is desirable.
A B 
Figure 3 – Mini-FLARE imaging system
Th e mini-FLARE near-infrared fl uorescence imaging system. A setup of the imaging system, including imaging 
head, fl exible gooseneck arm and monitor chart. B Imaging system on the operation room. Th e camera head 
(indicated with arrow) is covered in a sterile drape.
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Optimization of near-infrared 
fl uorescence cholangiography for open 
and laparoscopic surgery
Verbeek FP, Schaafsma BE, Tummers QR, van der Vorst JR, van der Made WJ, 
Baeten CI, Bonsing BA, Frangioni JV, van de Velde CJ, Vahrmeijer AL, 
Swijnenburg RJ.




During laparoscopic cholecystectomy, common bile duct (CBD) injury is a rare but 
severe complication. To reduce the risk of injury, near-infrared (NIR) fl uorescent 
cholangiography using indocyanine green (ICG) has recently been introduced as a 
novel method to visualize the biliary system during surgery. To date, several studies 
have shown feasibility of this technique. However, liver background fl uorescence 
remains a major problem during fl uorescent cholangiography. Th e aim of the current 
study was to optimize ICG dose and timing for NIR cholangiography using a quanti-
tative intraoperative camera system during open hepatopancreatobiliary (HPB) sur-
gery. Subsequently, these results were validated during laparoscopic cholecystectomy 
using a laparoscopic fl uorescence imaging system.
Methods
27 patients who underwent NIR imaging using the Mini-FLARE image-guided 
surgery system during open HPB surgery were analyzed to assess optimal dosage 
and timing of ICG administration. ICG was intravenously injected preoperatively 
at doses of 5, 10, and 20 mg, and imaged at either 30 min (early) or 24 h (delayed) 
post-injection. Next, the optimal doses found for early and delayed imaging were 
applied to 2 groups of 7 patients (n=14) undergoing laparoscopic NIR fl uorescent 
cholangiography during laparoscopic cholecystectomy.
Results
Median liver-to-background contrast was 23.5 (range: 22.1-35.0), 16.8 (range: 11.3-
25.1), 1.3 (range: 0.7-7.8), and 2.5 (range: 1.3-3.6) for the 5 mg/30 min, 10 mg/30 min, 
10 mg/24 h and 20 mg/24 h respectively. Fluorescence intensity of the liver was signifi -
cantly lower in the 10 mg delayed imaging dose group compared to the early imaging 
5 mg and 10 mg dose groups (P = 0.001), which resulted in a signifi cant increase in 
CBD-to-liver contrast ratio compared to the early administration groups (p < 0.002). 
Th ese fi ndings were qualitatively confi rmed during laparoscopic cholecystectomy.
Conclusion
Th is study shows that a prolonged interval between ICG administration and surgery 
permits optimal NIR cholangiography with minimal liver background fl uorescence.
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INTRODUCTION
Laparoscopic cholecystectomy is the most frequently performed abdominal surgi-
cal procedure, and one of the most common operations in Europe and the United 
States1,2. Surgical morbidity has been reported as 2-4%, however the incidence of 
major complications that require acute re-intervention is much lower3. A rare but 
serious complication of laparoscopic cholecystectomy is bile duct injury (BDI), with 
a reported incidence of 0.3-1.5%4,5. BDI is a feared surgical complication since it is as-
sociated with severe morbidity, impaired survival, and poor long-term quality of life6.
To reduce the risk of BDI, large retrospective and prospective studies have 
looked at the benefi t of routine intraoperative radiographic cholangiography (IOC) 
for detection of CBD stones and to identify or prevent bile duct injury. Whether 
this procedure should be performed routinely is still an active subject of debate, as 
systematic reviews are inconclusive7. However, several of the larger retrospective 
studies observe a decrease in frequency and severity of BDI when IOC is performed8. 
Limiting factors for performing radiographic laparoscopic cholangiography include: 
1) it requires specifi c expertise in the technique and its interpretation, 2) it involves 
the use of ionizing radiation, 3) it is time-consuming, and 4) it creates a risk for 
bile leakage and duct injury itself, since puncturing and cannulation of the cystic 
duct is required. Th ese limitations justify the quest for alternative, less complicated 
techniques to visualize biliary anatomy during cholecystectomy.
Recently, near-infrared (NIR) fl uorescent cholangiography using indocyanine 
green (ICG) has been presented as a novel, less invasive, and non-ionizing method 
to visualize the biliary system during surgery9-11. Circulating ICG is cleared by the 
liver and almost exclusively excreted into the bile12. Following intravenous injection 
of ICG, the extrahepatic bile ducts can be clearly visualized using a laparoscopic 
fl uorescence imaging system. Th e NIR fl uorescence window (700-900 nm) has 
several advantages for image-guided surgery, such as minimal autofl uorescence of 
the surgical fi eld and several millimeters penetration of the fl uorescent light through 
overlying tissue13,14. In addition, as NIR light is invisible to the human eye, illumina-
tion does not alter the surgical fi eld. In the largest series of patients published so far 
on the use of this technique during laparoscopic cholecystectomy, NIR fl uorescent 
cholangiography delineated biliary anatomy in the majority of patients before dissec-
tion of Calot’s triangle9.
Although hepatic excretion pharmacokinetics enable the use of ICG for fl uores-
cence imaging of the extrahepatic bile ducts, at the same time, retention of ICG in the 
liver can cause signifi cant background fl uorescence signal that impairs discrimina-
tion of bile ducts from liver tissue. To date, studies using ICG for NIR fl uorescence 
cholangiography have used variable doses that were injected only at time-points 
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directly prior to surgery15. We hypothesize that the excretion of ICG from the liver, 
and thereby the interval between intravenous ICG injection and surgery, would be 
one of the key determinants for optimal diff erentiation of bile duct signal from its 
surrounding tissue during fl uorescence cholangiography. Th e aim of the current 
study was to compare early and delayed imaging protocols using diff erent doses of 
ICG to optimize near-infrared cholangiography using a quantitative intraoperative 
camera system during open hepatopancreatobiliary (HPB) surgery. Th ese results 
were subsequently validated during laparoscopic cholecystectomy using a laparo-
scopic fl uorescence imaging system.
MATERIALS AND METHODS
Intraoperative Near-Infrared Imaging Systems
Intraoperative imaging during open surgery was performed using the Mini-Fluo-
rescence-Assisted Resection and Exploration (Mini-FLARE) image-guided surgery 
system, as described previously16. Briefl y, the system consists of 2 wavelength isolated 
light sources: a “white” light source, generating 26,600 lx of 400 to 650 nm light, and 
a “near-infrared” light source, generating 7.7 mW/cm2 of 760 nm light. Th e Mini-
FLARE imaging system was positioned 30 centimeters above the surgical fi eld. Color 
video and NIR fl uorescence images are simultaneously acquired and displayed in 
real time using custom optics and soft ware that separate the color video and NIR 
fl uorescence images.
Laparoscopic imaging was performed using two D-light fl uorescence laparoscopes 
(Tricam SLII and Image 1 High Defi nition, Karl Storz Endoscopes, Germany) through 
a standard 12-mm subumbilical trocar port. In this imaging system, 760-nm light, 
emitted by an internal light source, is guided through a special fl uid light cable to a 
30 degrees infrared-optimized rigid laparoscope containing an optical fi lter system. 
Th e system was used for intraoperative conventional imaging (white light mode) and 
real-time fl uorescence imaging (760-nm light, ICG mode) and allowed easy switch-
ing between white light mode and ICG mode by using a foot pedal. No overlay of 
conventional and fl uorescent images was possible, but anatomical orientation could 
be maintained due to the easy switching between light modes. Images are recorded 
using a charge-coupled device camera.
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Preparation and administration of Indocyanine Green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml (3.2 mM) 
stock solution. Of this stock solution 2, 4, or 8 mL, corresponding to doses of 5, 10, 
or 20 mg, was administered intravenously as a bolus.
Patients
To assess optimal dosage and timing of ICG administration for NIR fl uorescent 
cholangiography, patients from two HPB imaging trials for the identifi cation of 
pancreatic and liver tumors (NTR2213 and NTR2214 (Netherlands Trial Registrar, 
Dutch Cochrane Center, Amsterdam)) were analyzed separately. All patients in 
which the biliary anatomy was exposed were included. Th is resulted in a cohort of 27 
patients (Table 1). Patients received an intravenous bolus of 5 or 10 mg of ICG in the 
operating room 30 min before incision (early imaging) or 10 or 20 mg at 24 h prior 
to surgery (delayed imaging). NIR fl uorescence signal of the bile ducts and liver was 
quantifi ed using the Mini-FLARE imaging system.
Subsequently, to validate the fi ndings from open surgery, a total of 14 patients 
planning to undergo laparoscopic cholecystectomy were included to receive the opti-
mal doses of ICG for either early (n=7) or delayed (n=7) imaging. Laparoscopic im-
ages were acquired using the Tricam SLII fl uorescence laparoscope or Image 1 High 
Defi nition fl uorescence laparoscope (Karl Storz Endoscopes, Germany). Th is trial 
has been registered as NTR3686 in the Netherlands Trial Registrar, Dutch Cochrane 
Center, Amsterdam. All patients provided informed consent. Exclusion criteria were 
pregnancy, lactation, or an allergy to iodine, shellfi sh, or indocyanine green. Th e 
studies were approved by the Local Medical Ethics Committee of the Leiden Univer-
sity Medical Center and were performed in accordance with the ethical standards of 
the Helsinki Declaration of 1975.
Statistical Analysis
For statistical analysis, SPSS statistical soft ware package (Version 17.0, Chicago, IL) 
was used. Graphs were generated using GraphPad Prism Soft ware (Version 5.01, La 
Jolla, CA). Signal-to-background ratios (SBR) were calculated by dividing the fl uo-
rescent signal of the CBD by fl uorescent signal of surrounding adipose tissue or the 
liver. Signal-to-background (SBG), ratios were reported as median with range. To test 
diff erences between groups, the Kruskal-Wallis one-way analysis of variance test and 
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the Dunn’s Multiple Comparison Test (only computed if overall P < 0.05) were used. 
P < 0.05 was considered signifi cant.
RESULTS
Study Subjects
Patient characteristics are detailed in Table 1. Twenty-seven patients underwent open 
HPB surgery, of which 20 were planned for liver resection for colorectal metasta-
ses and 7 were planned for surgery with suspected ampullary or pancreatic head 
carcinoma. Subsequently, 14 patients that were planned for elective laparoscopic 
cholecystectomy for cholecystolithiasis were included to undergo laparoscopic NIR 
fl uorescence cholangiography.
Table 1 – Study subject characteristics (N = 41).
Characteristic Median [Range] or (%)
Age 61 [26 - 76]
BMI 25 [19 - 40]
Sex Male: 14 (34), Female: 27 (66)
Open surgery (N = 27)
Procedure:
- Resection of colorectal liver metastases 20 (74)
- Resection of pancreatic carcinoma 7 (26)
ICG dose/administration-imaging interval:
- 5 mg / 30 min 3 (11)
- 10 mg / 30 min 4 (15)
- 10 mg / 24 h 17 (63)
- 20 mg / 24 h 3 (11)
Laparoscopic surgery (N = 14)
Procedure:
- Laparoscopic cholecystectomy 14 (100)
ICG dose/administration-imaging interval:
- 5 mg / 30 min 7 (50)
- 10 mg / 24 h 7 (50)
Abbreviations: BMI: body mass index; ICG: indocyanine green
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Optimization of ICG dose and administration timing
Intraoperative NIR fl uorescence imaging was performed using the quantitative 
mini-FLARE imaging system to evaluate the eff ect of ICG dosage and post-injection 
imaging time for open surgery (Figure 1). Th e eff ect of the injected ICG dosage and 
timing on fl uorescence brightness was determined by comparing median signal-to-
background ratios (SBR) between diff erent groups (Figures 2 and 3).
Median liver-to-background contrast was 23.5 (range: 22.1-35.0), 16.8 (range: 
11.3-25.1), 1.3 (range: 0.7-7.8), and 2.5 (range: 1.3-3.6) for the 5 mg/30 min, 10 
mg/30 min, 10 mg/24 h, and 20 mg/24 h respectively (Figure 2a). Liver background 
contrast was signifi cantly lower in the 10 mg delayed imaging dose group compared 
to the early imaging 5 mg and 10 mg dose groups (P < 0.001).
To assess the infl uence of the liver background signal, the ratio between CBD and 
liver signal was determined. Median SBR, expressed as CBD-to-liver ratio, were 0.2 
(range: 0.2-0.3), 0.2 (range: 0.1-0.6), 2.3 (range: 1.1-6.2), and 1.7 (range: 1.6-2.9) for 
the 5 mg/30 min, 10 mg/30 min, 10 mg/24 h, and 20 mg/24 h, respectively. Again, a 
signifi cant diff erence was found between the early imaging 5 and 10 mg dose groups 
and the delayed imaging 10 mg dose group (P < 0.002) (fi gure 3). An example of this 
diff erence in contrast ratio is illustrated in Figures 1 and 4.
















Figure 1 – NIR fl uorescence imaging of the common bile ducts:
Color video (left  panel), NIR fl uorescence (middle panel), and a color-NIR overlay (right panel) of intraopera-
tive bile duct imaging. Upper row shows a patient undergoing pancreatoduodenectomy, 30 min aft er adminis-
tration of 10 mg ICG. Bottom row shows a patient who underwent liver resection for colorectal metastases, 24 
h aft er administration of 10 mg ICG. Arrows indicate the position of the common bile duct; “L” indicates the 
position of the liver and “Ad” indicates the localization of adipose tissue surrounding the biliary three. Circles 
are shown to give an example of the region-of-interests of liver, CBD and surrounding adipose tissue.
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Most importantly, when considering the ratio between the CBD and surrounding 
adipose tissue, no diff erences were found between dose groups (P = 0.47) (Figure 
2B). Th is indicates that the fl uorescence intensity of the CBD itself did not diff er 
between dose groups.
Validation during laparoscopic cholecystectomy
Subsequently 14 patients undergoing laparoscopic cholecystectomy were included and 
given the optimal doses found for early (5 mg/30 min, n = 7) and delayed (10 mg/24 
h, n = 7) imaging. Th e fi rst 8 patients were imaged using the Tricam SLII laparoscopic 
system, which has recently been reported11. However, brightness of the fl uorescence 
images in both dose groups was considerably lower compared to the images obtained 
with the Mini-FLARE system. To decrease this shortcoming a newly developed, next-
generation Image 1 “High Defi nition” laparoscopic system was used in the latter 6 
patients. Th e improved sensitivity of the CCD chip not only increased fl uorescence 
brightness but also allowed better anatomical orientation in fl uorescence mode. Intra-
operative NIR fl uorescence cholangiography permitted detection of the cystic duct in 
all patients. Although the laparoscopic NIR fl uorescence imaging system was unable 
to quantify the fl uorescence signal intensity, qualitative data analyses revealed a much 
higher liver signal in the 5 mg/30 min group compared to the 10 mg/24 h group (Fig-
ure 4). Th ese results were in concordance with our quantitative fi ndings during open 
surgery using the Mini-FLARE system as can be seen in Figures 1, 2, and 3.
a: b: 
Figure 2 – Evaluation of the eff ect of ICG dose and post-injection imaging time:
Eff ect of dose and timing was determined by comparing contrast ratios between concentration groups. Signal-
to-background ratios (SBR) for the liver and CBD were calculated. A background region-of-interest was drawn 
on surrounding (fatty) tissue. Figure A shows the eff ect on liver contrast ratio per dose group. Fluorescence 
intensity of the liver was signifi cantly lower in the 10 mg delayed imaging dose group compared to the early im-
aging 5 mg and 10 mg dose groups (P = 0.001), while CBD signal remains the same (Figure B). Points represent 
individual patient values and the line indicates the median.
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DISCUSSION
Th e current study demonstrates feasibility and optimization of NIR fl uorescence 
cholangiography during both open and laparoscopic HPB surgery. To our knowl-
edge this is the fi rst clinical study comparing the eff ect on dosage and timing of ICG 
administration for bile duct imaging using intraoperative NIR fl uorescence.
However, further optimization of the technology is still necessary. ICG is cleared 
from blood by the liver within seconds and appears in bile within minutes17. Th e ratio 
of CBD to liver NIR fl uorescence peaks or plateaus (depending on species) within 
2-6 h. We purposely chose to test the extremes of clearance time (30 min vs. 24 h) in 
this clinical study. However, future studies must explore intermediate time points in 
the hope that more clinically convenient timing, e.g., in the pre-op area for same day 
surgery, can be found.
NIR fl uorescent light has several advantages for intraoperative imaging. For ex-
ample, NIR light is invisible to the human eye, and therefore does not alter the look of 
the surgical fi eld. Further advantages of NIR light include high tissue penetration (up 
to several millimeters) and low autofl uorescence. Moreover, NIR fl uorescence imag-
ing is an inherently safe technique, as there is no ionizing radiation and no direct 
tissue contact, in contrast to intraoperative cholangiography or ultrasonography.
Figure 3 – Contrast ratio of CBD versus liver background:
Signal-to-background ratios (SBR) for the CBD versus the liver were calculated. A signifi cant increase in con-
trast ratio was found in the delayed imaging 10 mg dose group compared to the early imaging 5 and 10 mg dose 
groups (P < 0.002). Points represent individual patient values and the line indicates the median.
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Visualization of the biliary anatomy can be challenging during laparoscopic 
cholecystectomy. Previous performed studies have shown feasibility of NIR fl uores-
cence imaging for safe exploration of biliary anatomy9,10,18-25. Recently, feasibility of 
fl uorescent cholangiography has even been evaluated during robotic single-site cho-
lecystectomy26. However optimal dosage and timing were, thus far, not investigated. 
Aft er systemic injection, ICG is completely absorbed by the liver within several 
minutes. Subsequently, ICG is excreted in the bile, which allows NIR fl uorescence 
visualization of the biliary anatomy. Inherent to this, liver background remains a 
major problem during NIR fl uorescent cholangiography. Th is study shows that a 
dose of 10 mg ICG injected 24 h prior to surgery provides a signifi cantly lower liver 
background signal while the CBD signal remains stable (Figures 2 and 3). Th erefore, 
the contrast ratio between bile duct versus liver background is considerably higher, 
which allows optimal visualization of the extrahepatic bile ducts (Figures 1 and 4). 
A limitation of this method is the time window of approximately 24 h that is needed 
between intravenous injection of the contrast agent and start of surgery. Th is could 
be a disadvantage during day-case admissions of patients for an elective laparoscopic 
Color Fluorescence 
30 min Post-Injection 












24 h Post-Injection 
of 10 mg ICG 
1 cm 
Figure 4 – Laparoscopic fl uorescence imaging of the biliary anatomy: Color video (left  panel) and NIR fl uores-
cence (right panel; pseudocolored in blue) of laparoscopic bile duct imaging in two patients undergoing lapa-
roscopic cholecystectomy. 5 or 10 mg ICG was injected respectively 30 min or 24 h before surgery. Th e arrow 
indicates localization of the cystic duct; “L” indicates the position of the liver. Th ere is clearly less liver signal 
observed in the 10 mg/24 h group.
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cholecystectomy. Similarly, this time window cannot be used for patients suff ering 
from acute cholecystitis in which early surgery is preferred. Still, in these cases we 
argue that administration of ICG should be performed as early as possible following 
admission to allow the majority of the contrast agent to be cleared from the liver 
before NIR fl uorescent cholangiography is performed.
Currently, ICG and methylene blue are the only two NIR contrast agents that are 
approved for other clinical applications, however methylene blue is not suitable for 
bile duct imaging due to predominantly renal clearance in humans14. Novel NIR con-
trast agents have been developed, but presently lack regulatory approval. Our group 
has previously compared the use of diff erent contrast agents for NIR fl uorescent 
cholangiography in both a small and a large preclinical animal model17. Th is study 
showed that IRDye 800CW provided prolonged visualization of the biliary anatomy 
with reduced liver background fl uorescence when compared to both ICG and IR-
786. A signifi cant advantage of NIR imaging is that it can provide real-time guidance. 
However, to enable the surgeon to work under direct image guidance, navigation 
in relation to the surgical anatomy is obligatory. Further technical developments of 
(laparoscopic) NIR imaging systems are in progress aiming to improve the real-time 
intraoperative display of NIR fl uorophores27,28. A recently published case report of 
laparoscopic NIR fl uorescence imaging uses a camera system that is able to overlay 
the fl uorescence images of the biliary tract with conventional color images in real 
time29. Moreover, this case report also clearly shows the issue of liver background 
fl uorescence when using ICG injected shortly before surgery.
In conclusion, the current study demonstrates feasibility of NIR fl uorescent chol-
angiography for both open and laparoscopic surgery. Until novel NIR contrast agents 
become available for clinical use, only ICG can be applied for this purpose. A dosage 
of 10 mg administered 24 h before surgery appears to produce optimal results for 
NIR fl uorescent cholangiography during both open and laparoscopic surgery. When 
permitted by logistics, we would recommend using a prolonged interval between 
ICG administration and intraoperative bile duct imaging.
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SUMMARY
Intraoperative imaging using near-infrared (NIR) fl uorescence is a relatively new 
technique that can be used to visualize tumor tissue, sentinel nodes and vital anatomi-
cal structures. Th is thesis is divided in three parts. In part one the ability to visualize 
surgical margins using NIR fl uorescence imaging is demonstrated. Tumor visualiza-
tion is established using the clinically approved contrast agent indocyanine green, 
as well as newly developed tumor targeted probes. Th e proportion of laparoscopic 
procedures has steadily increased over the last two decades. A challenging aspect of 
this conversion to minimal invasive surgery is the lack of tactile information, making 
it of particular interest for the development and improvement of laparoscopic NIR 
fl uorescence imaging systems1. Part two focusses on the clinical implementation of 
NIR fl uorescence guided sentinel lymph node mapping for several indications (e.g. 
breast, skin and vulvar cancer). Besides visualization of structures that need to be 
resected (e.g. tumor tissue or sentinel nodes), NIR fl uorescence has also the potential 
to be of value for the identifi cation of structures that should be spared. In part three, 
we demonstrate the fi rst-in-human application of NIR fl uorescence guided ureteral 
visualization, and also the optimization of bile duct imaging for routine laparoscopic 
cholecystectomies.
Part I: Intraoperative evaluation of surgical margins
To date Indocyanine green and methylene blue are the only two NIR fl uorophores 
that are the approved for clinical application by the U.S. Food and Drug Administra-
tion (FDA) and European Medicines Agency (EMA). However both fl uorophores 
cannot be conjugated to tumor specifi c compounds such as antibodies or peptides. 
Th erefore, there is a strong need for novel clinically approved tumor-targeted dyes. 
Chapter 2 evaluates the use of a low dose fl uorescent dye ZW800-1 conjugated to 
the cyclic RGD peptide (cRGD) targeting integrin for colorectal cancer imaging and 
ureteral visualization. cRGD-ZW800-1 was successfully used in both subcutaneous 
and orthotopic mouse models to identify malignant cells. Two negative control 
groups (cRAD-ZW800-1 and ZW800-1 alone) were included to confi rm specifi city 
of cRGD-ZW800-1 in vivo. Mice in the negative control groups showed no tumor 
signal during in vivo imaging using the FLAREtm imaging system and ex vivo imag-
ing using the Odyssey scanner. cRGD-ZW800-1 showed clear uptake in both the 
subcutaneous and orthotopic colon cancer mouse model. Th e renal clearance of 
cRGD-ZW800-1 also allowed visualization of the ureter. Th e ability to visualize both 
tumor demarcation and the ureters could especially be of value during (complicated) 
lower abdominal surgery. Chapter 3 aims to test feasibility of using Methylene blue 
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as a NIR fl uorescent tracer for the detection of breast cancer. A total of 24 patients 
were included in this study. In 83% of patients, the tumor demarcation as identi-
fi ed by NIR fl uorescence imaging corresponded to histological presence of tumor. 
In addition, in one case surgical management was changed based on intraoperative 
NIR fl uorescence fi ndings, which avoided the need for a re-operation. Th is is the 
fi rst study to demonstrate the use of low dose MB for the real-time identifi cation of 
breast cancer using NIR fl uorescence, and can be considered as a promising proof-
of-concept of clinical image guided cancer surgery, especially as improved contrast 
agents will likely become available in the near future. In Chapter 4 the development, 
current application and future prospects of NIR fl uorescence imaging for hepato-
pancreatobiliary surgery are evaluated. To date, the technique has already shown 
potential to improve the intraoperative demarcation of various liver tumors and vital 
structures based on physiological clearance of ICG. Although, the obtained results are 
promising, large randomized controlled trials are essential to defi ne patient benefi t.
Part II: Sentinel lymph node imaging
In Chapter 5 the diagnostic accuracy of NIR fl uorescence for SLN mapping in breast 
cancer when used in conjunction with conventional techniques was evaluated. 
Patients were included at the Dana-Farber/Harvard Cancer Center and the Leiden 
University Medical Center. SLN identifi cation was successful in 94 of 95 subjects 
(99 %) using NIR fl uorescence imaging or a combination of both NIR fl uorescence 
imaging and radioactive guidance. NIR fl uorescence outperformed both radioactiv-
ity and blue dye staining in context of fi nding tumor-positive Sentinel Lymph nodes. 
Percutaneous lymphatic drainage could be visualized in 81% of patients, which 
facilitates in the sentinel node identifi cation. Moreover, no adverse events related to 
fl uorescence imaging were reported in this study, which confi rms safe application of 
NIR fl uorescence and ICG. In conclusion, this multi-center experience validates the 
accurate application of NIR fl uorescence imaging for the identifi cation of SLNs in 
breast cancer patients, but also calls into question what technique should be used as 
the gold standard in future studies. In Chapter 6 the performance of a hybrid NIR 
fl uorescence and radioactive tracer for SLN detection of breast cancer was evaluated. 
Th is study shows the ability of combining preoperative imaging and intraoperative 
guidance using a single tracer. Th e sentinel lymph nodes could be detected surgically 
by both γ radiation and NIR fl uorescence imaging in all (N = 32) patients. Using this 
hybrid tracer no additional injection in the surgical theatre is necessary, intraopera-
tive results are comparable to those provided by the use of ICG alone. In Chapter 7 
the same hybrid NIR fl uorescence and radioactive tracer is evaluated in melanoma 
patients. Th is study shows successful application SLN mapping with a single tracer 
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for both preoperative planning as well as intraoperative guidance. Th e FLARE cam-
era system used in this study was able to provide continuous “hands free” image 
guidance in relation to the surgical anatomy. In Chapter 8 the ability to visualize 
lymphatic drainage and intraoperative SLN visualization using NIR fl uorescence 
in bladder cancer is demonstrated. Unlike other cancers, bladder cancer requires 
special attention to injection technique. Th is study is the fi rst to optimize NIR tracer 
injection. Using the optimal administration protocol NIR fl uorescent lymph nodes 
could clearly be identifi ed during surgery. In Chapter 9 the implementation and 
added value of NIR fl uorescence imaging in vulvar cancer is investigated. Premixing 
of ICG with human serum albumin (ICG:HSA) is advocated to improve dye reten-
tion in the SLN. In this chapter the use of diff erent formulations of ICG for NIR 
fl uorescence guided SLN biopsy in vulvar cancer patients are evaluated. NIR fl uores-
cence outperformed blue dye staining in all patients. Moreover, ICG premixed with 
99mTc-nanocolloid seems optimal terms of the intraoperative detection rate and has 
the potential to shorten operating time because no lymphatic tracer administration 
is needed in the operating room.
Part III: Vital structure imaging
In Chapter 10 the fi rst-in-human application of fl uorescence guided identifi cation of 
the ureters using low-dose methylene blue is demonstrated. Intraoperative detection 
of the ureters was successful in all patients aft er intravenous infusion of methylene 
blue. Patients were divided in three dose groups (0.25, 0.5 and 1 mg/kg). No statis-
tical diff erences were observed between the dose groups; however the lowest dose 
group was considered optimal since the signal of the ureter in these patients was 
suffi  cient for early identifi cation of the ureter. In Chapter 11, the implementation of 
near-infrared fl uorescence cholangiography for both open and laparoscopic surgery 
is shown. Th e aim this study was to compare early- and delayed-imaging protocols 
using diff erent doses of ICG to optimize NIR cholangiography using a quantitative 
intraoperative camera system during open hepatopancreatobiliary (HPB) surgery. 
Th ese results were subsequently validated during laparoscopic cholecystectomy us-
ing a laparoscopic fl uorescence imaging system. Aft er intravenous administration, 
ICG is cleared by the liver and excreted into the bile. Based on this principle, the 
extra-hepatic bile ducts can clearly be visualized within minutes up till multiple hours 
aft er intravenous administration of ICG. Th is study shows that a prolonged interval 
between ICG administration and surgery permits optimal NIR cholangiography, as 
liver background signal is minimal.
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FUTURE PERSPECTIVES
For centuries surgeons could only use their eyes and hands to assess the presence 
and extent of malignant tumors. To date, many imaging modalities are available for 
preoperative surgical planning such as CT, MRI and PET/SPECT. However, during 
surgery, visual inspection and palpation remain the most important tools to deter-
mine the extent of the disease in relation to patient’s anatomy2. NIR fl uorescence 
imaging has the ability to facilitate real-time image guidance and can potentially 
fulfi ll an important complementary role during cancer surgery in the near future.
Over the last years, a great spinoff  has been made in the fi eld of NIR fl uorescence 
guided surgery. Th e availability of experimental NIR fl uorescence imaging systems 
and the clinically approved dyes Indocyanine Green and Methylene blue have al-
lowed NIR fl uorescence image-guided surgery to be introduced into clinical trials3-6. 
However, to permit this technique to become adapted as standard-of-care during 
cancer surgery, novel tumor targeted contrast agents are essential. In the literature, 
many preclinical studies have shown promising results using novel tumor specifi c 
contrast agents7-10. Th ough, the focus within the fi eld is currently shift ing towards 
clinical translation. For example, a clinical trial using Bevacizumab (Avastin®, Roche) 
conjugated to IRDye 800CW (LI-COR Biosciences, Lincoln, NE) is currently ongo-
ing under supervision of Professor van Dam and colleagues (UMCG, Groningen, the 
Netherlands). Bevacizumab is a monoclonal antibody against VEGF that has been 
approved by the FDA for systemic therapies since 2004. It can be a good strategy to 
choose an antibody that has already been approved for other purposes, as safety and 
toxicity profi les have been broadly investigated. However, the use of antibody-based 
dyes has some potential drawbacks for implantation in NIR fl uorescence guided 
surgery. First, antibodies have a half-life in vivo of several days; as a consequence 
the dye needs to be intravenously administered days before surgery. Second, due to 
the hepatic clearance of most antibodies high levels of background fl uorescence can 
occur during early imaging in the peritoneal cavity and the liver. Smaller imaging 
agents that can be cleared by the kidneys are not exposed to those disadvantages. 
Chapter 2 shows an example of a recently developed fl uorescent probe with minimal 
background uptake in the gastrointestinal tract. Nevertheless, the main hurdle for 
clinical translation of novel dyes is the fact that every new contrast agent has to go 
through a separate regulatory approval processes. Th is makes the clinical translation 
extremely costly and time consuming.
NIR fl uorescence imaging has several characteristics that are advantageous during 
surgery, including a relatively high penetration into living tissue (up to several mil-
limeters) and real-time, high-resolution optical guidance11-13. However, identifi cation 
of structures lying deeper in tissue can be challenging. Combining radioactive col-
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loids and NIR fl uorescence has recently been introduced to overcome this shortcom-
ing during sentinel lymph node mapping (chapter 7, 8 and 12)14-17. Th e currently 
used tracer for SLN mapping is based on ICG and 99mTc-nanocolloid, which are both 
clinically available. In the future, newly developed, fl uorophores with optimized 
fl uorescent capabilities such as IRDye 800CW or ZW800-1 (Th e FLARE Foundation, 
Wayland, MA) can potentially even facilitate easier sentinel node localization.
For many cancers, such as breast and colorectal cancer, a multidisciplinary ap-
proach, with standardized surgical, pathological, and increasingly a chemo- and 
radiotherapeutic workup has become the standard18-20. In addition, neoadjuvant 
therapy has become standard-of-care for selected breast and rectal cancer pa-
tients21-23. Th e shift  in paradigm from adjuvant to neoadjuvant therapy has resulted 
in increased tissue and organ conservation (e.g. in breast and rectal cancer)20,24. On 
the other hand, areas of infl ammatory tissue induced by the neoadjuvant therapy 
itself can make discrimination between malignant and healthy tissue during surgery 
even more diffi  cult. Especially in those cases, there remains a strong need for real-
time surgical guidance. On the contrary, a substantial portion of both breast and 
rectal cancer patients (up to 50% reported) have such a good response to neoadjuvant 
therapy that it leads to a complete histopathological remission of the tumor25-28. Th is 
means that no malignant cells can be identifi ed during histological assessment of the 
resection specimen aft er surgery. Th is has raised the question as to whether surgery 
can be avoided in a select cohort of patients. A problem is though that there is cur-
rently no validated imaging modality to evaluate whether a tumor has undergone 
complete remission aft er systemic or locoregional therapy29,30.
Fine-tuning the relation between tumor diagnosis, neoadjuvant treatment, preop-
erative evaluation and surgical planning will likely reduce surgical morbidity and im-
prove patient outcome. Molecular imaging, both preoperatively (e.g. using targeted 
PET tracers / photoacoustic therapy) and during surgery (using NIR fl uorescence 
tracers) can play a vital role in this process. Ideally, these newly designed tracers can 
be combined in one hybrid radioactive and fl uorescent compound.
Besides visualization of structures that need to be resected (e.g. tumor tissue and 
sentinel nodes) is it is of paramount importance to correctly identify structures that 
need to be spared (e.g. nerves, bile ducts or ureters) during surgery6,31. Based on their 
biodistribution and clearance pattern, indocyanine green and methylene blue can 
be easily used for the identifi cation of bile ducts and ureters respectively. However, 
as the incidence of iatrogenic damage to the ureter or bile duct is relatively low, it is 
expected that this technique mainly exposes its full potential in combination with 
tumor imaging. Dependent on their clearance pattern, tumor targeted dyes can not 
only be used to reveal tumor margins but also for the visualization of bile ducts or 
ureters6. Th is can be especially of value during laparoscopic liver or colorectal surgery.
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Another important factor for clinical acceptance of this technique will be the 
continued development of imaging systems, as a large proportion of currently used 
imaging systems are still in the experimental phase. To create a substantial impact 
on patient care it is essential that NIR fl uorescence imaging can be easily applied and 
imaging systems are aff ordable. Novel systems have shown improved image quality 
and resolution, better sensitivity, and increased usability. Over the last decade laparo-
scopic surgery has become standard-of-care for an increasing number of indications. 
As palpation is hampered during these procedures, there is an increased need for 
additional intraoperative imaging modalities making it of particular interest for the 
development and improvement of laparoscopic fl uorescence imaging systems. One 
of the major limiting factors of NIR fl uorescence imaging is its limited tissue penetra-
tion depth. Current studies report a penetration depth ranging from several mil-
limeters to, at most, one centimeter. To improve depth penetration, it is expected that 
future research will be more focused on the integration of several imaging modalities 
to overcome the shortcomings of a single modality. For example, by combining the 
benefi cial characteristics of radioactive and fl uorescence guidance, it is possible to 
create an imaging modality with superior depth penetration but also accurate real-
time localization.
In conclusion, novel image-guided modalities have the potential to play an impor-
tant role in the surgical management of future cancer patients. However, to assess true 
patient benefi t the optimization of contrast agents and imaging systems is essential. 
Despite the very promising results already obtained, the next decade will show if 
Image-Guided Cancer Surgery using NIR fl uorescence imaging delivers benefi ts to 
surgical outcome in day-to-day patient care.
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 NEDERLANDSE SAMENVATTING
Beeldgeleide chirurgie met nabij-infrarode (NIR) fl uorescentie is een relatief nieuwe 
techniek die het mogelijk maakt om de chirurg tijdens een ingreep waardevolle infor-
matie te verschaff en. NIR fl uorescentie heeft  de potentie om maligne tumorweefsel, 
schildwachtklieren en vitale structuren in real-time te visualiseren. 
Dit proefschrift  is verdeeld in drie delen. In Deel een wordt de mogelijkheid om de 
maligne tumoren te visualiseren met fl uorescente beeldvorming beschreven. Beeld-
vorming van tumorweefsel is onderzocht met zowel de klinisch beschikbare con-
trastmiddelen indocyaninegroen (ICG) en methyleenblauw als met nieuw ontwik-
kelde tumor-specifi eke contrastmiddelen. Deel twee van dit proefschrift  beschrijft  de 
klinische implementatie van NIR fl uorescentie geleide  schildwachtklierprocedures 
voor verschillende indicaties, waaronder het mammacarcinoom, het melanoom en 
het vulvacarcinoom. 
Naast de visualisatie van structuren die verwijderd moeten worden (maligne 
weefsel en schildwachtklieren), kan NIR fl uorescentie ook van waarde zijn bij de 
identifi catie van vitale structuren die tijdens de operatie juist gespaard moeten wor-
den, zoals bijvoorbeeld zenuwen, galwegen of ureters. Deel drie van dit proefschrift  
demonstreert the fi rst-in-human toepassing van NIR fl uorescentie geleide visualisa-
tie de ureter. Tevens wordt optimalisatie van galwegimaging voor laparoscopische 
toepassing beschreven.
Deel I: peroperatieve visualisatie van maligne tumoren 
Tot op heden zijn ICG en methyleenblauw de enige NIR fl uorophoren (contrastmid-
delen) die zijn goedgekeurd voor klinische toepassing door de U.S. Food and Drug 
Administration (FDA) en de European Medicines Agency (EMA). Beide stoff en zijn 
echter niet tumor-specifi ek en kunnen ook niet worden gekoppeld aan tumor speci-
fi eke bestandsdelen zoals antilichamen of peptides. Desondanks is de visualisatie van 
maligne tumoren toch mogelijk met ICG en methyleenblauw op basis van bepaalde 
fysiologische eigenschappen. De specifi citeit blijft  echter een belangrijk probleem, 
waardoor er een grote behoeft e bestaat aan de ontwikkeling van nieuwe tumor spe-
cifi eke contrastmiddelen.
In hoofdstuk 2 wordt het gebruik van een lage dosis van het fl uorescente contrast-
middel ZW800-1, gekoppeld aan het cyclische peptide RGD (cRGD), geëvalueerd 
voor de beeldvorming van zowel colorectale tumorcellen als ureters in verschillende 
diermodellen. In subcutane- en orthotope tumormodellen werd cRGD-ZW800-1 
succesvol toegepast om maligne cellen te identifi ceren. Twee negatieve controlegroe-
pen (cRAD-ZW800-1 en ZW800-1 alleen) werden gebruikt om de specifi citeit van 
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cRGD-ZW800-1 in vivo te evalueren. Muizen die in de negatieve controlegroepen 
werden geïncludeerd, lieten zowel tijdens in vivo beeldvorming met het FLAREtm 
imaging system als ex vivo met de Odyssey scanner geen adequaat tumorsignaal zien. 
cRGD-ZW800-1 Liet een signifi cant hoger tumorsignaal zien in zowel het subcutane 
als het orthotope tumormodel. De renale klaring van cRGD-ZW800-1 maakte het 
mogelijk om de ureters peroperatief te visualiseren met NIR fl uorescente beeldvor-
ming. De mogelijkheid om zowel tumorcellen als ureters te visualiseren met een 
contrastmiddel kan vooral van waarde zijn bij gecompliceerde chirurgische ingrepen 
in het kleine bekken.
Hoofdstuk 3 beschrijft  de mogelijkheid om borstkanker te detecteren met me-
thyleenblauw als fl uorescent contrastmiddel. In deze klinische studie werden 24 
patiënten geïncludeerd, bij 83% van deze patiënten kwam de tumorbeeldvorming 
door NIR fl uorescentie overeen met de histologische aanwezigheid van maligne 
cellen. Bij 1 patiënt werd de chirurgische besluitvorming aangepast op basis van de 
peroperatieve NIR fl uorescente beelden, waardoor een tweede operatie bij deze pati-
ent kon worden voorkomen. Dit is de eerste studie die de mogelijkheid demonstreert 
om borstkanker te detecteren met een lage dosis methyleenblauw in combinatie met 
NIR fl uorescentie.
In hoofdstuk 4 worden de ontwikkeling, de huidige toepassing en het toekomst-
perspectief van NIR fl uorescentie voor de hepatopancreatobiliaire chirurgie geëva-
lueerd. De waarde van ICG voor demarcatie van levertumoren en visualisatie van de 
galwegen is in de (pre)klinische setting reeds onderzocht. Het werkingsmechanisme 
hierbij is gebaseerd op de fysiologische klaring van ICG. Ondanks de veelbelovende 
klinische resultaten, zijn grote gerandomiseerde klinische trials noodzakelijk om het 
voordeel voor de patiënt aan te tonen.
Deel II: NIR fl uorescentie geleide schildwachtklierprocedure 
In Hoofdstuk 5 wordt de diagnostische accuratesse van NIR fl uorescentie geleide 
beeldvorming tijdens de schildwachtklierprocedure in relatie tot conventionele tech-
nieken bij borstkankerpatiënten onderzocht. Patiënten werden geïncludeerd in het 
Dana-Farber / Harvard Cancer Center en in het Leids Universitair Medisch Centrum. 
Bij 94 van de 95 patiënten (99%) kon de schildwachtklier succesvol worden geïdenti-
fi ceerd met behulp van NIR fl uorescentie alléén, of door middel van een combinatie 
van NIR fl uorescentie en radioactiviteit. Daarnaast bleek NIR fl uorescentie beter 
te presteren dan radioactiviteit en patentblauw bij het vinden van tumor positieve 
schildwachtklieren. Met NIR fl uorescentie bleek het mogelijk om bij 81% van de 
patiënten het drainagegebied percutaan in kaart te brengen, hetgeen bijdroeg aan een 
betere detectie van de schildwachtklier. Er werden geen allergische reacties waarge-
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nomen die een mogelijke relatie hadden met de ICG injectie of de NIR fl uorescentie. 
Deze studie bevestigt de accurate en veilige toepassing van NIR fl uorescentie en ICG 
voor de identifi catie van schildwachtklier bij het mammacarcinoom. 
Hoofdstuk 6 beschrijft  het gebruik van een hybride NIR fl uorescente en radioac-
tieve tracer voor de detectie van de schildwachtklier bij het mammacarcinoom. Deze 
studie laat de mogelijkheid zien van gecombineerde preoperatieve beeldvorming en 
peroperatieve navigatie met een fl uorescent-radioactieve tracer. De schildwacht-
klieren konden tijdens de chirurgische procedure worden gedetecteerd met zowel 
γ straling als met NIR fl uorescentie in alle (n = 32) patiënten. Deze techniek heeft  
als voordeel dat er geen extra ICG injectie op de operatiekamer noodzakelijk is. 
Daarnaast lijken de resultaten van deze studie overeen te komen met studies waarin 
alleen ICG is gebruikt. In Hoofdstuk 7 wordt dezelfde hybride NIR fl uorescente en 
radioactieve tracer gebruikt bij patiënten met een melanoom.
In Hoofdstuk 8 wordt de technische haalbaarheid van lymfeklier visualisatie met 
NIR fl uorescentie bij blaaskanker onderzocht; daarnaast werd getracht de injectie 
techniek bij deze tumoren te optimaliseren. De uitgebreidheid van lymfk lierresecties 
bij de behandeling van blaaskanker is nog onderdeel van discussie, waarbij ook de 
waarde van de schildwachtklier procedure nog onzeker is. 20 Patiënten met een inva-
sief blaascarcinoom, die reeds gepland waren voor een radicale cystectomie, werden 
prospectief geïncludeerd. De patiënten kregen tijdens operatie 1.6ml ICG:HSA in 4 
kwadranten rondom de tumor toegediend. Bij de eerste 5 patiënten werd tijdens lapa-
rotomie ICG:HSA subserosaal toegediend, bij de overige 15 patiënten werd middels 
cystoscopie vlak voor het begin van de ingreep ICG:HSA submucosaal toegediend. 
Fluorescente lymfebanen en lymfeklieren waren alleen zichtbaar in de groep waarin 
ICG:HSA cystoscopisch werd toegediend. Het vullen van de blaas na injectie bleek 
van toegevoegde waarde om lymfedrainage te bespoedigen waarbij in 11 van de 12 
patiënten (92%) een of meerdere lymfeklieren konden worden geïdentifi ceerd.  Dit 
onderzoek demonstreert het succesvolle gebruik van NIR fl uorescentie en ICG:HSA 
voor de visualisatie van schildwachtklieren en lymfedrainage in blaaskankerpatiën-
ten. Met name bij hoog risico patiënten zou deze techniek van toegevoegde waarde 
kunnen zijn bij het minimaal-invasief evalueren van de lymfeklierstatus. Ook kun-
nen potentieel aangedane lymfk lieren die buiten het standaard resectievlak liggen 
met deze techniek gedetecteerd en vervolgens uitgenomen worden.
In Hoofdstuk 9 wordt de toegevoegde waarde van NIR fl uorescente beeldvorming 
bij het vulvacarcinoom onderzocht. Voorgaande studies suggereren dat het mixen 
van ICG met humaan serum albumine (ICG:HSA) de retentie in de eerste echelon 
klier verhoogt. In dit hoofdstuk worden verschillende bereidingswijzen van ICG 
voor fl uorescentie geleide SLN biopsie bij het vulvacarcinoom onderzocht. NIR fl u-
orescentie bleek in alle groepen beter te presteren dan patentblauw. Daarnaast bleek 
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ICG gemixt met 99mTc-nanocolloid voor de detectie van de SLN in patiënten met een 
vulvacarcinoom, optimale resultaten te verschaff en. 
Deel III: peroperatieve beeldvorming van vitale structuren
In Hoofdstuk 10 wordt de peroperatieve visualisatie van de ureter met NIR fl uo-
rescente beeldvorming en methyleenblauw onderzocht. Iatrogene schade aan de 
ureter is een belangrijk probleem bij gecompliceerde chirurgische ingrepen in het 
kleine bekken. Omdat de diagnose van een ureterletsel in veel gevallen laat gesteld 
wordt, kunnen er ernstige complicaties optreden. In het verleden is getracht om 
met kleurstof de ureters te detecteren, omdat deze renaal geklaard wordt. Hiervoor 
was echter toediening van een hoge dosis methyleenblauw noodzakelijk. Omdat 
methyleenblauw ook fl uorescente eigenschappen heeft  in het NIR spectrum, kan 
deze stof al bij een zeer lage concentratie met fl uorescentie-camerasystemen worden 
gedetecteerd. Bij alle patiënten werden de ureters duidelijk gevisualiseerd middels 
NIR fl uorescentie. Deze studie demonstreert voor het eerst het succesvolle gebruik 
van NIR fl uorescentie en methyleenblauw voor de identifi catie van ureters tijdens 
chirurgie in het kleine bekken. Omdat het met NIR fl uorescentie mogelijk is om 
dieper door het weefsel te kijken met signifi cant lagere doses methyleenblauw, geeft  
deze techniek de chirurg op een veilige manier waardevolle informatie. Hoofdstuk 
11 demonstreert de optimalisatie en klinische toepasbaarheid van NIR fl uorescentie 
cholangiografi e tijdens zowel open- als laparoscopische galwegchirurgie. De laparo-
scopische cholecystectomie is wereldwijd een van de meest uitgevoerde chirurgische 
ingrepen. Galwegletsel is hierbij een zeldzame, maar ernstige complicatie. Nabij-
infrarode fl uorescente beeldvorming met ICG is een niet-invasieve techniek die het 
mogelijk maakt om de galweganatomie te visualiseren tijdens de laparoscopische 
cholecystectomie. In deze studie werden 41 patiënten geïncludeerd en verdeeld over 
verschillende groepen m.b.t. tijdsinterval en toegediende dosis. Een interval van 24 
uur tussen ICG toediening en chirurgie met een dosis van 10 mg bleek optimale 
contrast-visualisatie te geven. Fluorescente beeldvorming blijkt een veilige, en een 
goed toepasbare techniek te zijn voor identifi catie van de biliaire anatomie tijdens 
laparoscopische chirurgie. Toekomstige studies zijn noodzakelijk om de klinische 
meerwaarde verder te onderzoeken.
TOEKOMSTPERSPECTIEF
Slechts enkele decennia geleden had de chirurg alleen de beschikking over zijn 
eigen zicht en tastzin om peroperatief kwaadaardige afwijkingen in het lichaam te 
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identifi ceren. De afgelopen jaren zijn er veel beeldvormende technieken ontwikkeld 
(zoals Echo, CT, MRI en PET/SPECT) waarmee de aanwezigheid en uitgebreidheid 
van een kwaadaardig gezwel accuraat vast te stellen is. Peroperatief blijft  de chirurg 
nog voornamelijk afh ankelijk van zijn eigen zintuigen om de uitgebreidheid van een 
kwaadaardig gezwel vast te stellen 1. 
NIR fl uorescentie maakt het mogelijk om de chirurg tijdens de ingreep van real-
time informatie te voorzien en kan potentieel een belangrijke complementaire rol 
vervullen binnen de oncologische chirurgie.
In de afgelopen jaren zijn er belangrijke stappen gezet op het gebied van NIR 
fl uorescentie geleide chirurgie. De ontwikkeling van experimentele camerasys-
temen en het gebruik van de klinisch goedgekeurde contrastmiddelen (ICG en 
methyleenblauw) hebben een belangrijke rol gespeeld bij de uitvoering van de eerste 
klinische trials 2-5. Voor de verdere ontwikkeling van deze techniek is de klinische 
beschikbaarheid van nieuwe tumor-specifi eke contrastmiddelen echter van groot 
belang. Verschillende preklinische studies laten veelbelovende resultaten zien met 
nieuw ontwikkelde tumor-specifi eke contrastmiddelen 6-9. Een van de belangrijkste 
uitdagingen in het huidige stadium is de translatie van deze stoff en naar de kliniek. 
Dit is echter een zeer kostbaar en tijdrovend proces, te meer omdat elk nieuw con-
trastmiddel apart moet worden gevalideerd voor humaan gebruik. 
Een nadeel van NIR fl uorescentie is dat de identifi catie van diepgelegen structu-
ren  in het weefsel vaak niet mogelijk is 10-12.  Om te compenseren voor de beperkte 
dieptepenetratie van NIR fl uorescentie is recent een hybride tracer getest, die zowel 
fl uorescente als radioactieve eigenschappen bezit (hoofdstuk 7, 8 en 12)  13-16. Deze 
tracer bevat ICG en de radioactieve tracer 99mTc-nanocolloid, die beiden beschikbaar 
zijn voor klinisch gebruik.
Th ans is de behandeling van verschillende soorten kanker, zoals het mamma- en 
colorectaal carcinoom, multidisciplinair georganiseerd met gestandaardiseerde 
chirurgische-, neo-adjuvante- en pathologische protocollen 17-19. Het fi netunen van 
de relatie tussen de diagnose, de (neo)-adjuvante therapie en de resectie, heeft  de 
potentie om postoperatieve morbiditeit te verminderen en overleving te verbeteren. 
Moleculaire beeldvorming, zowel preoperatief (bv. met tumor specifi eke PET tracer 
/ fotoakoestische therapie) als peroperatief (bv. met NIR fl uorescentie) kan een 
cruciale rol gaan spelen in dit proces, waarbij idealiter één (hybride) radioactief en 
fl uorescent contrastmiddel wordt gebruikt om zowel de preoperatieve als peropera-
tieve beeldvorming te verzorgen. 
Naast de beeldvorming van structuren die moeten worden verwijderd  (zoals tu-
morweefsel en schildwachtklieren) is het van cruciaal belang om tijdens de operatie 
structuren te identifi ceren welke gespaard moeten worden (zoals zenuwen, galwegen 
en de urineleiders) 5,20. De biodistributie en het klaringspatroon van ICG en methy-
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leenblauw maakt het mogelijk om deze stoff en te gebruiken voor de beeldvorming 
van de respectievelijk de galwegen en de urineleiders. Door de lage incidentie van ia-
trogene letsels aan galwegen en urineleiders zal deze techniek vooral van meerwaarde 
zijn als aanvulling op de beeldvorming van aangrenzend maligne weefsel. Gebaseerd 
op het klaringspatroon blijkt het mogelijk te zijn om tumor specifi eke contrastmid-
delen óók te gebruiken voor de identifi catie van vitale structuren21. Dit kan in het 
bijzonder van meerwaarde zijn tijdens laparoscopische lever- of colorectale chirurgie
Een andere belangrijke factor voor de klinische toepasbaarheid van deze techniek 
is de verdere ontwikkeling van speciale NIR fl uorescentie camerasystemen, zeker 
gezien het feit dat een groot deel van de tot nu toe gebruikte systemen zich nog in een 
experimenteel stadium bevindt. Daarbij zal het focus eveneens op het gebruiksgemak 
en op de betaalbaarheid moeten liggen.
Gedurende de afgelopen 15 jaar heeft  de laparoscopische chirurgie veel terrein 
gewonnen en behoort het tot de standaardzorg voor een toenemend aantal chirur-
gische ingrepen. De integratie van Image-Guided Surgery binnen de laparoscopie 
is dan ook een logische vervolgstap, mede gelet op het feit dat de laparoscopie is 
gebaseerd op het gebruik van camerasysteem, beeldverwerking en monitor, waarbij 
de mogelijkheid ontbreekt om de tumor peroperatief te palperen. 
Concluderend kan worden gesteld dat nieuwe beeldgeleide modaliteiten de poten-
tie hebben om een belangrijke rol in de chirurgische behandeling van kankerpatiën-
ten te vervullen. Verdere ontwikkeling van contrastmiddelen en camerasystemen is 
echter noodzakelijk om het volle potentieel en het patiëntvoordeel van NIR fl uores-
centie aan te tonen. Ondanks de veelbelovende resultaten die reeds zijn behaald, zal 
het in de komende jaren duidelijk moeten worden of Image-Guided Surgery met NIR 
fl uorescentie een voordeel biedt in de dagelijkse chirurgische praktijk.
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